Protocol H9H-M C-JBEF (c) 
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and 
Efficacy of  a Novel Transforming Growth Factor–β Receptor  I  Kinase Inhibitor (Ga lunisertib)  
Administered in Combination  with Anti–PD-1 (Nivolumab) in Advanc ed Refractory Solid 
Tumours 
(Phase 1b) and in Recurrent or Refra ctory N on–S mall C ell Lung Cancer or  
Hepatocellular C arcinoma ( Phase 2)  
[STUDY_ID_REMOVED] 
Approval Date: 31-Jan-2017 
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b1. Pr ot o c ol H 9 H -M C -J B E F ( c)
A P h a s e 1 b / [ADDRESS_1200487] or –   R e c e pt or I Ki n a s e I n hi bit or 
( G al u ni s erti b) Ad mi ni st er e d i n C o m bi n ati o n wit h A nti – P D -1 
( Ni v ol u m a b) i n Ad v a n c e d R efr a ct or y  S oli d T u m ou r s
( P h a s e 1 b ) a n d i n R e c urr e nt or R efr a ct or y 
N o n – S m all C ell L u n g C a n c er or H e p at o c ell ul ar C ar ci n o m a
( P h a s e 2)
C o nfi d e nti al I nf or m ati o n
T h e i nf or m ati o n c o nt ai n e d i n t hi s pr ot o c ol i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of 
cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d 
s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al i n v e sti g ati o n of 
g al u ni s erti b ( L Y2 1 5 7 2 9 9 ) c o m bi n e d wit h ni v ol u m a b ( B M S -9 3 6 5 5 8) , u nl e s s s u c h p er s o n s 
ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d C o m p a n y or it s s u b si di ari e s.   
N ot e t o R e g ul at or y A ut h oriti e s :  t hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a 
a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e .  Eli Lill y a n d 
C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y p u bli c r el e a s e .  I n 
t h e U nit e d St at e s, t hi s d o c u m e nt i s su bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) 
E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n 
a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s .  
G al u ni s erti b ( L Y2 1 5 7 2 9 9 ) a n d ni v ol u m a b ( B M S -9 3 6 5 5 8)
T hi s i s a m ulti c e nt r e, n o nr a n d o mis e d, o p e n -l a b el, d o s e-e s c al ati o n P h a s e [ADDRESS_1200488] or y or r e c urr e nt
n o n – s m all c ell l u n g c a n c er or h e p at o c ell ul ar c ar ci n o m a .  
Eli Lill y a n d C o m p a n y
I n di a n a p oli s, I n di a n a U S A 4 6 2 8 5
Pr ot o c ol El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y: 1 7 A pr il 2 0 1 5
A m e n d m e nt ( a) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y : 2 4 J ul y 2 0 1 5 
A m e n d m e nt ( b ) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y :  [ADDRESS_1200489] 2 0 1 6
A m e n d m e nt ( c ) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y o n a p pr o v al d at e pr o vi d e d 
b el o w
A p pr o v al D at e: 3 1- J a n- 2 0 1 7 G M T
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 2
Galunisertib (LY2157299) /nivolumab2.Synopsis
Transforming growth factor –(TGF -β) is an important protein with tumo ur-prom oting activity.  
Mechanisms to explain this act ivity include tum our neovasculari sation (neoangiogenesis), 
immunosuppressio n
,and loss of tumo ur-immune surveillance both through production of 
immunosuppressive cy tokines and induct ion of immune suppressive cells and inhibit ion of 
antitumou
r immunit y, and increased migrat ion, invasio n,and metastases (Akhurst and Derynck 
2001; Derynck et al. 2001 ; Wick et al. 2001a, 2001b ; Siegel and Massagué 2003).  These 
combined effects on the tumo u
r microenvironment by  [CONTACT_4722] -β prom ote tum ourprogression; 
inhibit ion of this cytokine by a TGF -β receptor ty pe I kinase inhibitor is expected to arrest 
tumou
r growth and metastasis and improve immune function.
Programmed Cell Death–1 (PD-1)is expressed on activated T cells and can act to dam pen the
immune response. Tumo
ur cells overexpress programmed cell death –1 ligand ( PD-L1),which 
potenti ally leads to inhibi tion of  local immune response. PD-[ADDRESS_1200490] ive dose.  
This study  is a P hase 1b /2open -label study  that will  be conducted in [ADDRESS_1200491] of an open -label,dose-escalat ion assessment of the safet y and 
tolerabilit y of galunisertib administered at 50 mg dail y(QD) , 50 m g twi ce daily (BID) , 
80 m g 
BID, or 150 m g BID in combinat ion with nivo lumab 3 m g/kg in pat ients with advanced 
refractory  solid tum ours.  The Phase 2 p artof thisstudy  will be disease restricted and include 
2expansio n cohorts of patients in tum ou
rs with documented monotherapy  activit y with 
nivolumab (non –small cell lung cancer ; n =approximately  25patients) or galunisert ib 
(hepatocellular carcino ma[n= approximately  
25patients] ).  Patients in the 2cohorts will be 
enrolled independent ly and will be assigned to treatm ent concurrently ;enrolment for each cohort 
will be co mplete when thatcohort ha sreached the prespecified enrolment target. Galunisertib 
will be used to attempt to augment nivo lumab activit y via suppressio n of the immune 
suppressive function o f TGF -β at the maxim umtolerated dose orpharmaco logically  active dose.  
Addit ional cohorts of patients with specific alternative tumo ur histol ogies may be added and will 
requi re an amendment.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 3
Galunisertib (LY2157299) /nivolumab3.Table of Contents
A Phase 1b /2Dose Escalation and Cohort Expansion Study of the 
Safety, Tolerability ,and Efficacy of a Novel Transforming Growth 
Factor –Receptor I Kinase Inhibitor (Galunisertib) Administered in 
Combination with Anti –PD-1 (Nivolumab) in Advanced Refractory 
Solid Tumo urs (Phase 1b) and in Recurrent or Refractory Non –Small 
Cell Lung Cancer orHepatocellular Carcinoma (Phase 2)
Section Page
1. Protocol  H9H -MC-JBEF(c) A Phase 1b/2 Dose Escalat ion and 
Cohort Expansion Study  of the Safet y, Tolerabili ty and Efficacy o f a 
Novel  Transforming Growth Factor –Receptor I Kinase Inhibitor 
(Galunisert ib) Administered in Co mbinat ion with Anti –PD-1 
(Nivo lumab) in Advanced Refractory  Solid Tum ours (Phase 1b) an d 
in Recurrent or Refractory   Non –
Small Cell Lung Cancer or 
Hepatocellular Carcino ma (Phase 2) .................................................................................... 1
2. Synopsis ............................................................................................................................. 2
3. Table of Contents ................................................................................................................ 3
4. Abbreviat ions and Definit ions........................................................................................... 10
5. Introduction ...................................................................................................................... 15
5.1. Cancer Immunotherapy ................................................................................................ 15
5.2. Transforming Growth Factor –.................................................................................... 15
5.3. Programmed Cell Death–1 ........................................................................................... 16
5.4. Rationale for H9H -MC-JBEF Protocol Amendment (a) ................................................ 17
5.5. Rationale for H9H -MC-JBEF Protocol Amendment (b) ............................................... 19
5.6. Rationale for H9H -MC-JBEF Protocol Amendment (c) ................................................ [ADDRESS_1200492] ion and In Vitro/In Vivo Activit y of 
Galunisertib ......................................................................................................... [ADDRESS_1200493] ion and In Vitro/In Vivo Activit y of 
Nivo lumab ........................................................................................................... 26
5.10.3. Nonclinical Pharmacokinetics/Pharmacodynamics of 
Galunisertib ......................................................................................................... 26
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 4
Galunisertib (LY2157299) /nivolumab5.10.4. Nonclinical Toxico logy........................................................................................ [ADDRESS_1200494] to Follow -Up................................................................................... 45
6.3.4. Discontinuati on of  Study  Sites............................................................................. 45
6.3.5. Discontinuati on of  the Study ................................................................................ 45
7. Treatment .......................................................................................................................... 46
7.1. Materi als and Supplies .................................................................................................46
7.1.1. Galunisertib ......................................................................................................... 46
7.1.2. N ivolumab ........................................................................................................... 46
7.2. Study  Drug Administration .......................................................................................... 46
7.2.1. Dosing Schedule .................................................................................................. 47
7.2.2. Phase 1b Dose Escalat ion..................................................................................... 48
[IP_ADDRESS]. Dose -Limit ing Toxicit y Determination and Maximum 
Tolerated Dose Definit ion............................................................................... 49
[IP_ADDRESS]. Dose -Escal ation Method ................................................................................. 50
[IP_ADDRESS]. Pharmaco logically  Active Dose ...................................................................... 51
7.2.3. Phase 2 Cohort Expansio n.................................................................................... 51
7.2.4. Dose Adjustments, Delays, or Discontinuation from Study  
Drug ..................................................................................................................... 52
[IP_ADDRESS]. Galunisertib Dose Adjust ments and Delays, Criteria for 
Resumpt ion of Galunisertib Treatment, and 
Discontinuati on for Phase 1b and 2 .................................................................
52
[IP_ADDRESS].1. Galunisertib Dose Adjust ments and Delays ............................................... 52
[IP_ADDRESS].2. Criteria to Resume Treatment with Galunisert ib........................................ 52
[IP_ADDRESS].3. Discontinuati on from Galunisert ib............................................................ 53
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 5
Galunisertib (LY2157299) /nivolumab7.2.4.2. Nivo lumab Dose Adjust ments and Delays, Criteria for 
Resumpt ion of Nivo lumab Treatment, and 
Disconti nuati on in Phase 1b and 2 .................................................................. 54
[IP_ADDRESS].1. Nivo lumab Dose Adjust ments and Delays ................................................ 54
[IP_ADDRESS].2. Criteria for Resum ption of Nivo lumab Treatment ..................................... 55
[IP_ADDRESS].3. Discontinuati on from Nivo lumab.............................................................. [ADDRESS_1200495] ion......................................................................................................................... 65
8.1. Safety Evaluat ions........................................................................................................ 65
8.1.1. Safety Data Collection and Review ...................................................................... 65
8.1.2. Adverse Events .................................................................................................... 66
[IP_ADDRESS]. Serious Adverse Events .................................................................................. 67
[IP_ADDRESS]. Adverse Event and Serious Adverse Event Reporting ..................................... 68
[IP_ADDRESS].1. Prior to Administrati on of  Study  Drugs ..................................................... 68
[IP_ADDRESS].2. On Therapy ............................................................................................... 68
[IP_ADDRESS].3. Follow-Up Vi sits...................................................................................... 69
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 69
[IP_ADDRESS]. Summary  of AE/SAE Reporti ng Guidelines ................................................... 69
8.1.3. Other Safet y Measures ......................................................................................... 70
[IP_ADDRESS]. Detection of Aneurysm Format ion of the Ascending 
Aorta and Aorti c Arch (Thoraci c View) .......................................................... 70
[IP_ADDRESS]. Electrocardiograms ......................................................................................... 70
[IP_ADDRESS]. Echocardi ography /Doppler ............................................................................. 71
[IP_ADDRESS]. Cardi otoxi city Serum  Markers as Determined by  [CONTACT_861295] ...................................................................................................... 72
[IP_ADDRESS]. Pulse Oximetry ............................................................................................... 72
8.1.4. Safety Moni toring ................................................................................................ 72
8.1.5. Com plaint Handling ............................................................................................. 73
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 6
Galunisertib (LY2157299) /nivolumab8.2. Sample Collect ion and Test ing..................................................................................... 73
8.2.1. Samples for Study  Qualificat ion and Healt h Monit oring ....................................... 73
8.2.2. Samples for Drug Concentration Measurements 
Pharmacokinet ics/Pharmacodynamics .................................................................. 74
[IP_ADDRESS]. Pharmacokinet ic Samples ............................................................................... 74
8.2.3. Samples for Bi omarker Research .......................................................................... 74
[IP_ADDRESS]. Blood Sam ples................................................................................................ 75
[IP_ADDRESS]. Tumour Ti ssue................................................................................................ 75
8.2.4. Who le Blood for Pharmacogenetics ..................................................................... 76
8.2.5. Samples for Immunogenicit y Research .................................................................77
8.3. Efficacy Evaluations .................................................................................................... 77
8.4. Procedure/Sampling Co mpliance .................................................................................. [ADDRESS_1200496] igator Informat ion....................................................................................... 88
11.3.2. Protocol  Signatures .............................................................................................. 88
11.3.3. Final Report Signature ......................................................................................... 88
12. References ........................................................................................................................ 89
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 7
Galunisertib (LY2157299) /nivolumabList of Tables
Table Page
Table JBEF.6.1. Phase 1b Dose Levels .................................................................................... 42
Table JBEF.7.1. Dose Adjustments for Galunisertib ................................................................ 52
Table JBEF.8.1. Adverse Event and Serious Adverse Reporting Guidelines for Study  
H9H -MC-JBEF ............................................................................................. 70
Table JBEF.10.1. Summary  of Stati stical Power for Response Rates ......................................... 81
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 8
Galunisertib (LY2157299) /nivolumabList of Figures
Figure Page
Figure JBEF.6.1. Study  H9H -MC-JBEF design. ........................................................................ 41
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 9
Galunisertib (LY2157299) /nivolumabList of Attachments
List of Protocol Attachments
Attachment Page
Attachm ent 1. Protocol  JBEF Study  Schedule ...................................................................... [ADDRESS_1200497] Version 1.1 ............................................................ 114
Attachm ent 9. Protocol  JBEF Response Assessment in Neuro -Oncology (RANO) ............. 121
Attachm ent 10. Protocol  JBEF Echocardiographic Guidelines .............................................. 130
Attachm ent 11. Protocol  JBEF Management Algorithms for Immuno -Onco logy Agents ......135
Attachm ent 12. Protocol  JBEF CYP3A4 Modulators ............................................................ 143
Attachm ent 13. Protocol  JBEF Protocol Amendment H9H -MC-JBEF(c) Summary 
A Phase 1b/2 Dose Escalat ion and Cohort Expansion Study  of the 
Safety, Tolerabili ty and Efficacy of a Novel Transforming Growth 
Factor –βReceptor I Kinase Inhibitor (Galunisertib) Administered in 
Combinat ion with Anti –PD-1 (Ni volumab) in Advanced Refractory  
Solid Tumours (Phase 1b) and in Recurrent or Refractory  Non –Small 
Cell Lung Cancer or Hepatocellular Carcino ma (Phase 2)............................ 144
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 10
Galunisertib (LY2157299) /nivolumab4.Abbreviations and Definitions
Term Definition
ADA antidrug antibody 
AE Adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event (AE) can therefore be any 
unfav ourable and unintended sign (including an abnormal laboratory finding), symptom, 
or disease temporally associated with the use of medicinal (investigational) product, 
whether o r not related to the medicinal (investigational) product.
AFP -foetoprotein 
ALT alanine aminotransferase
ANC absolute neutrophil count
AST aspartate aminotransferase
AUC area under the plasma concentration -time curve 
AUC  area under the concentration -time curve during 1 dosing interval
BID twice daily
BNP brain natriuretic peptide
CI confidence interval
Cmax maximum observed drug concentration
Cmax,ss maximum observed drug concentration at steady state 
Cmin minimum observed plasma concentration (trough)
CNS central nervous system
complaint Any written, electronic, or oral communication that alleges deficiencies related to the 
identity, quality, purity, durability, reliability, safety, effectiveness, or performance of a 
drug o r drug delivery system.
compliance Adherence to all the study -related requirements, good clini cal practice (GCP) 
requirements, and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements 
defined by [CONTACT_861296] r esults are 
accurate.  Confirmation will either occur immediately after initial testing or will require 
that samples be held to be retested at some defined time point, depending on the steps 
required to obtain confirmed results.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 11
Galunisertib (LY2157299) /nivolumabCR complete response
CrCl creatinine clearance 
CRF/eCRF case report form/electronic case report form:  Sometimes referred to as clinical report 
form, a printed or electronic form for recording study participants’ data during a clinical 
study, as required by [CONTACT_760].
CRP clinical research physician
CRS clinical research scientist
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CYP cytochrome P450 
DC dendritic cell
DLT dose-limiting toxicity
ECG electrocardiogram
ECHO echocardiography  
ECOG Eastern Cooperative Oncology Group
EMT epi[INVESTIGATOR_018] -mesenchy mal transition
end of trial End of trial is the date of the last visit or last scheduled procedure for the last patient.
enrol Patients who are enrolled in the trial are those who have been assigned to a treatment and 
have received at least [ADDRESS_1200498] signed the informed consent form 
directly or through their legally acceptable representatives.
ERB/IRB ethical review board/institutional review board:  A board or committee (institutional, 
regio nal, or national) composed of medical and nonmedical members whose responsibility 
is to verify that the s afety , welfare, and human rights of the patients participating in a 
clinical study are protected.
GCP good clinical practice
GI gastrointestinal
HBV hepatitis B virus 
HCC hepatocellular carcinoma 
HCV hepatitis C virus 
HIV human immunodeficiency virus
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 12
Galunisertib (LY2157299) /nivolumabIB Investigator’s Brochure
ICD-O International Classification of Diseases for Oncology
ICF informed consent form
IFN- interferon -
informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate in a 
particular trial, after having been informed of all aspects of the trial that are relevant to the 
patient’s decision to participate.  Informed consent is documented by [CONTACT_3553] a written, 
signed and dated informed consent form.
INR internatio nal no rmali sed ratio 
interim analysis an analy sis of clinical study data that is conducted before the final reporting database is 
autho rised for data base lock
investigational 
productapharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical trial
investigator aperson responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible 
leader of the team and may be called the principal investigator.
IV intravenous
IWRS interactive web -response sy stem 
legal 
representativeAn individual, judicial, or other body authori sed under applicable law to consent on behalf 
of a prospective patient, to the patient’s participation in the clinical study.
Lilly Safety System global safety database that tracks and reports serious adverse and spontaneous events 
occurring while using a drug/drug delivery system
LLT lower -level term 
LV left ventricular
MedDRA Medical Dictionary for Regulatory Activities 
MGMT O6-methy lguanine -DNA methyltransferase
monitor aperson responsible for ensuring the investigator site complies with the monitoring plan, 
applicable local standard operating procedures ( SOPs )(if any), and global Medical SOPs.  
Monitors are trained on the investigational product(s), the protocol, inform ed consent 
document, any other written information provided to patients, relevant SOPs, International 
Conference on Harmonisation Good Clinical Practice guidelines (ICH -GCP), and all 
applicable laws (for example, privacy and data protection) and regulation s.  
MRI magnetic resonance imaging
MTD maximum tolerated dose
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 13
Galunisertib (LY2157299) /nivolumabNK natural killer
NCI Natio nal Cancer Institute
NSCLC non–small cell lung cancer 
open -label astudy in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participants are aware of the drug therapy received during 
the study
ORR objective response rate 
OS overall survival 
PAD pharmacologically active dose 
patient asubject with a defined disease
PD progressive disease
PD-1 programmed cell death –1
PD-L1 programmed cell death –ligand 1
PD-L2 programmed cell death –ligand [ADDRESS_1200499] Response Evaluation Criteria in Solid Tumo urs
rescreen to screen a patient who was previously declared a screen failure for the same study
Q2W every 2 weeks 
SAE serious adverse event
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 14
Galunisertib (LY2157299) /nivolumabscreen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical trial.  In this study, screening 
involves invasive or diagnostic procedures and/or tests (for example, blood draws).  For 
this ty pe of screening, informed consent for these screening procedures and/or tests shall 
be obtained; this consent may be separate from obtaining consent for the study.
screen failure apatient who does not meet 1 or more criteria required for participation in a trial
SD stable disease
sponsor the party  who takes responsibility for the initiation, management and/or financ ing of a 
clinical study
study completion occurs (that is, the scientific evaluation will be complete) following the final evaluation of 
patients’ overall survival (OS).  The final evaluation may occur before all patients reach 
the OS endpoint if this earlier evaluation will not alter the statistical interpretation of OS.  
S[LOCATION_003]R suspected unexpected serious adverse reactions
TGF- transforming growth factor –
TPO third -party organi sation
TTP time-to-progression 
ULN upper limit of normal
WHO World Health Organization
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 15
Galunisertib (LY2157299) /nivolumabA Phase 1b /2Dose Escalation and Cohort Expansion Study  
of the Safety , Tolerability  and Efficacy  of a Novel 
Transforming Growth Factor –Receptor I Kinase Inhibitor 
(Galunisertib) A dministered in Combination with A nti–PD-1 
(Nivolumab) in Advanced Refractory  Solid Tumou rs 
(Phase 1b) and in Recurrent or Refractory  Non –Small Cell 
Lung Cancer orHepatocellular Carcinoma (Phase 2)
5.Introduction
5.1. Cancer Immunotherapy
Cancer immunotherapy  rests on the premise that tumo urs can be recogni sed as forei gn rather 
than as self and can be effect ively attacked by  [CONTACT_20397]. Tumou
r progression 
may depend upon acquisit ion of trai ts that allow cancer cells to evade immunosurveillance and 
escape effective ,innate ,and adaptive immune responses ( Dunn et al. 2002; Pardoll 2003; 
Zitvogel et al . 2006; Jemal et al. 2011).  An effect ive response in this setting is thought to rely on 
immune surveillanc e of tumou
r anti gens expressed on cancer cells that ult imately results in an 
adaptive immune response and cancer cell death. Current immunotherapy  efforts attempt to 
reverse the immunosuppressio nto tum ou
r cells and antigens by [CONTACT_861297] .
T-cell st imulat ion is a complex process invo lving the integration of numerous posit ive,as well as 
negat ive,costimulatory  signals in addit ion to anti gen recog nition by [CONTACT_941] T -cell receptor 
(Greenwald et al. 2004) .Collect ively, these signals govern the balance between T -cell act ivation 
and tol erance. Programmed Cell Death –
1 (PD -1)is a member of the CD28 family of T -cell 
costim ulatory  receptors that al so includes CD28, CTLA- 4, ICOS, and BTLA (Nishimura and 
Honj o 2001) .PD-1 signal linghas been shown to inhibit CD
-28–mediated upregul ation of IL -2, 
IL-10, IL -13, interferon -(IFN -)and Bcl -xL. PD-[ADDRESS_1200500] ivation and expansio n of previously  activated cells. Evidence for a negative regulatory  
role of PD-1 com es fro m studi es of PD -1 deficient mice, which develop a variet y of autoimmune 
phenoty pes(Sharpe et al. 2007) .These results suggest that PD -[ADDRESS_1200501] genetic factors. Thus, PD -1 deficiency or inhibit ion is notaccompanied by a univ ersal l oss 
of tolerance to self -antigens.
5.2. Transforming Growth Factor –
Transforming growth factor –(TGF -)has been shown to be a tumo ur prom oter in advanced, 
metastati c cancer, while in normal tissue TGF -inhibits epi[INVESTIGATOR_861272] 
(deCaestecker et al. 2000; Massagu éet al. 2000; Derynck et al. 2001 ; Wakefield and 
Roberts 2002
; Bierie and Moses 2010). TGF -also modulates immune function by [CONTACT_169874] 
T-cell, neutrophil, mo nocy te, m acrophage, natural  killer ( NK)
–cell , carcino ma-associ ated 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 16
Galunisertib (LY2157299) /nivolumabfibroblast ,and carcino ma-cell–autonomous si gnallingin the tumo ur microenvironment ( Bierie 
and Moses 2006; Nagaraj and Datta 2010). Due to this regul ationand the el evated TGF -levels 
present inmany tum ou
r types, an environment favo urable for immune escape and tum ou r 
progression is created.  TGF -inhibit ion is then a reasonable hypothetical treatm ent opti on in 
patients wi th advanced cancer (Yingling et al. 2004). Inhibit ing TGF -is a novel approach that 
shoul d simul taneously  inhibi t tum o
ur spread, neoangiogenesis and improve the host’s ant itumour 
immune response. 
TGF -β also parti cipates in down -regul ation of the adaptive immune response (Ignotz and 
Massagué 1987; Bhowmick et al . 2004; Bierie and Moses 2006; Grady  and Markowi tz 200 8;
Padua and Massagu é2009) by [CONTACT_861298] y ofantigen-present ing cells including dendrit ic 
cells (DCs) (Rotzer et al. 2001; Grady  and Markowi tz 200 8
),B cells and cytotoxic T cells. For 
example , by[CONTACT_861299]-γsecret ion from act ivated T cells , 
decreased proliferat ion of these 
T cells occurs and TGF -β, thereby ,further compromises immune function.
TGF -β upregul atesthe expressio n and signa lling of the immunoregulatory  enzyme indo leamine 
2,3-dioxygenase by [CONTACT_861300] . Other Treg -dependent mechanisms that im pairthe 
generat ion of host immunit y also appear to be regulated by  [CONTACT_4722] -β, including CCL22 chemokine 
immuno suppressio n due to the abilit y of TGF -β to activate the CCL22prom oter.  The cy tokines 
regul ated by  [CONTACT_138727]22 induce chemotaxis for monocy tes, DCs, NK cells, and chronically act ivated 
T cells .  These m echanisms suggest that inhibit ion of the TGF -βpathway  will improve immune 
funct ion by [CONTACT_861301] T -cell and other 
immune cell funct ion(Hanks et al . 2013) .
TGF -β prom otes T -cell exhaust ion, a state of T- cell dysfunction, which is ident ified by 
[CONTACT_133434] n ofmarkers including PD -1,LAG -3, TIM -3and CTLA -4(Wherry  2011) .
5.3. Programmed Cell Death –1
PD-1 (cluster of different iation 279 ) is a cell surface signal ling m olecule that delivers inhibitory  
signals that regul ate the balance between T -cell activat ion and tol erance by  [CONTACT_861302], PD -L1 and PD -L2.  It is a 55-kD ty pe I transmembrane protein that is a member of the 
CD28 family o f T-cell costimulatory  receptors, which also includes CTLA -4, ICOS, and BTLA
(Freeman et al. 2000) .  PD -1 contains an intracellular membrane proximal immunoreceptor 
tyrosine inhibit ory motifand a m embrane distal  immunoreceptor ty rosine- based switch motif. 
PD-1 is primarily  expressed on activated T, B, and myelo id cells (Nishimura and Honjo 2001).  
Its ligands, PD -L1 (B7- H1/CD274) and PD -L2 (B7 -DC/CD273), have been shown to down -
regulate T -cell activation upon binding to PD -1 in both murine and human systems (Latchman 
etal. 2001; Carter et al. 2002) .  PD -1 delivers a negative signal by [CONTACT_861303] -2 to 
the phosphorylated ty rosine residue in the immunoreceptor ty rosine- based swi tch m otifin its 
cytoplasmic regi on(Chemnitz et al. 2004 ; Shep herd et al . 200 0).  
In humans, PD -L1 is constitutively expressed on macrophage -lineage cells, act ivated T cells, 
lung, vascular endothelial cells, and placental s yncyt iotrophobl asts(Keir et al . 2008) .  Aberrant 
expressio n of PD -L1 by [CONTACT_861304] a number of human malignancies
(Dong and Chen 2003; Konishi  et al . 2004; Thom pson et al . 2004; Ohigashi et al. 2005; 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 17
Galunisertib (LY2157299) /nivolumabThom pson et al . 2005a, 2005b; Tsushima et al. 2006) .  PD-L1 expressed by [CONTACT_861305] o f activated tumo ur-specific T cells in vitro (Chemnitz et al. 
2004) .  Moreover, the expressio n of PD -L1 m ay protect the tum ou
r cells from the induction of 
apoptosis by [CONTACT_20411] T cells (Azuma et al . 2008) .  Retrospective analyses of several human 
tumou
r types suggest that tumo ur overexpression (as measured by [CONTACT_9064] ) of 
PD-L1 may permit immune evasio n by [CONTACT_861306]. In renal cell carcino ma, high surface 
expressio n levels of PD- L1 on tum o
ur cells are related to tumo ur aggressiveness. Patients with 
high tumo u
r and/or lymphocy te PD -L1 levels are 4.5 times more likely to die from their cancer 
than patientsexhibit ing low levels of PD -L1 expressio n(Thom pson et al . 2004) .  In mult ivariate 
analysis, high expressio n of PD -L1 in melano ma is an independent predictor of vert ical growth 
of primary  melano mas and of worse outcome (Hino et al . 2010) .  
Following m ost vi ral infect ions
,the host is capable of elicit ing an effective innate and a daptive 
immune response to eliminate the virus and prevent reinfect ion. In some cases, chronic viral 
infect ion is established. In the setting of chronic viral infect ion, antigen specific CD8 T cells 
may demonstrate increased expression o f PD-1(Barber et al. 2006) .  These T cells have been 
termed “exhausted” due to their inabilit y to control the infect ing virus. Administration o f an 
antibody  that prevents PD -[ADDRESS_1200502] ion.
Thus blo ckage o f both TGF -βand PD- 1 coul d be expected to reverse the immunosuppression 
associ ated wi th these m olecules; the combinat ion of TGF -βand PD-[ADDRESS_1200503] ically to induce immune restoration and to im prove tum our control  and response.  
5.4. Rationale for H9H -MC-JBEF Protocol Amendment (a)
H9H -MC-JBEF protocol  was amended to i ncorporate requests related to safet y from the US 
Food and Drug Administration (FDA) submitted during review ending 26 -Jun-2015.  These 
consisted of:
Addit ion of [ADDRESS_1200504] of FDA, t hese addit ional cohorts are added to 
decrease any  potenti al risks to pati ents in the absence of combinat ion data 
with galunisertib and nivolumab to decrease pati ent ri sk.  The revised 
galunisertib starti ng dose (in Cohort 1) will be 50 mg daily (QD) on a 14 day  
on/14 day  off schedule; gal unisertib dosing in the new Cohort 2 will be 50 mg 
twice daily  (BID) on a 14 day  on/14 day  off schedul e.  Nivol umab dosing will 
remain the same .
Addit ion of ≥CTCAE Grade [ADDRESS_1200505] of AEs considered as DLTs to ensure pat ient safet y
Exclusio n of c onco mitant use of strong cytochrome P450 ( CYP )3A4 
inhibitors and inducers in order to minimi se the influence of potential drug 
interact ions on the galunisert ib/nivolumab co mbination in Phase 1b
Clarification of galunisertib administrati on in regard to food intake
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 18
Galunisertib (LY2157299) /nivolumabOther significant changes, modifications or clarifications made in this amendment but not 
requested by  [CONTACT_768198]:
Modificat ion of “glioma” to “glio blastoma” and remo val of“mult iforme” 
from “glioblastom a mul tiforme” to conform to the most recent World Heal th 
Organizat ion (WHO)guidelines
Addit ion of d osing informat ion used in 2 Phase 2 studi es (H9H -MC-JBAK 
[JBAK ]and H9H -MC-JBAL [ JBAL ]) to gal unisertib clinical background 
section
Revisio n of Inclusi on Cri terion 3 to rem ove eligibilit y for pati ents wi th 
gliosarco ma
Clarificat ion added to Inclusion Criterion [ADDRESS_1200506] recurrence of glio blastom a and to better define the requirement for 
patients wi th glioblastom a (International Classification of Diseases for 
Onco logy [ICD-O] 9440/3, WHO grade IV)
Clarificat ion of Inclusio n Cri terion 4 that for bi opsies, fine -needle aspi[INVESTIGATOR_861273]   
Revisio n of Inclusi on Cri terion 6 to requi re that pati ents wi th MGMT 
(O6-methylguanine -DNA methyl transferase) unmethylated newly  diagnosed 
glioblastoma may have received radiotherapy  only and not radi otherapy  and 
temozolomide
Clarificat ion was added to Exclusio n Cri terion 45 to indicate that patients are 
to be excluded for a history  of severe allergy  to study drug com ponents
Clarificat ions for dose adj ustments for gal unisert ib were added to 
Table JBEF .7.1and within Sect ion 7to align wit h the additions of the DLT of 
≥ CTCAE Grade 3 thrombocy topeni a with clinically  significant bl eeding and 
the 2 Phase 1b dose levels
Addit ion of on-study  serum  pregnancy  tests to be conducted predose on Day 1 
of every  cycle
Addit ion of the collect ion at baseline information on weight change f or the 
previous 3 months and that weight and weight change fro m baseline woul d be 
assessed
Inclusio n on Phase 1b pat ients in assessment of overall survival (OS)
Incorporation of addit ional inform ation on different galunisertib formulat ions 
in considerat ion of the add it
ion of the 50- mg galunisertib dose levels and 
corresponding 50- mg tablets
Addit ion of pharm acokinetic ( PK)time- matched electrocardiograms ( ECGs)
Modificat ions to the schedule of events ( Attachment 1 ) and the PK and 
immunogenicit y sampling schedule ( Attachm ent 4 ) to improve consist ency 
within the protocol and incorporate amendment changes
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 19
Galunisertib (LY2157299) /nivolumab5.5. Rationale for H9H -MC-JBEF Protocol Amendment (b)
H9H -MC-JBEF protocol  (a) was amended for the following reasons :
To be consistent with other nivo lumab clinical trials and to be able to assess toxicit ies 
between Study  JBEF and other nivo lumab clinical trials, this study  was designed wit h 
a 56-day DLT peri od, consistent with 2cycle lengths for gal unisert ib and 1cycle
length for nivo lumab.  
Many  Phase [ADDRESS_1200507] the definit ion of the maximum 
tolerated dose ( MTD), and it will assure adequate assessment of toxicit y at each dose l evel
and will allow more rapid determinat ion of the appropriate dose of galunisertib to use in 
combinat ion with nivo lumab.  Once this safet y assessment is completed, the study  can 
progress to the Phase 2 portion and allow pat ients with unmet m edical needs, particularly  
those wi th hepatocellular carcino ma (HCC )and gliobl astom a, to begin therapy  with potenti al 
benefit.
In Section 7.3,the eligibilit y check between the site and Lilly was removed. This was 
an error because the site monitor perf orms thi s review.
The allowance of a [ADDRESS_1200508] ECGs p erformed on 
mach inescalibrated for QTc Fridericia, and pat ients will be at the sites on Day  1 of 
these cycles .
Collect ion and testing of high- sensi tivity C-react ive protein was removed fro m this 
study  because this is a nonspecific inflammatory  marker thatmay reasonably  be 
elevated in patients with malign ancies and, if elevated, may not reflect abnormal 
cardi ac status if this is the sole indicator of cardiac abnormalit y.  
Clarificat ion has been added that pathol ogy notes must accom pany t issue biopsies.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 20
Galunisertib (LY2157299) /nivolumabIn Attachm ent 1 ,Study  Schedules, a requirement was added for echocardiography
(ECHO) at the 30 -day follow-up visit, and, for the Phase 2 portion, clarificat ion was 
provi ded that imaging is t o be collected centrally [see clarificat ion in Sect ion 5.5].  
InAttachm ent 2 ,Clinical Laboratory  Tests, cl arificati on was added that clinical 
chemistries and thyroid tests will be performed by  a central  laboratory (Lilly -
designated laboratory ).
5.6. Rationale for H9H-MC-JBEF Protocol Amendment ( c)
H9H -MC-JBEF protocol  (b) was am ended f or the fo llowing reasons:
Phase 2 portion of study :  toremove the glio blastoma cohort and update protocol text 
to reflect this change .  Results from [ADDRESS_1200509] indicated a lack of sufficient 
efficacy  with galunisert ibin glio blastom a.  
To cl arify the rati onale for the changes to the ECHOs in Attachment 1 made in 
protocol  amendment (b) (see Section 5.5bullet 6) :  the requi rement for ECHO 
(echocardiography ) at the 30 -day follow-up visit was restored into the protocol as this 
requi rement had been inadvertently remo ved during Amendment A; for the Phase 2 
porti on, clarificat ion was provided that imaging is to be collected centrally.  
Attachm ent 2 :  to add hepatit is B surface ant igen testing to match what i s already  
stated in Attachment 1 ,to addthat hepati tis testing at baseline will be assayed by a 
local and a Lilly -designated l aboratory and during the tri al will be perform ed by a 
Lilly -designated l aboratory ; and to cl arify in Attachment 2 the footnotes.  
Attachm ent 4 :  to add a ±[ADDRESS_1200510] ively inhibit the serine/threonine kinase 
of the TGF -receptor ty pe I ( see Section 5.10). The highest selected Phase 2 study dose for the 
JBAK and JBAL studies discussed below was 150 mg BID on a 14 day s on/14 days off schedule
(see the galunisert ib Invest igator’s Brochure [IB]Secti on6.1.1) .  
For detailed safet y informat ion, pleaserefer to the gal unisertib IB,Secti ons 3.2 and 6.2.
Non–Small Cell Lung Cancer 
No studi es have been conducted evaluat ing galunisertib in non– small  cell lung cancer ( NSCLC ).
Hepatocellular Carcino ma 
Study  JBAK is a 4-part,Phase 2 study  in HCC.  In this ongoing study , an interim analysis for 
Part A has reported response to galunisert ib in 109 patients with advanced, unresectable HCC
who ei ther failed or who were intolerant to sorafenib and had elevated α-fetoprotein (AFP) at 
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 2 1
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bbaseli ne ( A F P ≥ 1. 5 ti mes (x) u p per li mit of n or mal [ U L N ]) (Fai vre et al. 2 0 1 4; Gi a n nelli et al. 
2 0 1 4).  Patie nts were als o e val uate d f or res p o nse base d u p o n T G F- β 1 ser u m  le vels at baseli ne 
( <, ≥ 3 4 1 1 p g/ m L).  

  
 
 
  
 
  
 
  
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
M ore i nf or mat i on a b o ut t he k n o w n a n d e x pecte d be nefits, ris ks a n d reas o na bl y a nt ici pate d 
a d verse e ve nts ( A Es) ma y be f o u n d i n t he I B.  I nf or mat i on o n A Es e x pecte d t o be relate d t o t he 
i n vesti gati onal pr o d uct ma y be f o u n d i n Sect i on 7 ( De vel o p me nt C ore Sa fety I nf or mat i on) of t he 
I B.  I nf or mati on o n seri o us a d verse e ve nts ( S A Es) e x pecte d i n t he st u d y  p o p ulat i on i n de pe n de nt 
of  dr u g e x p os ure a n d t hat will be assesse d b y t he s p o ns or i n a g gre gate, peri o dicall y d uri n g t he 
c o urse of t he st u d y, ma y be f o u n d i n Sec tio n 6 ( Effects i n H u ma ns) of t he I B.
5. 8. Ni v ol u m a b
Ni v o l uma b (als o referre d t o as B M S -9 3 6 5 5 8) is a f ull y h u ma n m o n ocl o nal  a nti b o d y ( H u M A b; 
i m m u n o glo b uli n G 4 – S 2 2 8 P) t hat tar gets t he P D -1 cl uster of differe nt iati on 2 7 9 cell s urface 
me m bra ne rece pt or (see Secti o n 5. 1 0 ).  C CI
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 22
Galunisertib (LY2157299) /nivolumabSafety
For detailed safet y informat ion, pleaserefer to the nivo lumab IB ,Section 5.5.
The overall safet y experi ence wi th nivolumab is based on e xperience in approximately 
[ADDRESS_1200511] related AEs are thought to be due to the effects of inflammatory  cells on specific 
tissues.  A vari ety of preferred terms (PTs) have been used to describe similar kinds of 
organ -related AEs, with th e resul t being that AE frequency  tables organi sed by  [CONTACT_861307] -related AEs.  To address this issue, 
select AE categories were created.  Select AE categories group together the most common and
impact ful PTs by [CONTACT_631220] .  These categori es include the following: pulmo nary, 
gastrointestinal ( GI), hepatic, skin, endocrine, hypersensit ivity/infusio n react ion, and renal AEs .  
It is also useful to consider the management of nivolumab -related A Es by  [CONTACT_631220] ,as the 
diagnosti c work -up often requires excluding other potential diagnoses and, when appropriate, 
instituting specific management principles as outlined in Attachm ent 11 .
For suspected nivo lumab-related AEs, based on the severit y of the event, m anagement wi th 
immunosuppressants may be necessary .  In general, dose delays and observat ion are adequate for 
low
-grade AEs .  For moderate -and high -grade AEs, immunosuppressio n with corti costeroi ds 
shoul d be used.  Once the AE has begun to improve, corticosteroids can be tapered over 
approximately  3 weeks to 6 weeks (depending on the severit y of the AE) .  The m anagement of 
AEs consi dered related to any  combinat ion treatment is similar to the management of AEs 
caused by  [CONTACT_861308].
NSCLC Efficacy
Nivo lumab (Opdivo Bristol -Myers Squibb, Inc. [BMS] , [LOCATION_001], N ew York, [LOCATION_003]) was 
approved to treat patients with metastatic squamous cell NSCLC with progression on or after 
platinum -based chemotherapy (BMS 2014).
Study  209017 was a 1:1 randomi sed, open -label study  enrolling 272 patients with metastatic 
squamous NSCLC who had experience d disease progressi on during or after 1 prior platinum 
doubl et-based chemotherapy regimen.  Patients received nivo lumab (n =135) administered 
intravenously (IV) at 3 mg/kg every 2 weeks (Q2W) or docetaxel (n =137) administered IV at 
75mg/m2every  3 weeks.  The tri al dem onstrated a stati stically significant improvement in OS
(p=.[ZIP_CODE]) for patients randomly  assigned to nivolum ab as co mpared with docetaxel at the 
prespecified interim analysis (9.2 [95% CI: 7.3-13.3] months compared to 6.0 [95% CI: 5.1-7.3] 
months, respect ively) (BMS 2014).
Study  [ADDRESS_1200512] 10 m onths for all pati ents, confirmed objective response rate 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 23
Galunisertib (LY2157299) /nivolumab(ORR )was 15% (95% CI:  9%, 22%), of which all were PRs.  The median time to onset of 
response was 3.3 months (range: 1.7 to 8.8 months) after the start of nivo lumab treatment.  
Thirteen of the 17 patients (76%) wi th a confirmed response had ongoing responses wit h 
durati on ranging from 1.9+ to 11.5+ months; 10 of these 17 (59%) patients had durable 
responses o f 6 months or l onger (BMS 2014).
Substant ialmonotherapy  clinical act ivity has been observed in ≥ second -line NSCLC patients 
(n=129) treated in the completed Phase 1 m ultidose, dose -escalation study  of nivo lumab 
(CA209003). This study  showed ORR sof 22% (squam ous) to 26% (nonsquamous) at the 
3-mg/kg dose, greater than the historical ORR for secon d-line docetaxel (approximately 
8%-10%) ( Fossella et al. 2000; Shepherd et al. 2000; Hanna et al. 2004) and similar to that for 
first-line platinum doublet chemotherapy (approximately 25 %-30%) (Bel ani et al . 2008).  In 
addition, the 4 8-week PFS rate among NSCLC patients treated at the 3 mg/kg dose was 30
% 
(both nonsquamous and squamous).  By  [CONTACT_861309], the historical median PFS for second- line 
docetaxel is approximately  3 months (Fossella et al. 2000; Shepherd et al. 2000; Hanna et al. 
2004)
and that for f irst-line plat inum doublet chemotherapy is approximately 4 to 5.5 months 
(Scagliotti et al. 2008).  Among all CA209003 NSCLC patientswith a response, the median 
durati on of  response was 17 m onths .  Furtherm ore, the AEprofile for nivo lumab appears 
favourable versus platinum doublet chemotherapy ,as haematol ogic toxi cities are currently rare 
and the majorit y of nonh aematol ogic toxi cities are low grade and manageable .  
Hepatocellular Carcino ma 
There are no data published wit h nivo lumab in HCC.  APhase 1 dose-escalat ion study  to 
investigate the safet y, immunoregulatory  activity, PK, and preliminary  antitumour activit y of 
nivolumab in advanced HCC in patients with or without chronic viral hepat itis (CA209040) is 
currently ongo ing.  
Ina study  of tremelimu mab (an ant i–
CTLA -4 ant ibody )in HCC (Sangro et al. 2013) , 
investigators reported a good safet y profile; no patient sneeded steroids because of severe 
immune -mediated AEs. Some pati ents had a transient intense elevat ion of transaminases after 
the first dose but not fo llowing subsequent cy cles. PRrate was 17.6% and disease control rate 
was 76.4%. TTPwas 6.48 months (95% CI : 3.95–9.14). A significant drop in viral load wa s 
observed while new emerging variants of the hypervariable region 1 of hepat itis C virus (HCV) . 
HCV repl aced the predominant variants present before therapy , parti cularly in those patients 
with a more prominent drop in viral load. This antivi ral effect was associated with an enhanced 
specific ant i-HCV immune response.
Addit ional information may  be found in the nivo lumab IB ,Secti on 5.4 .  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 24
Galunisertib (LY2157299) /nivolumab5.9. Objectives
5.9.1. Primary Objective
Phase [ADDRESS_1200513] ive of the Phase 1 bpart of this study  is to assess the safet y and tol erabilit y of 
orally  dosed gal unisertib 14 days on/14 day s off in combination wit h IV nivolumab 3 m g/kg 
Q2W by[CONTACT_861310]-limit ing toxicit ies (DLTs) and the MTD or pharmaco logically act ive 
dose (PAD) of the co mbinat ion in patient s with advanced refractory solid tumo ursduring the 
first [ADDRESS_1200514] ive of the Phase 2part (expansion cohorts) of this study  is to assess the safet y 
of the combinat ion of galunisertib and nivo lumab in patien ts wi threfractory  or recurrent NSCLC
orHCC who have failed 1 prior line of therapy .  
5.9.2. Secondary Objectives
The secondary  objectives of this study  are:
to characteri se the PK of galunisert ib and nivo lumab when coadministered
tocharacteri se the immunogenicit yof nivolumab when administered in co mbinat ion with 
galunisertib
to estimate the OS rate following the final analysis/evaluat ion of OS and the landmark 
OS at 6, 12, and 18 months following the start of therapy with the combination of 
galunisertib and nivo lumab 
Phase 2only:  To assess the preliminary  antitumour activit yincluding PFS, ORR, 
durati on of  response, and time to response of the combinat ion of galunisertib and 
nivolumab in pat ients with NSCLC orHCC   
5.9.3. Exploratory Objective s
The exploratory  objectives of this study  are:  
to examine bio markers , including pharm acodynamic markers, relevant to galunisertib, 
nivolumab, immune cells/immune funct ioning and the di sease state, and to correlate these 
markers to clinical outcome
Phase 1b only:  To document the preliminary  antitumo
ur activit y of the combinat ion of 
galunisertib and nivo lumab  
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 2 5
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b5. 1 0. G e n er al I ntr o d u cti o n t o G al u ni s erti b a n d Ni v ol u m a b
5. 1 0. 1. M e c h a ni s m of A cti o n a n d I n Vitr o/I n Vi v o A cti vit y of 
G al u ni s erti b
T G F - has bee n s h o w n t o be a t u m o u r pr o m oter i n a d va nce d, metast atic ca ncer ( de Caestec ker 
et al. 2 0 0 0; Massa g ué et al . 2 0 0 0; Der y nc k et al. 2 0 0 1; Wa kefiel d a n d R o berts 2 0 0 2).  Se veral 
mec ha nis ms ha ve bee n pr o p ose d t o e x plai n t he t u m o ur- pr o m oti n g act i vity of  T G F- , s uc h as 
i ncrease d ne o vasc ularisatio n of  t he t u mo u r, i m m u n os u p pressi on lea di n g t o t he esca pe of t u m our-
i m m u ne s ur veilla nce, a n d i ncrease d mi grati o n a n d i n vasi o n res ulti n g i n metastasis ( A k h urst a n d 
Der y nc k 2 0 0 1; Der y nc k et al. 2 0 0 1; Sie gel a n d Massa g ué 2 0 0 3).  T hese c o m bi ne d effects of 
i m m u n os u p pressi on a n d t he t u m o u r micr oe n vir o n me nt c ha n ges i n d uce d b y TG F - pr o m ot e  
t u mo u r pr o gressi o n, a n d, t heref ore, a T G F- rece pt or t ype I ki nase i n hi bit or is e x pecte d t o ca use 
arrest of t u mo u r gr o wt h a n d metastasis i n patient s.  
T G F -β s hifts t he i m m u ne res p o nse fr o m a T h 1 (a nti-i nfla m mat or y) res p o nse t o a T h 2 
( pr oi nflam mat or y ) res p o nse, w hic h ca n be t u mo u r pr o moti n g.  I n vitr o a n d a ni mal st u dies ha ve 
s h o w n t hat in hi bit i on of t he T G F -β pat h wa y  ca n bl oc k acti vit y me diate d b y T r e g ul at or y cells 
a n d e n ha nce N K a n d C D [ADDRESS_1200515] i vity ( Lill y, data o n file ; Z h o n g et al . 2 0 1 0). T h ese data
s u g gest t hat re versi o n of t he pr o -t u mo u rige nic T h 2 -li ke milie u t o a m o re T h 1-li ke 
micr o -e n vir o n me nt b y bl oc ka de of t he T G F -β pat h wa y  ma y res ult i n i m pr o ve d o utc o mes i n 
t u mo u rs t ypi[INVESTIGATOR_1306] y u nres p o nsi ve t o sta n dar d c y t ot o xic t hera p y as well as tu m o u rs se nsiti ve t o 
sta n dar d c he m ot hera p y.  I n a d dit i on, t he re g ulat i on of e pit helial-mese nc h y mal tra nsit i on ( E M T)
a n d s u p pressi o n of ne oa n gi o ge nesis f urt her s u g gests t hat i n hi bit i on of T G F -β m a y re g ulate t he 
c o ntr ol of a n u m ber of t u m ou r t ypes.
  
 
 
 
 
 
 
 
 
 
G al u niserti b i n hi bits T G F-β – de pe n de nt cell si g nal li n g i n H C C cell li nes with eit her 
a nt i pr oliferati ve or a nti-i n vasi ve effects de pe n di n g o n t he m o del. I n t u mo u r sa mples fr o m 
pati e nts, i n hi bit i on of T G F -β si g nal li n g was ass ociate d wit h decrease d A F P le vels, i n hi biti on of 
pr oliferat i on a n d a p o pt osis i n d uc tio n ( Ser o va et al.  2 0 1 3). F urt her, r ece nt data fr o m a st u d y 
i n vesti gati n g t he t u m ou r effects of g al u niserti b ± s orafe ni b i n vari o us m o use m o dels of H C C a n d 
i n fres hl y gr o w n H C C s peci me ns fr om pat ient s de m o nstrate d t hat T G F -β si gnalli n g i n hi biti on 
usi n g g al u nisert i b ma y pre ve nt s orafe ni b -i n d uce d E M T, dela y t u mo u r gr o wt h, a n d i n d uce C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 2 6
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a ba p o pt osis i n vari o us H C C m o dels ( Ti jeras-Ra balla n d et al. 2 0 1 4 ).   
 
 
 
 
 
 
  
5. 1 0. 2. M e c h a ni s m of A cti o n a n d I n Vitr o/I n Vi v o A cti vit y of Ni v ol u m a b
Bl oc ka de of t he P D -[ADDRESS_1200516] u die d i n a variety of  precli nical i n vitr o 
assa ys, a n d a ntit u m ou r activit y usi n g a m uri ne a nalo g u e of  ni v ol uma b has bee n s h o w n i n a 
n u m ber of i m m u n oc o m pete nt m o use ca ncer m o dels ( B M S N o ncli nical St u d y Re p orts f or St u dies 
M D X 1 1 0 6 -0 2 3- R [ B M S 2 0 0 6a] , M D X 1 1 0 6-0 3 2 - R [ B M S 2 0 0 6 b], M D X 1 1 0 6- 0 0 3- R [ B M S 
2 0 0 6c] , a n d M D X 1 1 0 6 - 0 0 6- R [ B M S 2 0 0 6 d]). Base d o n t hese a n d ot her precli nical data, P D -[ADDRESS_1200517] i on i n se veral t u m ou r t ypes.
I n vitr o, ni v o l uma b bi n ds t o P D -1 wit h hi g h affi nit y (dr u g c o nce ntrati o n t hat pr o d uces 5 0 % of 
ma xi m u m effect = 0. 3 9 -2. 6 2 n M), a n d i n hi bits t he bi n di n g of P D -1 t o i ts li ga n ds P D-L 1 a n d 
P D -L 2 ( dr u g c o nce ntrati o n t hat re d uces t he ma xi m u m effect b y 5 0 % =  1 n M). Ni v o lu ma b
bi n ds s pecificall y t o P D -[ADDRESS_1200518] of 
ni v o l u ma b o n a nti ge n s pecific recall res p o nse i n dicates t hat ni v ol uma b a u g me nte d I F N -
secreti o n fr om C M V s pecific me m or y  T cells i n a d ose -de pe n de nt  ma n ner vers us 
is ot ype- matc he d c o ntr ol. I n vi v o bl oc ka de of P D-1 b y  a m uri ne a nal o g of ni v ol uma b e n ha nces 
t he a nt it u m o u r i m m u ne res p o nse a n d res ult i n t u m ou r rejecti on i n se veral i m m u n oc o m pete nt 
m o use t u m o u r mo d el s ( M C 3 8 a n d S A 1/ N) ( W olch o k et al. 2 0 0 9) .
F or m ore i nf or m at i on, pl ease refer t o t he ni v o l uma b I B , Secti o n 4.
5. 1 0. 3. N o n cli ni c al P h ar m a c o ki n eti c s/ P h ar m a c o d y n a mi c s of 
G al u ni s erti b
As deter mi ne d b y meta b o lis m st u dies i n rats, m ost of g al u niserti b was e xcrete d i n faeces , wit h 
3 meta b o lites acc o u nt i n g f or 39 % of t he d ose e xcrete d i nt o uri ne a n d faeces . T he f u nct i on a n d 
acti vit y of  t hese meta b olites ha ve n ot bee n defi ne d at t his ti me.
Male a n d fe male Fisc her 3 4 4 rats were gi ve n dail y oral d oses of gal u niserti b at 0, 1 5, 5 0, or 
1 5 0 m g/ k g f or 1 m o nt h. Mal e a n d fe male bea gle d o gs were gi ve n dail y oral d oses of gal u nisert i bC CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 2 7
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bat 0, 5 0, 2 5 0, or 5 0 0 m g/ k g f or 1 m o nt h.  
 
 
 
 
 
 
 
N o ncli nic al P h ar m ac o ki netic/ P h ar m ac o d y n a mic M o del
 
 
 
 
5. 1 0. 4. N o n cli ni c al T o xi c ol o g y 
 
  
 
5. 1 0. 5. Cli ni c al P h ar m a c o ki n eti c s of G al u ni s erti b
 
 
  
  
 
 
 C CI
C CI
C CI
C CI
C CIC CIC CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 2 8
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b 
 
 
 
 
 
 
    
 
   
.  
 
 
 
 
  
 
 
 
 
  
 
  
 
 
 
 
 C CI
C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 2 9
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b5. [ADDRESS_1200519] u die d i n 3 9 p ati e nt s wit h ca ncer ( B M S Cli nical St u d y Re p ort 
f or St u d y M D X 1 1 0 6-0 1 [ B M S, 2 0 1 1]) . T he si n gle -d ose P K o f ni v o l u ma b was li near a n d 
d ose -pr o p orti o nal  in t he ra n ge of 0. 3 m g/ k g t o 1 0 m g/ k g ( B M S N o ncli nical St u d y Re p ort f or 
St u d y  M D X 1 1 0 6- 0 2 5-R [ B M S, 2 0 0 6e]) . T he mea n ter m i nal half -life of  ni v ol u ma b ra n ge d 
bet wee n 1 7 a n d 2 5 da y s acr oss t he d ose ra n ge of 0. 3 m g/ k g t o 1 0 m g/ k g. Ge o metric mea n t otal 
cleara nce varie d fr o m 0. 1 3 m L/ h/ k g t o 0. 1 9 m L/ h/ k g, w hile mea n v o l ume of distri b uti o n varie d 
bet wee n 8 3 m L/ k g a n d 1 1 3 m L/ k g acr o ss d oses. T he cleara nce a n d half -life of ni v o l u ma b are 
c o nsiste nt wit h t hat of i m m u n o gl o bul i n G 4. T he m ult i ple-d ose P K of ni v o l u ma b gi ve n Q [ADDRESS_1200520] u dies ( B M S C li nical St u d y Re p ort f or St u d y M D X 1 1 0 6 [ B M S, 
2 0 1 3]) . M ult i ple-d ose P K of ni v o l u ma b f oll owi n g Q 2 W d osi n g was li near wit h 
d ose -pr o p orti o nal  increase i n C m a xa n d area u n der t he c o nce ntrati o n-ti me c ur ve ( A U C) i n 
1 d osi n g i nter v al ( A U C ) i n t he st u die d ra n ge of 0. 1 m g/ k g t o 1 0 m g/ k g.  Ni v o l uma b 
acc u m ulat i on wi t h Q 2 W d osi n g fre q ue nc y was i n t he ra n ge of 2. 9 t o 3. 3 base d o n A U C , 2. [ADDRESS_1200521] as ma c o nce ntratio n (tr o u g h) 
( Cmi n). A p o p ul atio n P K  mo d el  was de vel o pe d b y n o nli near mi xe d effect m o delli n g usi n g data 
fr om [ADDRESS_1200522]-or der eli mi nat i on. Ni v o l uma b P K  was 
f ou n d t o be li near, d ose i n de pe n de nt, a n d ti me i n varia nt. T he ge o metric mea n of ter mi nal 
half -life was 2 5. 6 da y s a n d t he t ypi[INVESTIGATOR_861274] 8. 8 m L/ h, w hic h are c o nsiste nt wit h t h ose 
of  full  hu ma n i m m u n o gl o b uli n a nti b o di es. Cl eara nce o f ni v o l u mab is i n de pe n de nt of d ose i n t he 
d ose ra n ge ( 0. 1 m g/ k g t o 1 0 m g/ k g) a n d t u m o u r t y pes st u die d. B o d y wei g ht n or mali se d d osi n g 
s h o we d a p pr o xi matel y c o nsta nt tr o u g h c o nce ntrati o ns o ver a wi de ra n ge of b o d y wei g hts.
5. [ADDRESS_1200523] u d y , 4 d os a ge le vels of g alu niserti b (at 5 0 m g Q D, 5 0 m g BI D,
8 0 m g BI D , or 1 5 0 m g BI D , gi ve n o n a 1 4 da ys o n/ 1 4 d a y s off sc he d ule) will be a d mi nistere d 
orall y  wi t h ni v ol u ma b 3 m g/ k g I V i n patie nts wit h a d va nce d refract or y s oli d t u m ou rs ( 1 c ycle = 
2 8 da y s).  
  
 
 
 
 
 
 
 C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 3 0
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b 
 
 
 
 
 
 
 
 
I n t he ni v ol uma b cli nical de vel o p me nt pr o gra m me , t he rec o m me n de d ni v ol u ma b m o n ot hera p y 
d ose a n d sc he d ule of 3 m g/ k g Q [ADDRESS_1200524] ace me nt t hera p y (e n d ocri n o pat hies) as i nstr ucte d i n t he 
ma na ge me nt g ui deli nes pr o vi de d i n Attac h me nt 1 1 .C CI
C CI
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 31
Galunisertib (LY2157299) /nivolumabBased on the nonclinical safet y profile for galunisertib, treatment inrats for [ADDRESS_1200525] that there is potential for 
enhanced toxicit y when nivolumab and galunisertib are administered in combinat ion.
However, given t he safet y profile o f nivolumab and gal unisert ib alone, the potential benefit s of a 
combinat ion study  are expected to outweigh the potential risks.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 32
Galunisertib (LY2157299) /nivolumab6.Investigational Plan
6.1. Study Population
Patients who do not meet the criteria for participat ion within the 28-day screening period (screen 
failure s) may be rescreened.  Note that repeating laboratory  tests during the 28 -day screening 
period does not constitute rescreening (any test that does not meet eligibilit y may be repeated 
within the 28 -day period and not considered a rescreening).  Screening laboratory tests m ay not 
be repeated more than twice in order to meet eligibilit yduring the [ADDRESS_1200526] sign a new informed consent form (ICF) and be 
assigned a new ident ificat ion number.  All required tests including laboratory  tests, 
electrocardi ogram s (ECGs
), echo cardi ograms (ECHOs ), mag netic resonance imaging 
(MRI )/computed tom ography  (CT)scans wit h contrast must be repeated in patients who are 
rescreened in a new 28 -day period(Attachment 1 ).
Prospective approval o f protocol  deviati ons to recrui tment and enro lment criteria (also known as 
protocol  waivers or exempt ions) is not permitted.  Any missing laboratory  or test resul ts 
precludes pati ent from being enrolled on this study until those laboratory  or test resul ts are 
available.  Local laboratories will be used to assess eligibilit y.  
6.1.1. Inclusion Criteria
Patients m ay be included in the study  if they  meet all  of the f ollowing cri teria during screening 
prior to fi rst dose of study  drug.
[1] For Phase 1b, must have advanced refractory  solid tum ours in any line o f 
therapy .  
[2] For Phase 2, must have 1 of the f ollowing tum o
ur types :  recurrent or 
refractory  NSCLC (any  histol ogy) orHCC with AFP ≥
200 ng/mL .  
[3] For Phase 2, m ust h ave histol ogical or cy tological  confirm ationof recurrent 
disease based upon standard diagnostic criteria for the tumo ur type.  
[4] New (nonarchived) baseline tumo ur biopsies (defined as a biopsy  specimen 
taken since co mpletion of the first -line treatment regimen) are required for all 
cohorts (see Section 8.2.1 ).  In addit ion, in the Phase [ADDRESS_1200527] agree to undergo an on -study  biopsy; pati ents in the Phase 1b 
partof this study  are strongly encouraged to agree to undergo an on -study  
biopsy .  
See Secti on [IP_ADDRESS] .  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 33
Galunisertib (LY2157299) /nivolumabFor Phase1bof the study , any  glioblastoma patients must have either a new biopsy  or 
archived tumo ur tissue available.  
Fine
-needle aspi[INVESTIGATOR_499754].
[5] For NSCLC ,HCC or other nonneuro -oncol ogy tumours: have measurable 
disease as defined by [CONTACT_44993]1.1(Eisenhauer et al. 2009 ; 
Attachm ent 8 ).  
For any  glioblastom apatient in Phase 1 bof the study :  have measurable disease as 
defined by [CONTACT_95733] (Wen et al. 2010
; Attachment 9 ).Patients with glioblastom amay 
have nonmeasurable disease if they have undergone resection and postresection 
radiation.  If measurable disease is present, at least 1measurable glioblastoma lesio n 
present prior to randomi sation must meet the follo wing criteria:
contrast -enhancing and clearly defined, bi -dimensionally  measurable margins 
AND
at least 2perpendicular diameters measuring 10mmx10mm (Note:  
MRI measurements will not include surgical cavit ies, cysts, or necroti c area)
[6] For Phase 2only, h ave had disease progression orbe refractory  or intol erant
to 1 prior line of therapy (first -line therapy) for recurrent or refractory  
NSCLC or HCC and have refused current ly approved second- line of therapy .  
First-line therapy is defined as therapy used to treat advanced disease. This 
may include mult iple chemotherapeutic, targeted or immunotherapeutic agents 
with or wi thout radiation therapy  and/or surgery .  Each subsequent line of 
therapy  is preceded by [CONTACT_388834]. A switch of an agent within the 
same drug class (eg, ci splat inum to carboplat inum)  within a regimen in order 
to manage toxi city does not define the start of a new line of therapy .  
For NSCLC :  
Prior lines of therapy must include a plat inum -based therapy .  Invest igational 
agents used in co mbinat ion with stand ard therapi [INVESTIGATOR_861275].   
Patients who 
received plat inum -based neoadj uvant or adj uvant therapy and subsequent ly 
received plat inum -based therapy  as fi rst-line of therapy  are eligible.
Patients who have completed neoadjuvant or adjuvant therapy  with a platinum 
doubl et and have experienced disease recurrence within 6 months of co mpleting 
the platinum doublet are eligible.
Tumours wi th driver m utations (epi[INVESTIGATOR_861276] n oncogene posit ive) treated wi th a 
tyrosine kinase inhibitor or crizotinib are eligible .  For pati ents who have 
progressed on a ty rosine kinase inhibitor or crizotinib or are intolerant to this 
targeted therapy , thatpatient must receive plat inum -based therapy prior to 
enrolment in this study .Documentation of such mutations must be available and 
entered into the electroni c case report form  (eCRF) .
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 34
Galunisertib (LY2157299) /nivolumabMaintenance or switch maintenance therapy after first -line chemotherapy will be 
considered part of the first-line regimen a nd is acceptable.
Patients who com pleted and progressed on a plat inum -containing regimen as 
adjuvant, neoadj uvant, or part of a course of chemoradiat ion therapy  given from  
locally advanced disease and developed recurrent (local or metastatic) disease 
within the [ADDRESS_1200528] atinum 
doubl et-based chemotherapy before discont inuat ion for toxi city.  If patients 
received only  1cycle of a platinum doublet and discontinue due to clear 
progression, that regimen should be counted as a prior line of therapy .
For HCC:
one prior line of therapy which must include sorafenib ,or patient must have 
progressed or been intolerant to sorafen ib for pati entsnot eligible for transarteri al 
chemoembo lisation.  Patients who had sorafenib for locally advanced disease or 
are intolerant to sorafenib are eligible . Patients may have had clinical progression 
only following sorafenib or l ocal therapy .  
must have Child -Pugh A only.  Patients may have any viral status (hepatit is B, 
hepat itis C, or none).
have a viral load <100 IU/mL
for hepatitis B patients , must be on a nucleoside analogue reverse transcriptase 
inhibitor (lamivudine, telbivudine, adefovir, tenofovir, or entecavir)
[7] Are 18 years of age
[8] Have given written informed consent prior to any  study -specific procedures
[9] Have adequate organ funct ion, including:
For Phase 1b only:
Have sufficient h aematol ogical  function, defined as a platelet count of 
100x10 9/L, haemoglobin concentrati on 9.0g/dL or 5.6 mmo l/L, and 
absolute neutrophil count (ANC) 1.5x10 9/L.  Pati ents m ay receive 
erythrocyte transfusio ns to achi eve this h aemoglobin level  at the discreti on of  
the invest igator (at least 3 days before starting treatment with study  drug ).  
Initial treatm ent m ust not begin unt il 2 days after the erythrocyte transfusio n 
and after the confirmat ion of h aemoglobin level  ≥9 g/dL.
Have sufficient hepatic funct ion, defined as bilirubin 1.5xULN (except 
patients with Gilbert Syndro me who must have a total bilirubin level of 
<3.0xULN) and alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) l evels 3.0xULN.  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 35
Galunisertib (LY2157299) /nivolumabSerum  creat inine 1.5 × inst itutional ULN OR m easured or calculated CrCl 
(glomerul ar fil tration rate can also be used in place of creat inine or CrCl; 
Attachm ent 7 ) ≥50mL/min for pati ents wi th creat inine levels ≤1.5x 
institutional ULN.  
For Phase 2only:
For all Phase 2 cohorts:
Renal:  Serum creat inine 1.5 × institutional ULN OR measured or calculated 
CrCl  (glomerular fil tration rate can al so be used in pl ace o f creatinine or CrCl; 
Attachm ent 7 ) ≥50mL/min for pati ents wi th creat inine levels ≤1.5x inst itutional 
ULN.  
Neurol ogic:  Pati ents wi th ≤ Grade 2 neuropathy  are eligible and may  enrol .
For NSCLC cohort only :
Haematol ogic:  pl atelets 100x10 9/L, and h aemoglobin 9g/dL or 5.6 mmo l/L, 
ANC 1.5x10 9/L.Patients may  receive ery throcyte transfusio ns to achieve this 
haemoglobin level  at the discreti on of  the investigator (at least 3 days before 
starting treatment with study  drug ).Initial treatm ent m ust not begin unt il 2 days 
after the erythrocyte transfusio n and after the confirmat ion of h aemoglobin level  
≥9 g/dL.
Have sufficient hepatic funct ion, defined as bilirubin 1.5xULN (except pati ents 
with Gilbert Syndro me who must have a total bilirubin level o f <3.0xULN) and 
ALT and AST level s 3.0xULN.  
For HCC cohort only :
Haematol ogic:  platelets 50 x 10 9/L, h aemoglobin 9g/dL or 5.6mmo l/L, 
ANC 1.5x10 9/L. Patients may  receive ery throcyte transfusio ns to achieve this 
haemoglobin level  at the discreti on of  the investigator (at least 3 days before 
starting treatment with study  drug ). Initial treatm ent m ust not begin unt il 2 days 
after the ery throcyte transfusio n and after the confirmat ion of h aemoglobin level  
≥9 g/dL.
Hepatic:  bilirubin ≤2.5xULN (except pati ents wi th Gilbert Syndro me who must 
have a total bilirubin level o f <3.0xULN) , ALT, and AST ≤5.0xULN. 
Prothrombin t ime/internat ional norm alised rati o (INR) ≤2.3; or prothrombin t ime
6 seconds above control .
[10] Patients wi th recent m ajor surgery  must have recovered, in the opi[INVESTIGATOR_3078] n of the 
investigator, from the toxicit y and/or com plicat ions from  the intervent ion 
before starting therapy .
[11] Have an INR or prothrom bin time ≤1.5x ULN , except as noted for HCC 
patientsin Inclusion Criterion 
9, unless patient is receiving stable dose 
anticoagulant therapy .  These pati ents are eligible as long as prothrombin t ime
or INR i s within therapeut ic range o f the intended use of the anticoagulant.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 36
Galunisertib (LY2157299) /nivolumab[12] Have a performance status of 0 or 1 on the Eastern Cooperative Oncology  
Group (ECOG) scale (refer to Attachment 6 ).
[13] Have discontinued previous treatm ents f or cancer for at least [ADDRESS_1200529] 42 day s for 
mitomycin -C or ni trosoureas
[
14]Are reliable and willing to beavailable for the duration of the study  and are 
willing to follow study  procedures
[15] Use an approved contraceptive method (for example, intrauterine device, birth 
control  pi[INVESTIGATOR_3353], or barri er device), if appropriate (male and female pat ients with 
reproduc tive potenti al) during the study  and for [ADDRESS_1200530] a failure rate of <1%.
[16]Women of childbearing potential must have a negative -human chorionic 
gonadotropin pregnancy test document ed wi thin [ADDRESS_1200531] she is pregnant while 
participat ing in this study , she shoul d immediately discontinue study  treatm ent 
and inform her treating physician immediately .  If pregnancy is confirmed,
patient will be discont inued fro m treatm ent.
[17]Have an est imated life expectancy of ≥12 weeks , in the j udg
ement of the 
investigator
[18]Are able to swallow tablets
6.1.2. Exclusion Criteria
Potenti al study  patients m ay not be included in the study  if any of the following apply during 
screening.
[19] Have received treatment within 28 days or 5 half -lives (whichever is longer) 
of the ini tial dose of study  drug wi th an investigational product or 
nonapproved use of a drug or device (other than the study  drug/devi ce used in 
this study )for noncancer indicat ionsor are concurrent ly enrolled in any other 
type of medical research judged not to be scient ifically or medically  
compatible with this study.
[20] For Phase 2 only, m ore than 1 prior line o f therapy for thei r tumou r type.
[21] Have moderate or severe cardiovascular disease:  
have the presence of cardiac disease, including a myocardial  infarct ion within 
6months pri or to study  entry , unstable angina pectoris, [LOCATION_001] Heart 
Associ ation Class III/IV congestive heart failure, or uncontrolled hypertensio n
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 37
Galunisertib (LY2157299) /nivolumabhave baseline elevated cardiac enzymes as fo llows: brain natriuretic peptide 
(BNP )or Cy statin C el evated m ore than [ADDRESS_1200532]
have documented major ECG abnormalit ies (not respond ing to medical 
treatm ents)
have major abnormalit ies documented by  [CONTACT_861311]:
omoderate or severe heart valve funct ion defect including moderate or severe 
valve stenosis or regurgitation 
oleft ventri cular (LV) ejection fraction <50%, evaluation based on the 
institutional lower limi t of normal
ohave septal aneurysm or other heart aneury sm  
oany aneurysm of the major vessels
For addi tional details, refer to the attached ECHO guidelines (Attachm ent 10 ).
[22] Have a serious conco mitant sy stemic disorder including act ive infect ion with 
human immunodeficiency virus (HIV) (HIV 1/2 ant ibodies) . 
[23] Active infection wit h hepatit is B virus (HBV)(posit ive hepat itis B surface 
antigen) ;HCV is allowed only  in HCC pat ients. HCC patients a t risk for 
HBV reactivat ion (as defined by[CONTACT_14181]
–hepati tis B core antibody  posi tive) are 
only eligible in the HCC cohort ; see Inclusio n Cri terion 6.
[24] Are receiving immunosuppressive agents (eg, cy closporine ) for any  reason 
except for corticosteroids for transfusions .  In the Phase 1 bporti on of  the 
study , l
ow-dose corti costeroi ds for glioblastoma are permitted (eg ,prednisone
10mg [approximately equivalent to 2 m g of dexamethasone ] or less daily  or 
equivalent dose of other corticosteroid).
[25] Have had p rior monocl onal ant ibody therapy  within 28 days before 
Study Day 1 or not recovered ( ≤ Grade 1 or at baseline) from AEs (except for 
fatigue or alopecia) due to agents administered more than 28 days earlier.
[26] Have had p rior therapy  with an ant i–PD -1, anti – PD-L1, anti –PD-L2, 
anti-CD137, or anti –
cytotoxi c T lymphocy te-associated ant igen-4 ant ibody  
(including ipi[INVESTIGATOR_861277] 
T-cell co -stimulat ion or checkpo int pathways) or a TGFβ R1 kinase inhibitor.   
[
27] H ave a second concurrent primary  malignancy that, in the judg ement of the 
investigator and Lilly, may affect the interpretation of results .
[28]
Have prior malignancies .  Pati ents wi th carcino ma in situ of  any ori gin and 
patients wi th pri
or malignancies who are in remission and whose likelihood of 
recurrence is very low (such as basal cell carcino ma), as j udged by  [CONTACT_861312] (CRP), are eligible for this study . The Lilly CRP 
will approve enrolment of patients with prior malignancies in remissio n before 
these patients are enrolled.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 38
Galunisertib (LY2157299) /nivolumab[29] Receiving any concurrent antineoplast ic therapy (ie, chemotherapy, hormonal 
therapy , immunotherapy , extensive, nonpalliat ive radiat ion therapy , or 
standard or investigat ional agents) .  
[30]Have had prior radiotherapy  within [ADDRESS_1200533] 
recovered fro m all radiation -related toxi cities, not requi re more than l ow-dose 
corticosteroids (except for low -dose corti costeroi ds for glioblastoma in the 
Phase 1b porti on of  the study , eg,prednisone 10 mg or less daily or equivalent 
dose of other corticosteroid), and not have had radiation pneumo nitis.  A 
1-
week washout is permitted for p alliat ive radiat ion to non -CNS disease with 
Lilly physician approval.
[31] For glioblastoma patientsin the Phase [ADDRESS_1200534] 
diffuse leptomeni n
geal disease.
[32] P atients with known act ive central nervous system (CNS) metastases and/or 
carcino matous m eningi tis. Patients with stable, previously treated brain 
metastases may participate if neurologic symptoms have reso lved, they have 
been o ff steroids for at least [ADDRESS_1200535] dose of study 
treatm ent.
[
33]Have a ctive known or suspected autoimmune disease or a documented history 
of autoimmune disease, or a syndro me that requires systemic steroids or 
immunosuppressive agents.  Patients with vitiligo, alopecia, type I di abetes 
mellitus, residual hypothy roidism due to autoimmune condit ion only requiring 
thyroid replacement therapy  (must be on a stable dose started prior to study  
entry ), 
and/or psoriasis not requiring chronic and systemic 
immunosuppressive treatment, are permitted to enrol if the above listed 
condi tions are not expected to rec ur in the absence of an external trigger . 
[34] Patients requi ring escalating or chronic supraphysiologic doses of 
corticosteroi ds for control  of their disease at randomi sation are excluded.  
However, p atients with resolved childhood asthma/atopy ,who req uire 
intermittent use of bronchodilators or local steroid inject ions,who have
hypothy roidism  stable on thyroidreplacement therapy  at study  entry ,or who 
have Sjögren’s syndro me are eligible for the s tudy.
[35] Patients wi th Crohn’s disease are not eligible.
[
36]For glioblastoma patientsin the Phase [ADDRESS_1200536] 6 m onths pri or to randomi sation.  
[
37]Concurrent treatment with Novo -Tumor Treating Fields ®(Novocure ;Haifa, 
Israel ) is not permitted .  Prior whol e brain or gamma knife radiosurgery  is 
permitted for the treatment of glioblastoma or metastati c brain lesio ns.  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 39
Galunisertib (LY2157299) /nivolumab[38] Have e vidence of interstit ial lung disease that is sym ptom atic or may interfere 
with the detecti on or m anagement of suspected drug -related pulmo nary 
toxicity or active, noninfectious pneumonit is.
[
39]Have an act ive infect ion requiring systemic therapy .
[40] Be a pregnant or nursing wo man.
[
41]Have received a live vaccine wit hin [ADDRESS_1200537] dose of study  
treatm ent.  Exam ples o f live vaccines include, but are not limit ed to, the 
following:  m easles, m umps, rubella, chicken pox, yellow fever, rabies, 
Bacillus Calmette –Guérin, and typho id vaccine.  Seasonal influenza vaccines 
for inject ion are generally killed virus vaccines and are allowed; however, 
intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and 
are not allowed.
[42] Have a GI condi tion that m ay affect drug absorpti on.
[
43]Have a history  or current evidence of any  condi tion, therapy , or laboratory  
abnorm ality that might confound the results of the study , interfere wi th the 
patient's parti cipat ion for the full durat ion of the study , or is not in the best 
interest of the patient to parti cipate, in the opi[INVESTIGATOR_3078] n of the treating invest igator.
[44] Have known psychiatric or substance abuse disorders that in the opi[INVESTIGATOR_3078] n of the 
investigator would interfere wit h cooperation wit h the requirements of the 
study .
[45] Have a history  of severe allergy or hy persensi tivity to study  drug com ponents
(including mo noclonal antibody  therapy) .
[46] For Phase 1b only: Conco mitant use of strong CYP3A4 inhibitors and 
inducers is prohibited. See Attachment 12 .
[
47]For HCC patients only :
have known HCC wit h fibro -lamellar or mixed histology
have presence of clinically relevant ascites
have a history  of hepat ic encephalopathy
have had a liver transplant 
have experienced any Commo n Termino logy Cri teria for Adverse Events 
(CTCAE) Grade 3 or 4 GI bleeding or any  variceal bleeding epi[INVESTIGATOR_861278] 
3months pri or to enrolment requiring transfusio n or endoscopic or operative 
intervent ion.  (Pati ents wi th any bleeding epi[INVESTIGATOR_861279] -threatening 
during the 3 months prior to enrolment are excluded, regardless of transfusion or 
intervent ion status.)
have oesophageal or gastric varices that require immediate intervention (eg, 
bandi ng, sclerotherapy ) or represent a hi gh bleeding ri sk in the opi[INVESTIGATOR_3078] n of the 
investigator or consult ing gastroenterologist or hepatologist
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 40
Galunisertib (LY2157299) /nivolumab6.2. Summary of Study Design
This is a Phase 1b /2study  that will be conducted in [ADDRESS_1200538] part (Phase 1 b)of the study  
will consist of a n open -label,dose-escalat ion assessment of the safet y and tol erabili ty of 
galunisertib administered at 50 mg QD (Cohort 1) ,50 m g BID (Cohort 2), 80 mg BID
(Cohort 3),and 150 mg BID (Cohort 4)administered with nivo lumab 3 mg/kg Q2W in patients 
with advanced refractory  solid tum o
urs(Figure JBEF .6. 1).  The second part (Phase 2)of the 
study will be disease restricted to include 2expansio n cohorts in patients with recurrent or 
refractory  NSCLC (
n= approximately  25patients)orHCC (n =approximately 25patients ) 
receiving nivolumab 3 mg/kg Q2W plus galunisertib at the dose determined from the Phase 1b 
part. Addit ional expansio n of individual cohorts may occur depending upon activit y based upon 
a 2-stage design after 3 cy cles.  Details are found in S ection10.1.1 .  NSCLC has a histori cally  
good activit y under nivo lumab monotherapy ;HCC hasdocum ented activit y with galunisertib
therapy .  
Addit ional cohorts of patients with specific alternative tumo u
r histol ogies may  be added , but this 
additionwill require an amendment.
Safety assessments including laboratory  assessments, PK blood draws, vi tal sign collect ion, 
medical history , wei ght and at baseline change in weight for previous [ADDRESS_1200539] dose of co mbination 
treatm ent.  ECGs will be collected as described in Attachm ent1and Attachm ent 4 .  ECHOs will 
be co llected at baseline and every  8 weeks (end o f every other cy cle).  
Addit ionally imaging 
exam inations will be performed approximately every  8 weeks (end of every  other cycle).  
Efficacy measures will be assessed fo llowing every other treatm ent cy cle(end of Cycles 2, 4, 
etc). Disease assessment with CT and/or MRI, as appropriate, will be performed at baseline and 
approximately  between Days [ADDRESS_1200540] dose 
in the next cy cle (or approximately every  8 weeks) ,until disease progression or patient
withdraw alfrom the study .  
Treatment decisio ns related to patient management and whether to treat a patient with advanced 
refractory  solid tumo urs with addi tional cycles of study  therapy  will be based on RECIST
version1.1for all study  patients except patie nts with glioblastom a
,for whom  treat ment decisio ns 
will be based on RANO criteria .  
At the sponsor’s discretion, scans and measurements may be collected and reviewed by 
[CONTACT_102451] v ersion1.1/RANO criteria at a later date, or at any  time 
during the study .  
The pl anned durat ion of treatment is not fixed; pat ients will remain on study treatment until they 
fulfil 1 of the cri teria for study  discont inuat ion (Section 6.3). Patients demonstrating a benefit 
from treatment m ay continue on combinat ion therapy if the patient and invest igator feel that the 
patient is benefit ing fro m treatm ent.  If a patient experiences an AEthat requires the patient be 
discontinued fro m 1 of the 2 study  drugs, the pati ent shoul d continue on the other study  drug 
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 4 1
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b( Sectio n 7. 2. 4 ).  La n d mar k a nal ysis of all st u d y  patie nts will occ ur at 6, [ADDRESS_1200541] t o f ol l o w-u p.  P at ient s will be f oll owe d f or s ur vi val 
a p pr o xi matel y e v er y 1 2 wee ks ( ± 7 da ys) u ntil deat h or e n d of trial.  T his f ollo w -u p m a y  occ ur 
t hr o u g h a p h o ne call, e mail, or visit b y t he patie nt or t he patie nt's careta ker.
Refer t o Attac h me nt [ADDRESS_1200542] u d y sc he d ule.
A b bre viati o ns :  a p pr o x = a p pr o xi matel y; BI D = t wice dail y; I V = i ntra ve n o us; 
H C C = he pat ocell ular carci n o ma; n = n u m ber of patie nts; N S C L C = n o n – s mall cell 
l u n g ca ncer; Q 2 W = e ver y ot her wee k; Q D = dail y; T B D = t o be deter mi ne d.
Fi g ur e J B E F . 6. 1. St u d y H 9 H -M C -J B E F d e si g n.C
C
IC CIC CI
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 42
Galunisertib (LY2157299) /nivolumab6.2.1. Phase 1b Dose Escalation
A 3+ 3 + 3 designwill b e used to assess the safet y of g alunisert ib given in co mbinat ion with 
nivolumab 3 mg/kg. Beginning wit h Cohort 3 or 4, 1additional patient will be enrolled in each 
dose l evel for a total  of 4 pati ents per dose l evel to allow for unforeseen discontinuation not due 
to a DLT before the DLT period is completed (see Secti on [IP_ADDRESS] ). A cy cle length for the 
combinat ion of nivolumab and galunisert ib is defined for the purpose of this study  to be 28days. 
The dosages during dose escalat ion are provi ded in Table JBEF .6.1.  The DLT observat ion 
period will last for 8 weeks or to the complet ion of Cy cle 2, whichever is longer.  
After determining the MTD, PAD, or ifdose escalati on is completed without identifying the 
MTD and to further explore pharmacodynamic /biomarker obj ectives, [ADDRESS_1200543] 50 mg QD of galunisertib cannot be combi ned safely  with nivo lumab 3 m g/kg, then
following the review o f available safety ,PK,and pharmacodynamic data at the dose 
escalat ion/cohort review meet ings, a lower dose of nivo lumab may be considered and tested wit
h 
galunisertib at 50mg oralQD.  
Table JBEF .6.1. Phase 1 bDose Levels
Cohort /Dose 
LevelTotal Number of 
Evaluable PatientsGalunisertib
(PO)Nivolumab
(IV)
1 n=3 to approx 15 50 mg QD 14 days 
on/14 days off3 mg/kg Q2W
2 n=3 to approx 15 50 mg BID
14 days on/14 days off3 mg/kg Q2W
3 n=3 to approx 15 80 mg BID
14 days on/14 days off3 mg/kg Q2W
4 n=3 to approx 15 150 mg BID
14 days on/14 days off3 mg/kg Q2W
Total n=12 to approx 60total
Abbreviations:  approx = approximately; BID = twice daily ; IV = intravenous; PO = orally; Q2W = every 2 weeks ; 
QD = daily .
6.2.2. Phase 2Cohort Expansion
The purpose of the cohort expansio ns is to gather addit ional safet y, PK, tolerabilit y, preliminary 
efficacy  and pharmacodynamic informat ion regarding the combin ation of galunisert ib and 
nivolumab 3 mg/kg.  Once the safet y profile of all doses tested has been characteri sed and the 
MTD or PAD of combined administration of galunisertib and nivo lumab has been defined in the 
Phase 1b part, the Phase 2cohort expansions will be init iated at the MTD, or PAD.  Treatment 
doses in the cohort expansion groups will not exceed the MTD.  Two expansio n cohorts will be 
tested in order to demonstrate efficacy o f the combinat ionin NSCLC and HCC . If
DLT -equivalent toxici ties occur in 33% or more of patients within a tumo ur-specific cohort 
expansio nin the first 2 cy cles, then investigators and the Lilly CRP will assess the nature and 
severit y of these toxi cities.  No addi tional patients will be accrued unt il this sa fety review i s 
completed and a decisio n is made eit her to continue at the current dose or to deescalate the dose 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 43
Galunisertib (LY2157299) /nivolumaband define a new dose for the expansio n phase. The NSCLC cohort (NSCLC has demo nstrated 
activit y with nivo lumab monotherapy )and the HCC cohort (HCC has docum ented m onotherapy  
activit y withgalunisert ib)will be used to assess activit y of the combinat ion.  Addit ional cohorts 
could be considered after revi ewing the Phase 1b dose-escalat ion data to further explore activit y 
of the combinat ion.Any addit ions would require an amendment.
Approximately  
25patients will be init ially enrolled in each cohort. These cohorts may be 
expanded depending upon activit y observed in each individual cohort. These pat ientswill be 
enrolledto allow for a more precise estimate of the ORR in these tumo urtypes where 
preliminary data or Phase 3data have suggested activit y for monotherapy .  See Section 7.2.[ADDRESS_1200544] 6 cycles if in the opi[INVESTIGATOR_3078] n of the 
investigator and the Lilly physician the patient is deriving benefit .  
Continuous evaluation of toxicit y in the cohort expansio ns will be performed throughout 
enrolment in the expansio n cohorts.  If the rate of DLT -equival entevent s exceeds 33% in the 
first 2 cy cles, the findings will be discussed and further enrolment may be interrupted.  If an 
expansio n cohort is discont inued due to toxicit y, a new cohort may be init iated at a previously 
tested l ower dose level.
6.2.3. Study Completion and End of Trial
Study  com pletionoccurs (that is, the scient ific evaluat ion will be complete) fo llowing the final 
evaluat ion of pat ients’ OS.  The final evaluation may  occur before all pat ients reach the OS 
endpo int if this earlier evaluat ion will not al ter the statist ical interpretati on of  OS. Invest igators 
will cont inue to fo llow the study  schedule for all patients unt il notified otherwise by  [CONTACT_11007] .
“End of trial” refers to the date of the last visit or last scheduled proced ure for the last p atient.
6.2.4. Definitions of Study Periods 
Terms used to describe the periods during the study are defined below:
Baseline or screening (= patient entering the study):   begins when the ICF is signed 
and ends at the first study  treatm ent (or at discont inuat ion, if no treatment is given).
Study Treatment Period:   begins at the first study treatment (= patient is enrolled in 
the study) and ends on the date the decisio n to di scontinue the patient fro m combinat ion 
treatm entor if the patient has previously  discontinu ed fro m 1 or the 2 study  drug, ends on 
the date the decisio n to discont inue the patient from remaining study drug .  
Safety Follow -Up:  
begins the day  after the pati ent and the invest igator agree that the 
patient will no l onger continue combinat ion treatment and includes [ADDRESS_1200545] igator agree that the 
patient will no l onger continue study  treatm ent and lasts approximately  30days.  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 44
Galunisertib (LY2157299) /nivolumabo100-Day Follow -U p begins the day  after the 30-day follow-up visit and lasts 
approximately  
70days or app roximately 100 days after the patient is no longer 
receiving study  treatm ent.  
oLong -Term Follow -
Upbegins the day  after 100 -day follow-up is com pleted and 
continues unt il the pat ient’s death or end of trial (approximately  every 12 weeks
± 7daysthe pati ent will be contact[INVESTIGATOR_530]).  
Study Completion :occurs (that is, the scient ific evaluat ion will be co mplete) fo llowing 
the final analysis/evaluat ion of OS.  
End of Trial:   
The term “end of trial” refers to the date of the last visit or last scheduled 
procedure for the last patient (includes fo llow-up peri ods).  The end of trial occurs after 
study  com pletion,and after the last patient has discontinued study  treatm ent and 
completed the 100 -day follow-up (if applicable).
6.3. Discontinuations
If a patient withdraws informed consent, he or she must not be contact[CONTACT_133392] n and consent.  Lilly may cont inue to use previously co llected 
medical research data prior to the withdrawal consistent with the original authori sation.
6.3.1. Discontinuation of Patients Inadvertently Enrolled
The cri teria for enrolment m ust be fo llowed explicit ly. If the invest igator site ident ifies a patient 
who did not meet enrolment criteria and who was inadvertent ly enrolled, the sponsor must be 
notified.   If the sponsor ident ifies a pat ient who did not meet enrolment criteria and who was 
inadvertent ly enro lled, the invest igator site will be notified. A discussio n must occ ur between 
the sponsor CRP and the invest igator to determine whether the patient may cont inue in the study , 
with or wi thout invest igational product.   Inadvertent ly enro lled pat ients may be maintained in the 
study  and on investi gational product when the LillyCRP agree swith the invest igator that it is 
medically appropriate for that patient. The patient may not continue on study  treatm ent if the 
Lilly CRP does not agree with the invest igator’s determinat ion that it is medically  appropri ate for 
the pati ent to conti nue. The invest igator must ob tain documented approval from the Lilly CRP 
to allow the inadvertently enrolled patient to continue in the study  with or wi thout invest igational 
product.
6.3.2. Discontinuation of Patients 
Patients will  be discont inued fro m the study  drug and/or from the study  in the fo llowing 
circumstances:
Enrolment in any other clinical trial involving an investigational product or enrolment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study .
Invest igator/physician decisio n
othe invest igator/physician decides that the patient should be discontinued from the 
study or study drug(s)
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 45
Galunisertib (LY2157299) /nivolumaboif the pat ient, for any  reason, requi res treatm ent with another therapeutic agent 
that has been demo nstra ted to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  drug(s) occurs prior to introduction of the other 
agent
Patientdecision
othe patientor the pati ent’s designee (for example, legal guardian) requests to be 
discontinued from the study or study  drug .  
Sponsor decision
oSponsors stop the study  or stops the patient’s participat ion in the study  for 
medical, safet y, regul atory , or other reasons consistent with applicable laws, 
regul ations, and good clinical pract ice (GCP)
The patient is nonco mpliant with study  procedures and/or treatment (Section 7.6).
The patient experiences unacceptable toxicit y.  If the pat ient discont inues from 1 study  
treatm ent due unacceptable toxicity(see Sect ion [IP_ADDRESS].[ADDRESS_1200546] ion [IP_ADDRESS].3 for nivo lumab discont inuation), the pati ent shoul d cont inue on the 
other study  treatm ent.  
The patient beco mes pregnant.
The reason for and date ofdiscont inuat ion from study treatment will be co llected for all pat ients.  
The Date of Discont inuat ion(for any  of the above reasons) from study treatment is to be reported 
on the case report form ( CRF).  
Patients who discont inue from study  treatm ent will have 
follow-up proced ures performed as shown in the s tudy schedule ( Attachment 1 ).
6.3.3. Patients Lost to Follow -Up
A pat ient would be considered lost to fo llow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_17066].
6.3.4. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ethical review board 
(ERB) of the study  site judges it necessary for any  scientific, m edical , safet y, regul atory , ethi cal, 
or other reason s consi stent wi th applicable laws, regulat ions, and GCP .
6.3.5. Discontinuation of the Study
The study  will be di scontinued if Lilly , while considering the rights, safet y, and well -being o f the 
patient(s), judges it necessary  for any  scientific, medi cal, safet y, regulat ory, ethi cal, or other 
reasons consistent with applicable laws, regulations, and GCP .
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 46
Galunisertib (LY2157299) /nivolumab7.Treatment
7.1. Materials and Supplies
7.1.1. Galunisertib
Galunisertib (50 m g) will  be supplied in open -label blister packs or other appropriate packaging 
of uncoated, round white tablets.  Galunisertib (80 and 150 m g) will be supplied in open -label 
blister packs or other appropriate packaging of film- coated, paracapsule -shaped tablets that are 
light y ellow/yell ow in appearance .  No  prem edicatio n is required for galunisertib.
All materials must be stored at room temperature within temperature range specified on the 
materi al label in the original container and to keep out of the reach of children.  Tablets should 
not be opened, crushed, or disso lved.  The material will be labelled according to regul atory  
requi rements of the country .  Shoul d the ty pe of clinical tri al material  packaging change, it will 
adhere to country -specific regulat ions.  
The tablet sshoul d rem ain in the blister pack until just prior to administration.
Clinical stu dy materials will be l abelled according to the country ’s regul atory  requi rements .  
7.1.2. Nivolumab
Nivo lumab Inject ion, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to 
opalescent, colourlessto pal e yellow liquid, which may contain light (few) particulates. The 
drug product is a sterile, nonpyrogenic, single -use, isotoni c aqueous sol ution formulated at 
10mg/mL in sodi um citrate, sodi um chloride, m annitol, diethylenetriaminepent aacetic acid 
(penteti c acid), and polysorbate 80 (Tween TM80), pH 6.[ADDRESS_1200547] presentations is the vial fill vo lume.
Clinical study  materials will be l abelled according to the country ’s regul atory  requi rements.
7.2. Study Drug Administration
The invest igator or designee is responsible for:
explaining the correct use of the investigational agents and planned duration of 
each individual’s treatment to the site personnel or patient/legal representative
verifying that instructions are fo llowed properly
maintaining accurate records of study  drug di spensati on, destructi on,and 
collect ion, and returning or destroying all unused medicat ion to Lilly or its 
designee at the end of the study
verifying co mpletion of patient diary for galunisertib dosing during Cycles 1and 2 
of both Phase 1b and 2
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 4 7
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bPat ient s will be i nstr ucte d t o c o ntact t he i n vesti gat or as s o o n as p ossi ble if t he y ha ve a c o m plai nt 
or pr o bl e m wit h t he st u d y dr u g(s) s o t hat t he sit uati on ca n be assesse d.
7. 2. 1. D o si n g S c h e d ul e
T his st u d y  defi nes [ADDRESS_1200548] a n ne d d urat i on of treat me nt is n ot fi xe d; pat ie nts will re mai n o n st u d y treat me nt u ntil t he y 
f ulfil [ADDRESS_1200549] u d y  disc o nti n uati on ( Secti o n 6. 3 ).  Patie nts de m o nstrati n g a be nefit 
fr om treat me nt ma y c o nti n ue o n t he c o m bi nat i on t hera p y.
G al u niserti b
Eac h patie nt will ta ke g alu niserti b orall y 1 4 da ys o n ( Da ys 1 t o 1 4) / 1 4 da ys off ( Da ys 1 5 t o 2 8) . 
I n t he P hase 1b p art of  t he st u d y, g alu nisert i b will be gi ve n i n a d ose -escalati o n sc he ma ; i n t he 
P hase 2 , galu niserti b will be gi ve n at t he P hase 1 b selecte d d ose.  
 
 
 
 
 
  
 
 
 
 
 
 
Ni v ol u m a b
P ati e nts s h o uld recei ve ni v o l u ma b at a d ose of 3 m g/ k g as a 3 0 -mi n ute I V i nf usi o n, o n Da ys 1 
a n d 1 5 of eac h treat me nt c ycle.  
D o si n g calc ulati ons s h o ul d be base d o n t he b o d y  w eig ht assesse d at baseli ne.  It is n ot necessar y  
t o recalc ulate s u bse q ue nt d oses if t he patie nt’s wei g ht is wit hi n 1 0 % of t he wei g ht use d t o 
calc ulate t he pre vio us d ose .  All d oses s h o ul d be r o u n de d t o t he nea rest milli gra m.  C CI
C CI
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 48
Galunisertib (LY2157299) /nivolumabNivo lumab may  be dosed wi th no fewer than [ADDRESS_1200550] ion, 100 mg/10 mL (10 mg/mL) and 40 mg/mL (10 mg/mL)
Nivo lumab injection is to be administered at a dose of 3 mg/kg as a [ADDRESS_1200551] ion 
can be infused undiluted (10 mg/mL) or diluted with 0.9% Sodium Chloride Inject ion, USP or 
5%Dextrose Inject ion, USP to protein concentrations as low as 0.35 mg/mL.  In structi ons for 
dilution and infusio n of nivo lumab injection may be provided in the clinical protocol, pharmacy 
binder, or pharmacy reference sheet .  Care must be taken to assure sterilit y of the prepared 
solution as the product does not contain any  antimic robial preservative or bacteriostatic agent .  
No incompat ibilities between nivo lumab and polyvinyl chl oride, non -PVC/
non-(di(2-ethylhexyl)phthalate) IV components, or glass bottles have been observed.
Clinical study  materials will be l abelled according to the country ’s regul atory  requi rements .  
7.2.2. Phase 1b Dose Escalation
The MTD (or PAD) of galunisert ibdefined during Phase 1b will be used for Phase 2 .  
Four dose levels will be investigated ( Table JBEF .6.
1).  Dose escalat ion isdescribed in 
Secti on7.2.2.2 .
Because this is a dose-escalation partof the study , data will  be evaluated on an ongoing basis 
until the MTD , or PAD ,is determined .  
Safety data, in particular AEs, will be the primary  criteria for the dose escalation.  In addit ion, if 
available at the time of dose
-escalat ion decisio n, PKwill be used as secondary /supporting data 
for dose escalat ion.  No  dose escalat ion can occur without prior discussio n and agreement 
between the invest igator and the Lilly study  team s; the decisio n will be documented in writ ing.  
Based on the ongoing safety  reviews, m odificat ions to the dose -escalat ion strategy  or other 
design elements may be made via protocol amendment to ensure patient safet y.
No intrapatient dose escal ation is allowed during Phase 1b wit hin Cycle s1 or 2.  Intrapatient 
dose reduction is permitted for a DLT if a lower dose of galunisertib has been established to be 
safe in combinat ion with nivo lumab and the patient, in the opi[INVESTIGATOR_3078] n of th e invest igator and the 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 49
Galunisertib (LY2157299) /nivolumabLilly physician, is deriving benefit.  Subsequent cycles may be dose adjusted as outlined in 
Secti ons [IP_ADDRESS].1 ,[IP_ADDRESS].2 , [IP_ADDRESS].1 ,and [IP_ADDRESS].2 .
Dose escalat ionwill be based on the number of DLTs experienced during Cycle s 1 and 2 .
[IP_ADDRESS]. Dose -Limiting Toxicity Determination and Maximum Tolerated Dose 
Definition
DLT i s defined as an AE during Cycle s 1or 2 (8 we eks) that is possibly related to either study  
drug and fulfils any 1 of the fo llowing cri teria using the National Cancer Ins titute’s (NCI ’s) 
CTCAE v ersion4.03:
  CTCAE Grade 3 nonh aematol ogic toxici ty.  Excepti ons that will not be 
considered a DLT are :
onausea, vo miting,diarrh oea, and constipation that can be controlled wit h 
treatm ent
ofatigue relieved by [CONTACT_9075], limit ing self -care and/or activit ies of daily  living
oanorexia not associated with significant weight loss (weight loss of 
>10% baseline) or malnutrit ion (eg, inadequate oral caloric and/or fluid 
intake); tube feeding or total parenteral  nutritionindicated
oGrade 3 elevations of ALT and/or AST, without evidence o f other hepatic 
injury , in the setting of preexist ing hepat ic metastasis and baseline elevation 
of these val ues may  not be considered a DLT if agreed by  [CONTACT_861313]
CTCAE Grade 4 h aematol ogical toxicity of >5 days durat ion
any febrile neutropenia
≥CTCAE Grade 3 thrombocy topeni a with clinically  significant bl eeding
for nivo lumab, any toxicit y occurring during Cycles 1 or 2 managed by 
[CONTACT_861314] [IP_ADDRESS] .
any other significant toxicit y deemed by  [CONTACT_861315] (for example, any  toxicity that i s 
possibly  related to the study  medicat ion that requires the withdrawal o f the pati ent 
from the study  during Cycles 1 or 2)or resul ts in the pat ient getting <75% of the 
total doses or l eads to hol ding galunisertib for >2 weeks
Although no i ntrapati ent dose escalat ion or reducti on is allowed, f or the purposes of patient
management, DLTs will lead to dose interruption regardless of the cycle in which a DLT occurs 
(see Section [IP_ADDRESS] for specific guidelines).
For the purpose of this study , the MTD i s defined as the highest tested dose that has less than 
33% probabilit y of causing a DLT.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 50
Galunisertib (LY2157299) /nivolumab7.2.2.2. Dose -Escalation Method
Cohorts 1 and 2
A 3+ 3 +3 design will be used to assess the safet y of galunisertib given in combinat ion with 
nivolumab 3 mg/kg.  The dosages during dose escalat ion are provided in Table JBEF .6.1.  The 
DLT observat ion peri od will last for [ADDRESS_1200552] 75
% of the cohort -specified doses of galunisert ib were taken (see 
Secti on7.6.3 ).  Patients who receive fewer than 3 out of 4 nivo lumab doses or less than 75% of 
galunisertib doses for reasons other than AEs or DLTs shoul d be repl aced.
Cohorts 3 and 4
A 3 + 3 + 3 design will be used to assess the safet y of galunisert ib given in co mbinat ion with 
nivolumab 3 m g/kg. The dosages during dose escalat ion are provided in Table JBEF .
6.1.  The 
DLT observat ion peri od will last for [ADDRESS_1200553] 
3patients in each dose level co mplete the DLT period and the fourth patient discont inues for 
non
-DLT reasons prior to complet ing the DLT period, the dose l evel will be considered 
successfully co mpleted.  Thus, depending on the number of DLTs observed, the minimum 
number of evaluable patients will be 3, 6,or 9.  For the cohort expansio ns,up to 4 pati ents will 
be enrolled to ensure the minimum number of eval uable pat ients is achieved (6 or 9 patients).
For the purpose of making decisio ns on dose escalation fro m a safet y perspect ive, patients will 
be considered evaluable if they have received at least [ADDRESS_1200554] 75% of the cohort -specified doses of 
galunisertib were taken (see Section 7.6.3 ).  Patients who receive fewer than 3 of 4 nivolumab 
doses or <75% of galunisertib doses for reasons other than AEs or DLTs should be replaced if 
the minimum number of evaluable pat ients has not been reached.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 51
Galunisertib (LY2157299) /nivolumabIf no DLTs occur in a cohort of 3 or 4 evaluable patients at the lower dose level, a new 
cohort of 4 patients will be treated at the higher dose level.
If 1 of 3 or 4 evaluable pat ients experiences a DLT, up to 4 addit ional pat ients (dose level 
expansio n) will be enro lled into the cohort so that a minimum of 6 patients will be evaluable.   
The dose escalat ion can proceed if the DLT rate is <33%. If the DLT rate is 33%, up to 
4additional patients (dose l evel expansio n) will be enrolled into the cohort so that a 
minimum o f 9 pati ents will be evaluable. The dose escalat ion can proceed if the DLT rate is 
<33%. If the DLT rate is ≥33%, then that dose level will be determined to have exceeded the 
MTD or the intended maximum dose of galunisertib.
If the DLT rate is >33% (for example, 2 of 3 or 4 evaluable pa tients experiences a DLT ),that 
dose level will  be determined to have exceeded the MTD or the intended maximum dose of 
galunisertib.
[IP_ADDRESS]. Pharmacologically Active Dose 
The PAD of a targeted agent is not necessarily the same as the MTD.  The PAD of galunisertib
will be assessed using an appropriate pharmacodynamic marker.  
7.2.3. Phase 2Cohort Expansion
Once the safet y profile o f all doses tested has been characteri sed and the MTD or PAD of 
combined administration o f galunisertib and nivo lumab has been defined in the Phase 1b part, 
the cohort expansions will be init iated.  
The Phase 2part of the study  will initially include 2expansio n cohorts (NSCLC and HCC [n= 
approximately  25patientsper cohort ]). Additional cohorts of patients with specific alternative 
tumour hi stologies may be added and woul d requi re a protocol  amendment .  If DLT -equivalent 
toxicities occur in 33% or more of patients within a tumo ur
-specific cohort expansio n, then 
investigators and the Lilly CRP will assess the nature and severit y of these toxi cities. No 
additional patients will be accrued unt il this safet y review is completed and a decisio n is made 
either to continue at the curren t dose or to deescalate the dose and define a new dose for the 
expansio n phase .  Treatment in all [ADDRESS_1200555] of 3 mg/kg nivo lumab IV on Days 1and 
15and galunisertib given orally at the dose determined during the Phase 1
bpart on a schedule of 
14days on/14 days off (taken on Days 1- 14).  A cycle is 28days.  
Continuous evaluation of toxicit y in the cohort expansio ns will be performed throughout 
enrolment in the expansio n cohorts.  If the rate of DLT -equivalent events exceeds 33% inthe 
first 2 cy cles, the findings will be discussed and further enrolment may be interrupted.  If an 
expansio n cohort is discont inued due to toxicit y, a new cohort may be init iated at a previously 
tested l ower dose level.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 52
Galunisertib (LY2157299) /nivolumab7.2.4. Dose Adjustments ,Delays , or Discontinuation from Study Drug
[IP_ADDRESS]. Galunisertib Dose Adjustments andDelays , Criteria for Resumption of 
Galunisertib Treatment, and Discontinuation for Phase 1 band 2
[IP_ADDRESS].1. Galunisertib Dose Adjustments and Delays
During Phase 1b Cycle s 1and [ADDRESS_1200556] ions 7.2.4. 1.2and [IP_ADDRESS] .
Table JBEF .7.1summarizes dose adjust ment for pati ents experiencing the following events that 
are considered possibly related to galunisert ib during Phase 1 bCycle 3and bey ond and during 
Phase 2.  Gal unisert ib will be omitted until the event resolves .
Table JBEF .7
.1. Dose A djustments for Galunisertib
Events Possibly Related to Galunisertib Adjustment
ANC <0.5x10 9/L for longer than 7 days, or 
ANC <1.0x10 9/L with a single temperature of 
>101F/38.3 C or a sustained temperature of 
>100.4 F/38C for >1 hourGalunisertib will be omitted until the event resolves .  
In Phase 1b, no dose reduction is permitted; in Phase 2, 
galunisertib should be reduced by 1 (Phase 1b) cohort 
dose level (see Table JBEF.6.1).   If the event has not 
recovered by [CONTACT_2006] 1 of the subsequent cycle, then 
galunisertib should be permanently discontinued.
Platelet count <25x10 9/Lor platelet count <50 x 10 9/L 
with bleedingGalunisertib will be omitted until the event resolves .  
In Phase 1b, no dose reduction is permitted; in Phase 2, 
galunisertib should be reduced by 1 (Phase 1b) cohort 
dose level (see Table JBEF.6.1).   If the event has not 
recovered by [CONTACT_2006] 1 of the subsequent cycle, then 
galunisertib should be permanently discontinued.
CTCAE Grade 3 or 4 nonh aematologic toxicity Galunisertib will be omitted until the event resolves .  
In Phase 1b, no dose reduction is permitted; in Phase 2, 
galunisertib should be reduced by 1 (Phase 1b) cohort 
dose level (see Table JBEF.6.1).   If the event has not 
recovered by [CONTACT_2006] 1 of the subsequent cycle, then 
galunisertib should be permanently discontinued.  
Abbreviations:  ANC = absolute neutrophil count; CTCAE = Common Terminology Criteria for Adverse Events.
[IP_ADDRESS].2. Criteria to Resume Treatment with Galunisertib
Patients m ay resume treatm ent wi th galunisert ib when the drug-related AE(s) resolve(s) to 
Grade ≤1 or baseline, with the fo llowing except ions:
Nonh aemato logic toxi city must resolve to CTCAE Grade 0, 1, or baseline level before 
resuming treatment (with the except ion of alopecia, fat igue, skin rash, nausea, vo miting, 
constipation, or diarrhoea that can be controlled with treatment).  
Haematol ogic toxi city must resolve to a l evel that, in the opi[INVESTIGATOR_3078] n of the invest igator, is 
reasonable to allow for continuat ion of treatment.
Patients with baseline Grade [ADDRESS_1200557]/ALT or total bilirubin who require dose delays for 
reasons other than a 2- grade shift in AST/ALT or to tal bilirubin may resume treatment in 
the presence o f Grade [ADDRESS_1200558]/ALT OR total bilirubin .
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 53
Galunisertib (LY2157299) /nivolumabIf dosing is delayed for galunisertib -related AEs such that the patient cannot resume galunisert ib 
treatm ent by  [CONTACT_2006] [ADDRESS_1200559] the dosage redu ced to the next lower 
(Phase 1b) dose l evel ( see Table JBEF .6.1).   If the Phase 2 galunisert ib dose is 50 m g QD, no 
dose reduction will be allowed .  
If galunisert ib dosing is o mitted during the 14 -day dosing period, dosing with galunisert ib may 
resum e within that same 14- day dosi ng period, to conclude as originally scheduled ,if the patient 
has adequately  recovered from  the toxi city that requi red the g alunisert ib to be held. If the 
galunisertib cannot resume during that 14 -day dosing period, it should continue to be held until 
Day 1 of the next cy cle.  
If both galunisertib (see directions above) and nivo lumab (see direct ions in Section [IP_ADDRESS].1 ) are 
held, each drug may be resumed per the direct ions for each individual drug .  
In case of a dose delay o f galunisert ib, pati ents can conti nue nivolumabtreatm ent (at invest igator 
discreti on).
No pati ent will have his/her galunisert ibdose reduced more than once.  Reescalat ion to the 
previous galunisert ibdose is acceptable in the absence o f continuing toxicit ies.  If subsequent 
galunisertib dose reducti on is requi red after reescalati on, the pati ent m ust be maintained at the 
reduced dose level for all remaining cycles.  
[IP_ADDRESS].3. Discontinuation from Galunisertib
If dosing is delayed for galunisertib -related AEs such that the patient cannot resume galunisert ib 
treatm ent by  [CONTACT_2006] [ADDRESS_1200560] the dosage reduced to the next lower (Phase 1b) dose level (see Table JBEF .
6.1).  If 
the Phase 2 galunisertib dose is 50 mg QD, no dose reduction will be allowed. If in the 
investigator’s opi[INVESTIGATOR_861280] y is related to both study  drugs, both drugs should be withheld.   
If moderate or severe heart valve toxicit ies are observed o r a patient develops an aneurysm , the 
patient m ust immediately be discont inued from galunisertib treatm ent (f or defini tions see 
Attachm ent 10 , incl uding references on the ECHO assessment based on the Guidelines of the 
American and European Societ ies of Cardiac Echocardiography ).  These events will be 
considered serious AEs (SAEs) and should be reported to Lilly per standard SAE reporting 
requi rements (Table JBEF .8.
1).  Exceptions to this rule must be approved by [CONTACT_861316].   
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 54
Galunisertib (LY2157299) /nivolumabPatients with combined Grade [ADDRESS_1200561]/ALT AND total bilirubin value s meeting discont inuat ion 
param eters shoul d have treatm ent permanent ly discontinued.
If a patient experi ences an AEthat requires the patient be discontinued from galunisert ib, the 
patient shoul d continue on nivo lumab (if the pati ent has not previ ously  metdiscont inuation 
criteria for nivol umab) .  If in the invest igator’s opi[INVESTIGATOR_3078] n the toxi city is related to both study  drugs, 
both drugs should be held.
[IP_ADDRESS]. Nivolumab Dose Adjustments and Delays , Criteria for Resumption of 
Nivolumab Treatment, and Discontinuation in Phase 1 band 2
Intra patient dose escalat ion
sor reducti ons of nivo lumab arenot allowed in eit her Phase 1b or 
Phase 2.  
[IP_ADDRESS].1. Nivolumab Dose Adjustments and Delays
Dose delay  criteria specified below apply  for all  nivol umab -related AEs. Nivo lumab must be 
delayed unt il treatment can resume.   There will be no dose reductions for nivo lumab.
Nivo lumab administration should be delayed for the fo llowing:
Any Grade ≥2 nonskin, drug
-related AE, with the following except ions:
oGrade 2 drug -related fat igue or laborat ory abnormalit ies do not require a 
treatm ent delay
Any Grade 3 skin, drug -related AE
Any Grade [ADDRESS_1200562], ALT, or total bilirubin:
oGrade [ADDRESS_1200563], ALT, or total bilirubin that is wit hin normal 
limits, delay dosing for drug -related Grade ≥[ADDRESS_1200564], ALT, or total bilirubin wit hin the Grade 1 toxicit y 
range, delay dosing for drug -related Grade ≥[ADDRESS_1200565], ALT, or total b ilirubin 
within the Grade 2 toxicit y range, del ay dosing if these becom e 2x baseline levels 
during the study .  
Any AE, laboratory  abnorm ality, or intercurrent illness which, in the judg ement of the 
investigator, warrants delaying the dose of study  medi cation
If nivolumab dosing is o mitted on Day s1 or 1 5of a cycle, dosing wit h nivolumab will be
resum ed 14 days later (next scheduled dose) as per the or iginal  schedule if the pati ent has 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 55
Galunisertib (LY2157299) /nivolumabadequately  recovered from  the toxi city that requi red the nivo lumab to be held . If the nivolumab
cannot be resumed on the fo llowing Day  1 or 15, it shoul d continue to be held until the next 
Day 1or 15.  Galunisertib shoul d continue as scheduled.
If both g alunisertib (see directions in Sect ion [IP_ADDRESS].1 ) and nivo lumab (see direct ions above) are 
held, each drug may be resumed per the direct ions for eac h individual drug.  
[IP_ADDRESS].2. Criteria for Resumption of Nivolumab Treatment
Patients m ay resume treatm ent wi th nivo lumab when the drug -
related AE(s) resolve(s) to 
Grade ≤1 or baseline, with the fo llowing except ions:
Patients m ay resume treatm ent in the presence of Grade 2 fat igue
Patients who have not experienced a Grade 3 drug -related skin AE may  resume treatm ent 
in the presence of Grade 2 skin toxicit y 
Patients wi th baseline Grade [ADDRESS_1200566]/ALT or total bilirubin who require dose delays for 
reasons other than a 2-gr ade shift in AST/ALT or total bilirubin may resume treatment in 
the presence o f Grade [ADDRESS_1200567]/ALT OR total bilirubin
Drug -related pulmo nary toxicity, diarrh oea, or coliti s must have resol ved to baseline 
before treatment is resumed. Patients with persistent Grade [ADDRESS_1200568] 1 month may be eligible for retreatment if 
discussed wi th and approved by  [CONTACT_92338]
Drug -related endocrinopathies adequately controlled with only physio logic horm one 
replacement m ay resume treatm ent after consultation with the Lilly  CRP
Dose delay  of nivo lumab which results in treatment interruption of >6 weeks require treatment 
discontinuat ion, wi th except ions as noted above.  
[IP_ADDRESS].3. Discontinuation from Nivolumab 
Nivo lumab treatment shou ld be permanent ly discont inued for the fo llowing:
any Grade 2 drug -related uveit is, ey e pain or bl urred visi on that does not respond to 
topi[INVESTIGATOR_475026] 1 severit y within the retreatment period 
OR requi res systemic treatment 
any Grade 3 nonskin, drug -related AElasting >[ADDRESS_1200569] ions, and endocrinopathies:
oGrade [ADDRESS_1200570] acement do not requi re discont inuat ion
oGrade 3 drug -related laboratory abnormalit ies do not require treatment 
discontinuat ion except:
oGrade 3 drug -related thrombocytopenia >7 day s or associ ated wi th bleeding requi res 
discontinuat ion
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 56
Galunisertib (LY2157299) /nivolumabany drug- related liver funct ion test abnormalit y that m eets the following criteria require 
discontinuat ion:
oAST or ALT >8xULN
ototal bilirubin >5xULN
oconcurrent AST or ALT >3xULN and total bilirubin >2xULN
ofor HCC pati ents only:
oAST or ALT >10xULN for >[ADDRESS_1200571] or ALT >15xULN irrespect ive of durat ion
oTotal  bilirubin >8xULN i rrespect ive of durat ion for patient s with elevated 
bilirubin at study  entry  or >5xULN for those with normal total bilirubin at entry
oConcurrent AST or ALT >3xULN and total bilirubin >5xULN for patients 
entering treatment with a norm al bilirubin and up to 8xULN for patients with 
elevated bili rubin
Patients wi th combined Grade [ADDRESS_1200572]/ALT AND total bilirubin values meeting 
discontinuat ion parameters should have treatment permanent ly discont inued .
any Grade 4 drug -related AEor laboratory abnormalit y, except for the following events 
which do not require discont inuat ion:
oGrade 4 neutropenia 7 days
oGrade 4 lymphopenia or leukopenia
oisolated Grade 4 amylase or lipase abnormalit ies that are not associated with 
symptoms or clinical manifestati ons of  pancreat itis. The Lilly CRP shoul d be 
consulted for Grade 4 amylase or lipase abnormalit ies.
oisolated Grade 4 electroly te imbalances/abnorm alities that are not associated with 
clinical sequelae and are corrected with supplementation/appropriate management 
within 72 hours of their onset
oGrade 4 drug -related endocrinopathy  AEs (such as adrenal insufficiency, 
adrenocorti cotropi c horm onedeficiency, hyper thyroi dism or hy pothy roidism, or 
glucose intol erance )which resolve or are adequately  controlled with physi ologic 
horm one repl acement (corti costeroi ds, thy roid horm ones) or gl ucose -controlling 
agents, respectively, may not require discont inuation after discussio n with and 
approval  from the Lilly CRP
any event that leads to delay  in dosing last ing >6 w eeks fro m the previous dose requires 
discontinuat ion, wi th the f ollowing exceptions:
oDosing delays to allow  for prolonged steroid tapers to manage drug -related AEsare 
allow ed. Prior to reinitiating treatment in a patient with a dosing delay lasting 
>6weeks from the previous dose, the Lilly CRP must be consulted. Tumour 
assessments should continue as per protocol even if dosing is delayed. Periodic study 
visits to assess safety and laboratory studies should also continue every 6 w eeks or 
more frequently if clinically indicated during such dosing delays.
oDosing delays lasting >6 weeks from the previous dose that occur for 
nondrug -related reasons may be allow ed if approved by [CONTACT_242934] . Prior to 
reinitiating treatment in a patient with a dosing delay lasting >[ADDRESS_1200573] be consulted. Tumour assessments should continue as per protocol even if 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 57
Galunisertib (LY2157299) /nivolumabdosing is delayed. Periodic study visits to assess safety and laboratory studies should 
also continue every 6 w eeks or more frequently if clinically indicated during such 
dosing delays.
any AE, laboratory  abnorm ality, or intercurrent illness which, in the judg ement of the 
investi gator, presents a substant ial clinical risk to the patient wit h cont inued nivo lumab 
dosing
If a pat ient experiences an AE that requires the patient be discontinued from nivo lumab, the 
patient shoul d continue on gal unisert ib (if the patient has not previously met discont inuation 
criteria for gal unisert ib).If in the invest igator’s opi[INVESTIGATOR_3078] n the toxi city is related to both study  
drugs, both drugs should be held.  
7.2.5. Study Treatment beyond Disease Progression by [CONTACT_150115] 1.1
Accumulat ing evidence indicates a minorit y of patients treated with immunotherapy  may derive 
clinical benefit despi[INVESTIGATOR_470318] ( PD).  
Nonglioblastoma Patients
Nonglioblastoma patientstreated with nivo lumab and galunisert ib will be permitted to continue 
treatm ent bey ond ini tial RECIST versio n1.1–defined PDif they meet the following criteria:
investi gator -assessed clinical benefit and do not have rapid disease progression
tolerance of study  drug s
stable performance status
treatment beyond progression will not delay an imminent intervent ion to prevent serious 
complicat ions of disease progressi on (eg, CNS m etastases)
patientprovides written informed consent prior to receiving addit ionalnivolumab 
treatm ent, using an ICF describing any reasonably  foreseeable risks or di scomf orts, or 
other alternat ive treatment options
The decisio n to continue treatment should be discussed with the Lilly  CRP and docum ented in 
the study  records.  A radiogra phic assessment/scan should be performed wit hin 8weeks o f 
original  PDto determine whether there has been a decrease in the tumo ur size or continued PD.  
The assessment of clinical benefit should be balanced by  [CONTACT_861317]/galunisertib.  If the investigator feels that the nivo lumab/galunisert ib patient 
continues to achieve clinical benefit by  [CONTACT_43893], the patient should remain on the 
trial and cont inue to receive monitoring according to Attachment 1 .  For the patients who 
contin ue nivo lumab/gal unisertib study  therapy  beyond progressi on, further progression is 
defined as an addit ional 10% increase in tumo ur burden vo lume from time of init ial PD.  Thi s 
includes an increase in the sum of all target lesio ns and/ or the development of new measurable 
lesions.  Treatm ent shoul d be discont inued permanent ly upon documentation of further disease 
progression.  New lesio ns are considered measurable at the time of init ial progressio n if the 
longest di ameter is at l east 10 mm (except for pathol ogical lymph nodes which must have a short 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 58
Galunisertib (LY2157299) /nivolumabaxis o f at least 15 mm).  Any new lesio n considered nonmeasurable at the time of init ial 
progression may  becom e measurable and therefore included in the tumo ur burden vo lume if the 
longest di ameter increases to at least 10 mm (except for pathological lymph nodes which must 
have a short axis of at least 15 mm).  
Global deterioration of healt h status requiring discontinuat ion of treatment without object ive 
evidence of disease progression at that time should be repor ted as “symptomat ic deterioration .”  
Every  effort shoul d be made to document object ive progression (ie, radiographic confirmat ion) 
even after discont inuat ion from treatm ent.
Glioblastoma Patients
Standard treatment for glio blastomas (including radiat ion therapy  and tem ozolomide) may  resul t 
in a transi ent increase in tumou r enhancement (pseudoprogression) in a subset of patients that 
eventually subsides wit hout any  change in therapy .  Pseudoprogressi on m ay be difficult to 
different iate fro m true tum our progression and may have important implicat ions for pati ent 
management.  In order to minimis e premature di scontinuat ion of study  medicati on and 
distinguish pseudoprogression fro m PD, 
patients init ially meeting radio logic criteria for di sease 
progression ma y continue receiving study  medication until confirmat ion of progression with an 
MRI performed approximately [ADDRESS_1200574] be met :  
1) T he patient is believed to demonstrate clinical benefit as determined by [CONTACT_1275] .  
2)The patient is tolerating study  medicat ion.  
Patients wi th confirmed progression (approximately  12 weeks after init ially assessed 
progression) will discont inue stu dy medicat ion and enter the fo llow-up/survival phase of the 
study .  If progressi on is confirmed, then the date of disease progression will be the first date the 
patient met the criteria for progression. In those cases in which radio logic progressi on canno t be 
different iated fro m pseudoprogression and it is the investigator’s opi[INVESTIGATOR_160781] a surgical resect ion 
to obtain tumo ur tissue for hi stopathol ogy is in the patient’s best interests, a surgical resect ion 
may be performed fo llowing consultat ion with the Lilly CRP . Tumou
r biopsy  samples (bl ocks 
or slides) must be submitted for central review by a neuropathologist to minimi se any 
interobserver variat ion in the histopathologic assessment of progression versus treatment -related 
changes. If tumo ur pathology  confirms progression, then the patientwill be discont inued fro m 
study  medicat ion per protocol discont inuat ion criteria and the date of progression will be the day  
that it was fi rst suspected. If tumo ur pathology  reveals treatm ent-related changes and does not 
confirm disease progression, the patientmay cont inue study  medicat ion. An MRI after the 
resection is required prior to treatment continuat ion. The patientwill then continue all 
on-treatment tumo u
r assessments as per the treatment schedule (Attachment 1 ).  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 59
Galunisertib (LY2157299) /nivolumabCentral Neuropathologic Review  of Tumo ur Samples after Biopsy or Resection 
In those cases in which radio logic progressi on cannot b e different iated fro m pseudoprogression 
and the patientundergoes a biopsy or diagnost ic surgical resect ion to obtain tumo ur tissue for 
histopathology  analysis, representative tumo ur tissue samples will be reviewed locally and 
submitted for central review by a neuropathol ogist. If there is discordance between the central 
and local neuropathologic determinat ion of progressio n versus treatment -associ ated changes 
(pseudoprogression), then a second central neuropathologic review will be performed and serve 
as the final adjudicat or of  the histopathologic determinat ion.Central review of histopathology  
will be blinded to the patient treatm ent arm  assignment. Specific instructions will be provided to 
the invest igative sites regarding the requirements for submiss ion of tum o
ur tissue for central 
neuropathologic review. If tumo u
r tissue is not available for central neuropathology  review, the 
reasons for not submitting t issue for central review must be clearly  documented by  [CONTACT_861318] .
7.2.6. Management Algorithms for Immuno -Oncolo gy Agents
Immuno-oncol ogy agents are associ ated wi th AEs that can differ in severit y and durati on than 
AEs caused by [CONTACT_20451]. Nivo lumab is considered an immuno -oncol ogy agent in 
this protocol . Early recognit ion and management of AEs ass ociated wi th immuno -oncol ogy 
agents may mit igate severe toxicit y. Management 
algorithms have been developed to assist 
investigators in assessing and managing the fo llowing groups of AEs:
GI
renal
pulmo nary
hepatic
endocrinopathy
skin
neurol ogical
The above algorithms are found in Attachment [ADDRESS_1200575] with fever, chills, rigo urs, headache, rash, pruritus, arth ralgias, 
hypotension, hypertensio n, bronchospasm, or other allergic -like reactions. All Grade 3or4 
infusio n reactions shoul d be reported within 24 hours to the Lilly CRP and reported as SAE sif 
anymeet the criteria. Infusio n reactions should be graded according to NCI CTCAE 
(version4.03
) guidelines.   No blood sample will be collected with any infusio n reaction .  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 60
Galunisertib (LY2157299) /nivolumabTreatment recommendat ions are provided below and may be modified based on local treatment 
standards and guidelines, as appropriate:
For Grade 1 symptoms :  (mild reaction; infusion interruption not indicated; intervent ion not 
indicated):
Remain at bedside a nd m onitor patient until recovery from symptoms. The fo llowing 
prophylact ic premedications are recommended for future infusio ns:  diphenhydramine 
50mg (or equivalent) and/or acetaminophen/paracetamo l [ADDRESS_1200576] 
30minutes before addit ional n ivolumab administrations.
For Grade 2 symptoms :  (moderate reacti on requi red therapy  or infusio n interrupti on but 
responds prompt ly to symptomatic treatment (eg, ant ihistamines, nonsteroidal ant i-inflammatory  
drugs, narcotics, corticosteroids, bronchodilat ors, IV fluids); prophylact ic medicat ions indicated 
for 24 hours):
Stop the nivo lumab infusio n, begin an IV infusio n of norm al saline, and treat the patient
with diphenhydramine 50 m g IV (or equivalent) and/or acetaminophen/paracetamol 
325to 1000 mg; remain at bedside and monitor patient until reso lution of symptoms. 
Corti costeroi d and/or bronchodilator therapy  may also be administered as appropriate. If 
the infusion is interrupted, then restart the infusio n at 50% of the original infusio n rate 
when sy mptom s reso lve; if no further complicat ions ensue after 30 minutes, the rate may 
be increased to 100% of the original infusio n rate. Moni tor patient closely. If symptoms 
recur, then no further nivolumab will be administered at that visit.
For future infu sions, the fo llowing prophylact ic premedications are recommended :  
diphenhydramine 50 m g (or equivalent) and/or acetaminophen/paracetamo l [ADDRESS_1200577] 30 minutes before nivo lumab infusio ns. If 
necessary , corti costeroi ds (up to 25 mg of Solu- Cortef ®or equivalent) may be used.
For Grade 3 or 4 symptoms :  (severe reaction, Grade 3 :  prolonged [ie, not rapi[INVESTIGATOR_53892]/or brief interruption of infusio n]; recurrence of symptoms 
following init ialimprovement; hospi[INVESTIGATOR_861281] (eg, renal 
impairment, pulmo nary infiltrates). Grade 4 :  Life-threatening; pressor or vent ilatory  support 
indicated):
Immediately discontinue infusio n of nivo lumab. Begin an IV infusio n of norm al saline 
and treat the patientas fo llows:  Reco mmend bronchodilators, epi[INVESTIGATOR_238] 0.2 to 1 mg of 
a 1:1000 sol ution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10 000 
solution injected slowly for IV administration, and/or diphenhydrami ne 50 mg IV with 
methylpredniso lone 100 m g IV (or equivalent), as needed. Patient shoul d be m onitored 
until the invest igator is comfortable that the symptoms will not recur. Nivolumab will be 
perm anent ly discont inued. Investigators should fo llow their i nstitutional guidelines for 
the treatment of anaphylaxis. Remain at bedside and monitor patient until recovery o f the 
symptoms.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 61
Galunisertib (LY2157299) /nivolumabIn case of late -occurring hypersensit ivity symptoms (eg, appearance of a locali sed or generalis ed 
pruri tus wi thin 1 week after treatm ent), symptomatic treatment may be given (eg, oral 
antihistamine or corticosteroids).
7.3. Method of Assignment to Treatment
This study  is open -label for Phase 1b and Phase 2. No dose escalat ions (that is, to the next 
cohort) can occur without prior discussion and agreement between the invest igator and the 
responsible Lilly CRP or clinical research scient ist (CRS ); the decision will be documented in 
writing. All pat ients must b egin study  treatm ent wi thin 7 days of enro lment by [CONTACT_861319]
-
response system ( IWRS ).
For Phase 1b , if investigators have eligible patients who have consented concurrently, more than 
3patients (Cohorts 1 and 2) or 4 patients (Cohorts 3 or 4) may be entered at a particular dose 
level provided that accrual has not ceased due to excessive toxicit y.  This enrolment procedure is 
allowed because of the advanced disease state of this pat ient populat ion and the screening 
involved in defining eligibil ity.  This event should be approved by [CONTACT_861320].
All patients who enter Phase 2will be assigned to nivolumab /galunisert ib combinat ion therapy
by [CONTACT_10966].  
7.4. Blinding
The ent ire study  is open label.
7.5. Concomitant Therapy
Growth factors and ery thropoi etin are allowed per American Societ y of Clinical  Oncol ogy or 
National Com prehensive Cancer Network guidelines.  Granulocy te col ony-stimulating factors 
must be discont inued at least [ADDRESS_1200578] ic corticosteroi ds (such as, 
predniso lone, m ethylpredniso lone or dexamethasone) to pr event transfusio n react ions.  No other 
therapy , including routine use of growth factors or experimental medicat ions (for example, 
immunotherapy  or other not approved medication) will be permitted while the pat ients are on the 
study .  
Immunosuppressive age nts (eg, cyclosporine) will not be allowed , except for glio blastoma for 
which low
-dose corticosteroids will be permitted (eg ,prednisone 10 mg [approximately 
equivalent to 2 mg of dexamethasone ] or less daily or equivalent dose of other corticosteroid).
Immu nosuppressive doses of systemic steroids will not be allowed except as outlined in
Attachm ent 11 .  
Any concurrent ant ineoplastic therapy (ie, chemotherapy, hormonal therapy, immunotherapy, 
extensive, nonpalliat ive radiat ion therapy , or standard or invest igational agents for treatment of
NSCLC ,HCC, or any other tumo urtype) will  not be all owed.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 62
Galunisertib (LY2157299) /nivolumabPatients are permitted the use of topi[INVESTIGATOR_2855], ocular, intra- articular, intranasal, and inhalat ional 
corticosteroi ds (wi th minimal systemic absorption). Adrenal replacement steroid doses >10 mg 
daily predniso ne are permitted. A brief (less than 3 weeks) course of corticosteroids for 
prophylaxis (eg, con trast dy e allergy ) or f or treatment of nonautoimmune condit ions (eg, 
delayed -type hypersensi tivity react ion caused by a contact [CONTACT_20435]) is permitted .
Patients shoul d receive full supportive care during the trial.  Appropriate documentation for all 
forms of prem edicat ions, supportive care, and concomitant medicat ions must be captured for 
each cy cle in the CRF.  Concomitant palliat ive and supportive car e for disease -related symptoms 
(including bisphosphonates and RANK -L inhibitors) is allo wed if init iated prior to first dose of 
study  therapy . Prior palliat ive radiotherapy must have been co mpleted at least [ADDRESS_1200579] 1 week before, during and 1 week after radiat ion. Patients should be closely 
monitored for any  potenti al toxi city durin g and aft er receiving radiotherapy , and AEs shoul d 
resolve to Grade ≤1 prior to resuming nivo lumab. In the NSCLC cohort, nontarget brain lesio ns 
andnontarget bone lesio ns wi thout lung tissue included in the planned radiat ion field may 
receive palliat ive radiotherapy . Details of palliative radiotherapy should be documented in the 
source records and eCRF. Details in the source records should include :  dates of treatment, 
anatomical site, dose administered and fract ionation schedule, and AEs. If warranted, symptom s 
requi ring palliat ive radiotherapy should be evaluated for object ive evidence of disease 
progression.  
In addit ion, any disease progression requiring other forms of specific antitumo ur therapy  will 
also necessitate early discont inuat ion from the study .  Appropri ate docum entati on for all  forms 
of prem edicat ions, supporti ve care, and concomitant medicat ions must be captured on the CRF.  
Replacement hormonal therapy initiated before study  entry  will be all owed.
Concomitant use of strong CYP3A4 inhibitors and inducers is prohibited in Phase 1b to 
minimi se the influence of potential drug interactions on the galunisertib /nivo lumab combinat ion.  
See Attachm ent 12 for guidance on restricted medications .
All conco mitant m edicat ions should be recorded throughout the patient’s participat ion in the 
study .
7.6. Treatment Compliance
7.6.1. Galunisertib Compliance
Patient com pliance wi th galunisert ib will be assessed at each visit.  Compliance will be assessed 
by [CONTACT_81257], review of diary (diary  for Cycles 1 and 2 only ), and counting returned 
tablets.  Devi ations from  the prescribed dosage regimen should be recorded on the CRF.  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 63
Galunisertib (LY2157299) /nivolumabFor patients who are significant ly nonco mpliant (<75% of expected study  drug taken in a visit 
interval ), invest igative site personnel must counsel patients on the importance of study drug 
compliance and drug accountabilit y.  Pati ents who are consistently out of the compliance range 
may be discont inued.  If these patients are discont inued for reasons other than A Es or DLTs, they  
shoul d be repl aced. A Lilly representative should be contact[CONTACT_861321].  
The fo llowing procedures will be empl oyed to ensure appropri ate drug accountabilit y:
Drug accountabilit y will be emphasi sed at the start- up m eeting.
Drug accountabilit y will be monitored throughout the study .
Each patient should be instructed to return all study -drug packaging and unused material 
to the study  site at each visi t.  The study  site will  keep a record of all drug dispensed to 
and returned by  [CONTACT_861322] .  Study  site personnel  will return or 
destroy  (as requested) all unused study  drug for all pati ents.
P
atients will  keep a study  diary  for the first 2 cy cles (56 days) to document that they  are taking 
galunisertib as prescribed.
7.6.2. Nivolumab Compli ance
Nivo lumab will be administered IV at the invest igational si te, under the di rection of the 
investigator.  As a result, a patient’s co mpliance wit h study  drug administration is ensured.  
Patients shoul d attend scheduled clinic visit s and must comply  with study  criteria under thei r 
control .  Deviat ion(s) fro m the prescribed dosage regimen should be recorded on the CRF.  
7.6.3. Evaluable Phase [ADDRESS_1200580] 2 cycle sof 
study  treatm ent (56 days) will be deemed nonevalu able for assessment of a dose level and may  
be replaced within the same dose level, unless they experience a DLT prior to withdrawal. If the 
patient is noncom pliant during Cycle [ADDRESS_1200581] ive, patients will 
be considered evaluable if :
they have received at least [ADDRESS_1200582] 2 cycles 
(56days)
they took at least 75% of the cohort -specified dose of galunisert ib
Patients who have received less than 3 out of 4 nivolumab do ses or less than 75% of galunisert ib 
doses for reasons other than AEs or DLTs should be replaced.  In addition, in Phase 1 b, pati
ents
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 64
Galunisertib (LY2157299) /nivolumabwith dosing del ays in Cycles 1 and 2 of ≥[ADDRESS_1200583] igator(s) and the Lilly CRP or CRS to ensure adequate PK data, 
unless accrual to that cohort has stopped due to a DLT.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 65
Galunisertib (LY2157299) /nivolumab8.Safety , Pharmacokinetic, Pharmacody namic, and 
Efficacy Data Collection
8.1. Safety Evaluations
Safety is the primary endpoint of this Phase 1b/2study  as determined by  [CONTACT_861323] 4.03.  All patientswho receive at least one dos e of galunisertib or nivo lumab will be 
evaluated for safet y as measured by [CONTACT_621363], SAEs, deaths, laboratory  
abnorm alities, and weight and weight c hange fro m baseline, assessed during treatment and for 
approximately  [ADDRESS_1200584] regularly scheduled study  visit s at the clinical site as shown in the s tudy 
schedule ( Attachm ent 1 ).  Safet y assessments including AE co llection, laboratory  assessments, 
vital sign collecti on,oxygen saturati on by  [CONTACT_737468] (al so m onitor am ount of 
supplemental  oxygen if applic able) ,weight, medical history  (screening only )and physical 
examinat ions will be performed during the study . Addit ionally , peri pheral  blood will  be 
assessed for HBV DNA, HCV RNA , and HCC antiviral act ivity.  
Imaging studies will be performed every [ADDRESS_1200585] 
will be administered if applicable.  Other clinical laboratory  tests will also be collected.  
Study  procedures and their timing are described in the study schedule ( Attachment 1 ).  
Attachm ent [ADDRESS_1200586] igator remains responsible for fo llowing, through an appropriate healt h care option,
AEs that are serious , considered related to study treatment or the study ,or that caused the patient 
to discont inue before completing the study .  The pati ent shoul d be f ollowed unt il:  
the event is resolved, 
the event is no longer considered to be drug- related, 
the event beco mes stable or returns to baseline, 
a new treatment is init iated for the patient, or
the pati ent di es or is l ost to foll ow-up.  
Frequency of AEand SAE follow-up evaluati on is left to the discret ion of the invest igator.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 66
Galunisertib (LY2157299) /nivolumabThe timing of all safet y evaluat ions is shown in the study schedule ( Attachment 1 ).  
Table JBEF .8.1presents a summary o f AE and SAE reporting guidelines.  Table JBEF .8.1also 
shows which database or system is used to store AE and SAE data .
8.1.2. Adverse Events
Lilly has standards for reporting AEs that are to be fo llowed regardl ess of applicable regulatory  
requi rements that m ay be less stringent.  A clinical study  AE is any untoward medical occu rrence 
in a pati ent or clinical invest igation subject administered a pharmaceut ical product and which 
does not necessarily  have a causal  relati onship wi th this treatm ent.  An AE can therefore be any  
unfavo urable and unintended sign (including an abnormal l aboratory  finding), symptom, or 
disease tem porally associ ated wi th the use of m edicinal (invest igational) product, whether or not 
related to the medicinal (invest igational) product .  Any clinically  significant findings from 
laboratory  resul ts, vital sign m easurements, etc, that occur should also be reported to Lilly or its 
designee as an AE .  
Lack of drug effect is not an AE in clinical studies because the purpose of 
the clinical study  is to establish drug effect.
The invest igator, monitor, and sponsor will review the collected data regularly for evidence of 
AEs.  All pat ients will be assessed routinely for AEs as outlined in the study  schedule.  All AEs 
observed will be graded using CTCAE v ersion4.03.
The NCI CTCAE v ersion4.03will serve as the reference document for choosing appropriate 
termino logy for, and grading the severit y of, all AEs and other symptom s. All AEs observed 
will be graded using CTCAE v ersion4.0.  Any minor version of CTCAE v ersion4.0 (for 
example, version 4.03) may be used for thi s study .  Minor CTCAE v ersion4.[ADDRESS_1200587] ingthe 
appropriate sy stem  organ cl ass and assessing severit y grade based on the intensit y of the event.  
Note that both CTCAE term (actual or coded) and severit y grade m ust be sel ected by  [CONTACT_861324].  This co llection is in addition to verbat im text used to 
describe the AE.
In addit ion to collect ing the AE verbat im, the CTCAE term, and the CTCAE severit y grade, AE 
verbat im text will also be mapped by [CONTACT_861325] (MedDRA) dict ionary.
Cases of pregnancy that occur during maternal or paternal exposures to study  drug shoul d be 
reported.  Data on foetaloutcom e and breast feeding should be collected, if feasible, for 
regul atory  reporting and drug safet y evaluat ion.
Upon docum entati on of  pregnancy , the pati ent m ust be rem oved from  the study  and treatment 
with study  drugs m ust be stopped immediately.
In addit ion to AEs and pregnancy events as noted above , the f ollowing safet y informat ion is 
collected, even in the absence o f an AE:overdose, medicat ion error, drug
-drug interaction and 
cases o f suspected transmissio n of infect ious agents via study  drug and drug -induced liver injury.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 67
Galunisertib (LY2157299) /nivolumabFor all enrolled pat ients, study  site personnel will record the occurrence and nature of each 
patient’s preexist ing condit ions, including clinically  significant si gns and symptoms of the 
disease under treatment in the study .  While the pati ent is on study , site personnel will re cord any  
change in these preexist ing condit ion(s) and the occurrence and nature of any  AEs.  In addit ion 
all AEs related to protocol  procedures are reported to Lilly or desi gnee.
If a patient’s dosage is reduced or treatment is discontinued as a result of an AE, study  site 
personnel must clearly  report to Lilly  or its desi gnee via CRF the circumstances and data leading 
to any  such dosage reduction or discont inuat ion of treatm ent.  
Invest igators will be instructed to report to Lilly or its designee their as sessment of the potential 
relatedness of each AE to protocol procedure, study  drug via CRF.
The invest igator decides whether he or she interprets the observed AEs as ei ther rel ated to 
disease, to the study  medicat ion, study  procedure, or other concomitant treatm ent or pathologies.  
To assess the relat ionship of the AE to the study  drug, the fo llowing termino logies are defined:
Related:   a direct cause and effect relat ionship between the study  treatm ent and 
the AE i s likely.
Possibly related:   a cause and effect relat ionship between the study  treatm ent and 
the AE has not been demonstrated at this time and is not probable, but is also not 
impossible.
Unrelated:   without question, the AE is definitely not associated with the study  
treatm ent.
As per Lilly’s standard operating procedures all “related” and “possibly  related” AEs and SAEs 
will be defined as related to study  drug.
[IP_ADDRESS]. Serious Adverse Events
Planned surgeries should not be reported as SAEs unless the underlying medical condit ion has 
worsened during the course of the study .
Planned hospi [INVESTIGATOR_861282]’s medical history  at the time of study enrolment shoul d not be 
considered SAEs.  Hospi[INVESTIGATOR_861283] a preci pi[INVESTIGATOR_88291] (for example, for the administration of study therapy or other protocol -requi red 
procedure) should not be considered SAEs.
An SAE is any  AEduring thi s study  that resul ts in 1 of the f ollowing outcom es:
death
initial or prolonged inpatient hospi[INVESTIGATOR_73256] (except for study  drug 
administration)
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 68
Galunisertib (LY2157299) /nivolumabcongenital anomaly/birth defect
considered significant by  [CONTACT_240235] m edical events that may not result in death, be life -threatening, or require 
hospi [INVESTIGATOR_861284], based on appropriate medical judg emen t, they  
may jeopardi se the pati ent and m ay requi re medical  or surgi cal intervent ion to prevent one of the 
outcom es listed in this definit ion.  
SAEs due to disease progression, including death, should not be reported unless t he investigator
deems them to b e possibly related to the study  drug.
Study  site personnel  must al ert Lilly or its desi gnee of  any SAE within [ADDRESS_1200588] igator becomes aware of SAEs occurring afte r the pati ent’s partici pation in the tri al 
has ended, and the invest igator believes that the SAE is related to a protocol procedure or study 
drug, the invest igator should report the SAEs to the sponsor, and the SAEs will be entered in the
Lilly Safety  Syst em.
Reco mmendat ions for reporting SAEs may  be found in Attachm ent 5 .
Inform ation on SAEs expected in the study  popul ation independent of drug expos ure and that 
will be assessed by  [CONTACT_92356].  
[IP_ADDRESS]. Adverse Event and Serious Adverse Event Reporting
Data on SAEs that occur before the end of trial will be stored in the col lection database and the 
Lilly S afety  
System .
[IP_ADDRESS].1. Prior to Administration of Study Drugs
AE or SAE collection begins after the patient has signed informed consent and has received 
study  drug.  If a pati ent experi ences an AE or SAE after signing informed consen t but pri or to 
receiving study  drug, only  AEs and SAEs related to protocol procedures are required to be 
collected.
[IP_ADDRESS].2. On Therapy
All AEs and SAEs, regardless of relatedness to study  drugs or protocol  procedures, occurring 
while the patient is receiving study drug m ust be reported to Lilly or its designee.  A patient is 
considered to be receiving study  drug from  the time he/she receives the first dose of study  drug 
to when he/she receives the last dose of study  drug.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 69
Galunisertib (LY2157299) /nivolumab8.[IP_ADDRESS]. Follow -Up Visit s
All AEs and SAEs , regardless of relatedness to study  drug(s) or protocol procedures, occurri ng 
during the safet y follow-up visit s occurring at approximately [ADDRESS_1200589] be reported to Lilly or its designee (Attachment 1 ).  
For the Phase 1 b part only, fo llowing the safet y assessments (which occur after the patient 
discontinues from  study  treatm ent) whi ch mark the end of the follow -up visi t, the pati ent will  be 
discontinued fro m the study , unless there is an ongoing AE or SAE that is possibly  related to 
study  drug or protocol procedures .  In this instance, the patient should be fo llowed in subsequent 
follow-up visits unt il the event is resolved, the event is no longer considered to be drug -related, 
the event beco mes stable or returns to baseline, a new treatment is init iated for the patient, or the 
patient dies or i s lost to f ollow -up.
For the Phase 2
partonly, f ollowing the safet y assessments (which occur after the patient 
discontinues from  study  treatm ent)which mark the end of the follow -up visi t, the pati ent will  be 
followed only for survival (overall and 6, 12, and 18 months) , unless there is an ongoi ng AE or 
SAE that is possibly related to study  drug or protocol procedures .  In this instance, the patient 
shoul d be f ollowed in subsequent fo llow
-up visi ts unt il the event is reso lved, the event is no 
longer considered to be drug -related, the event become s stable or returns to baseline, a new 
treatm ent is init iated for the patient, or the patient dies or is lost to fo llow-up.
If it is deemed to be in the best interest of the patient to start a new ant icancer treatment prior to 
the scheduled end of the fo llow-up visit, the fo llow-up vi sit durati on may  be shortened. In this 
case, the fo llow-up assessments should be co mpleted prior to the init iation of the new therapy.
After the fo llow-up visit s, AEs are not required to be reported unless the invest igator feels the 
AEs were rel ated to ei ther study  drug, drug delivery  system , or a protocol  procedure. If an 
investigator becomes aware of SAEs believed to be related to protocol procedures or study  drug , 
theinvest igator should report the SAE to the sponsor, and the SAE will be entered in the Lilly  
Safety System .
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are SAEs that are not listed in the
Develo pment Core Safet y Informati on(galunisert ib IB Section 7) or Reference Safet y 
Inform ation for Adverse Drug Reactions (nivo lumab IB Section 5.6) and that the invest igator 
ident ifies as related to study drug or procedure.  The [LOCATION_002] [ADDRESS_1200590] ive 2001/20/EC ,and the associated detailed guidances or nati onal 
regul atory  requi rements in partici pating countri es requi re the reporting of S[LOCATION_003]Rs.  Lilly has 
procedures that will be fo llowed for the recording and expedi ted reporting of S[LOCATION_003]Rs that are 
consistent with glo bal regulatory  regul ationsand the associated detailed guidances.
[IP_ADDRESS]. Summary of AE/SAE Reporting Guidelines
The AE and SAE reporting guidelines are summari sed in Table JBEF .8.
1.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 70
Galunisertib (LY2157299) /nivolumabTable JBEF .8.1. Adverse Event and Serious A dverse Reporting Guidelines for 
Study H9H-MC-JBEF
Timing Types of AEs/SAEs ReportedCollection 
DatabaseLilly Safety 
System
Prestudy (baseline assessments)
(Starts at the signing of informed 
consent and ends just before the 
first dose of study drug)Preexisting conditions
All AEs
All SAEs regardless of relatedness x
x
x x
On therapy
(Starts at first dose of study 
drug[s] and ends at last dose of 
study drug [s])All AEs
All SAEs regardless of relatednessx
x x
Follow -up v isits
(Starts just after the last dose of 
combinatio n treatment and ends 
when end of study safety 
assessments are completed 
[2visits at approximately [ADDRESS_1200591] dose of study 
drugs ])All AEs
All SAEs regardless of relatednessx
x x
Subsequent follow -up visits, if 
necessary for patient monitoring Ongoing AEs possibly related to 
study drug(s) or protocol procedures
All SAEs related to protocol 
procedures or study drugx
x x
Patient no longer on study All SAEs related to protocol 
procedures or study drug that the 
investigator becomes aware ofx
Abbreviations:  AEs = adverse events; SAEs = serious adverse events.
8.1.3. Other Safety Measures
[IP_ADDRESS]. Detection of Aneurysm Formation of the Ascending Aorta and Aortic 
Arch (Thoracic View)
MRI or CT scan wit h contrast of the chest will be performed and assessed locally at the site at
baseline screening and every [ADDRESS_1200592] be used throughout the 
study  for that pati ent.  
[IP_ADDRESS]. Electrocardiograms
For each patient, a 12 -lead ECG will be co llected a s indicated in Attachm ent 1 and 
Attachm ent 4 .  Please see Attachm ent 4 for specific ECG times matched wit h PK blood draws.
For each patient, 12-lead digital ECGs will be obtained as single ECGs according to the study 
schedule ( Attachm ent 1 ).  Pati ents m ust be supi[INVESTIGATOR_17044]  [ADDRESS_1200593] ion.  ECGs may  be obtained at addit ional times 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 71
Galunisertib (LY2157299) /nivolumabwhen deemed clinically  necessary .  Collecti on of  more ECGs than expected at a particular time 
point is allowed when needed to ensure hi gh-quali ty records.
ECGs will be interpreted by  a qualified physician (the invest igator or qualified designee) at the 
site as soon after the time of ECG collect ion as possible and ,ideally ,while the patient is st ill 
present, to determine whether the patie nt meets entry  criteria and for immediate patient 
management, should any clinically relevant findings be identified.
If a clinically significant quantitative or qualitat ive change fro m baseline is ident ified after 
enrolment , the invest igator will assess th e pati ent for sym ptoms (for example, palpi[INVESTIGATOR_53895], near 
syncope, syncope) and to determine if the pat ient can cont inue in the study .  The invest igator or 
qualified designee will be responsible for determining if any  change in patient m anagement i s 
needed a nd must docum ent hi s/her review of the ECG printed at the time of evaluat ion.
All digital ECGs will be electronically  transmi tted to a central  ECG l aboratory  designated by  
[CONTACT_11007].  A cardio logist at the central  ECG l aboratory will then conduct a full overre ad on the ECG 
(including all intervals); a report based on data from this analysis will be issued to the 
investigat ive site.  All data from the overreads will be placed in the Lilly database for analyt ical 
and study -report purposes.
It is recogni sed that E CG interpretations by [CONTACT_093] (or qualified designee) and by [CONTACT_672590] l aboratory  may be different.  When there are differences in ECG 
interpretati on between the invest igator (or qualified designee) and the cardio logist a t the central 
ECG laboratory , the invest igator (or qualified designee) interpretation will be used for study  
entry  and immediate subject management.  Interpretations fro m the cardi ologist at the central  
ECG laboratory  will be used for data analysis and rep ort-writing purposes.
The invest igator (or qualified designee) must document his/her review of the ECG printed at the 
time of evaluat ion, the final overread ECG report issued by [CONTACT_81131] , and any  
alert reports.
Other safet y measures include assessments of physical examinat ions, preexist ing condit ions, 
transfusio ns and hospi[INVESTIGATOR_692532], and AEs.  Pati ents will  be assessed before each visit by  [CONTACT_861326] v4.0.
[IP_ADDRESS]. Echocardiography/Doppler
Echocardi ography  with Doppl er will be l ocally  assessed for enrolment and safet y decisio ns by 
[CONTACT_861327].  Individuals so 
qualified must be identified at each site. The same person should be responsible for reading the 
ECHOs on any  individ ual study  patient.  ECHOs will be as indicated in Attachment [ADDRESS_1200594] for data analysis and study  report wri ting purposes.  
Cardi otoxi city: ECHO/Doppler imaging will include the fo llowing assessments and other 
standard evaluat ions (see Attachm ent 10 ):  an increase of 1 or more grades in the 
semiquantitative valvular insufficiency, LVfunction, or right ventricular systolic pressur e 
(norm al, mild, m oderate, severe based on local laboratory  limits).  After a normal baseline 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 72
Galunisertib (LY2157299) /nivolumabECHO, if a subsequent ECHO demonstrates an abnormalit y, then a repeat ECHO should be 
perform ed after 14 days.  If results confirm the abnormalit y at repeat ECHO, then the patient will 
be discont inued fro m study  treatm ent.  If findings are normal, then the patient will cont inue 
treatm ent per study  protocol .  If patient has clinically significant cardiac findings at 30 -day 
follow-up visit, ECHO will be repeated every 2 cycl es (approximately  every 2 m onths).  If no 
clinically significant cardiac findings at the last cardiac assessment conducted within the las t 
30days and pati ent has started another treatment, 30 -day follow-
up visit will not be performed.  
If no clinic ally significant cardiac findings at 30 -day follow
-up vis it, 1 m ore ECHO will be 
perform ed after 2 m onths unless the patient is receiving another treatment.  If the patient is 
receiving another form of treatment, further cardiac assessments will not be per formed.
[IP_ADDRESS]. Cardiotoxicity Serum Markers as Determined by [CONTACT_861328]/Doppler, the fo llowing serum markers will be fo llowed f or increases:
BNP:  an increase in BNP above [ADDRESS_1200595] which is 
sustained at 2consecutive, scheduled blood draws
troponin I:  above the ULN (with testing confirmatio n at the central laboratory )
cystati n C
See Attachment 1 for timing.
[IP_ADDRESS]. Pulse Oximetry
Patients will  have assessments of oxy gen saturati on by [CONTACT_737468] (al so m onitor 
amount of supplemental oxygen if applicable) at screening and during the study  (Attachm ent 1 ). 
If a patient shows changes on pulse oximetry or other pulmo nary-related si gns (hypoxia, fever) 
or symptoms (eg ,dyspnoea, co ugh, fever) consistent with possible pulmo nary-related si gns 
(hypoxia, fever) or symptoms (eg, dyspnoea , cough, fever) consistent with possible pulmo nary 
AEs, the patientshoul d be immediately  evaluated to rul e out pulm onary toxicity, according to 
the susp ected pulmo nary toxicit y management algorithm in Attachment [ADDRESS_1200596] operating procedures.   The 
Lilly CRP/CRS will, as is appropriate, consult with t he functionally  independent Gl obal Pati ent 
Safety therapeuti c area physician or CRS , and periodically review:
trends in safety  data
laboratory  analy tes
AEs
If a study  patient experiences ≥Grade [ADDRESS_1200597] igator.  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 73
Galunisertib (LY2157299) /nivolumabExcept for patients with liver metastases or HCC, for any pat ient who experiences 
elevated ALT > 3xULN and elevated total bilirubin >[ADDRESS_1200598] igator.  
For pati ents with liver m etastases or HCC entering the study wit h ALT between ULN and 
5xULN, m onitoring shoul d be tri ggered at ALT >2xbaseline.
Details for hepat ic monitoring depend upon the severit y and persistence of observed laboratory  
test abnorm alities.  To ensure patient safety  and comply  with regulatory  guidance, the 
investigator is to consult with the Lilly CRP/CRS regarding collect ion of specific reco mmended 
clinical informat ion and fo llow-up laboratory  tests (see Attachm ent 3 ).
8.1.5. Complaint Handling
Lilly collects complaints on study  drugs used in clinical studies in order to ensure the safet y of 
study  participants, m onitor quali ty, and f acilitate process and product improvements.
Com plaint s related to nivolumab or concomitant drugs are reported direct ly to the manufacturers 
of those dr ugs in accordance with the package insert.
The invest igator or his/her designee is responsible for handling the fo llowing aspects of the 
complaint process in accordance with the instructions provided for this study :
recording a complete descript ion of the complaint reported and any associated AEs using 
the study -specific co mplaint forms provided for this purpose
faxing the completed complaint form within [ADDRESS_1200599] igation, he/she will return a copy  of the 
product complaint form with the product.
8.2. Sample Collection and Testing
Attachm ent [ADDRESS_1200600] ions in this study.
Attachm ent 2 lists the spe cific tests that will be performed for this study .  
Attachm ent 3 lists the hepat ic monitoring tests for treatment -emergent abnormalit ies.  
Attachm ent 4 contains the PK, bio marker ,and immunogenicit y sampling schedules.
8.2.1. Samples for Study Qualification and Health Monitoring
Bloodwill be co llected to determine whether patients meet inclusio n/exclusio n criteria and to 
monitor pati ent heal th.
New baseline tumo ur biopsies (defined as a biopsy specimen taken since complet ion of the prior 
systemic regimen [see Incl usion Criterion 4 in Sectio n 6.1.1 ])are required at screening for all 
patients other than glioblastom apatients .  
For glioblastoma patients at screening, either new
biopsy or archived tumo ur tissue is required.  
Due diligence should be used to ensure that tumo ur specimen (not normal adjacent or tum ou r 
margins) is provided.  Pathology  notes accom panying the ti ssue willalso be requested.   
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 74
Galunisertib (LY2157299) /nivolumabInvest igators must document their review of each laboratory  safety  report.
Samples co llected for specified laboratory tests will be destroyed wit hin60 days of receipt of 
confirmed test results.  Tests are run and confirmed prompt ly whenever scient ifically 
appropriate.  When scientific circumstances warrant, however, it is acceptable to retain samples 
to batch the tests run, or to retain the samples u ntil the end of the study  to confirm  that the resul ts 
are valid.  Certain samples may be retained for a longer period, if necessary, to comply wit h 
applicable laws, regulat ions, or l aboratory  certificati on standards.
8.2.2. Samples for Drug Concentration Measurem ents 
Pharmacokinetics/Pharmacodynamics
PK and pharmacodynamic samples will be collected as specified in Attachm ent 4 .
[IP_ADDRESS]. Pharmacokinetic Samples
At thevisits and t imes specified in the study schedul e, blood sam ples will  be collected to 
determine the plasma concentrations of galunisertib andserum  concentrations of nivolumab .  
Serum  nivo lumab PK concentrations will be measured to derive the C minand at specified visits.  
A maximum of 3samples m ay be collected at additional t ime po ints during the study  if 
warranted and agreed upon between both the investigator and Lilly. Instructi ons for the 
collect ion and handling of blood samples will be provi ded by [CONTACT_456] .  The actual date and 
time (24-hour clock time) of each sampling will be recorded.   A patient diary will co llect the 
time of all galunisertib doses taken during the first [ADDRESS_1200601] ion of galunisert ib.  Dose informat ion (dose time and amount of 
dose) m ust be collected for the day  of sampling and the [ADDRESS_1200602] patient visit f or the study .
8.2.3. Samples for Biomarker Research
To understand the relat ionship between cancer, genet ics, and response to therapy , this study  may 
analyse biomarkers relevant to galunisert ib, nivo lumab, immune cells/immune funct ioning,and 
the disease state .  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 75
Galunisertib (LY2157299) /nivolumabThe fo llowing samples are mandatory  (requi red), except as indicated otherwise:
 blood sam ples for bi omarker research (see Sect ion [IP_ADDRESS] )
 tumour tissue (newly biopsied or archived) (see Section [IP_ADDRESS] )
whole blood for DNA collect ion(pharmacogenet ic analysis) (see Sect ion8.2.4 )
Sample collect ion including blood (serum, plasma, whole blood) and tumourtissue samples will 
occur at specified time points as indicated in Attachment 1 and Attachm ent 4 .  
[IP_ADDRESS]. Blood S amples
Blood (serum , plasma, peripheral  blood m ononuclear cells, and who
le blood) will be used for the 
analyses o f biomarkers related to galunisertib, nivo lumab, immune cells/immune funct ioning 
within the disease state , and cancer -related condi tions .  Potenti al pharmacodynamic and/or 
circulat ing markers may include, but are not limited to:  disease specific markers (eg ,AFP in 
HCC) ,factors important in disease (eg ,viruses in HCC), gene expressio n,exoso me isolation and 
associ ated assays, and/orcirculat ing tumo ur DNA isolation and associated assays .  
Samples may  be stored for a m aximum of [ADDRESS_1200603] pati ent visi t for the tri al.  
[IP_ADDRESS]. Tumo ur Tissue
Collect ion of tum ou
r tissue samples (either newly  biopsied or archived) is m andatory  (requi red) 
for parti cipation in this study , as fo llows:
In addit ion to the screening requirement of collecting newly biopsied tumo
urtissue, other 
biopsies during the study  are also requi red for patients wi th cancers other than glioblastom aand 
are opti onal for pati ents wi th glioblastoma .
For nonglioblastoma patients, 2 treatment biopsy  groups will be randomly assigned by [CONTACT_861329] o f the pati ent is ori ginally enro lled by [CONTACT_10966].  For the Phase 1b partof the study ,the 
2treatm ent bi opsy groups wil l be rando mly assigned; for the Phase 2 part,the 2treatm ent bi opsy  
groups will be rando mly assigned within each cohort.  These on -treatm ent bi opsies are al so 
mandatory :
Approximately  50% of  patients will have their on-treatm ent bi opsy  on Cycle 1 Day 15 
+
3days (post second nivo lumab treatm ent).  If a patient’s second nivo lumab dose is 
delayed, the biopsy will still occur on Cy cle 1 Day 15 +3 day s.  
Approximately  50% of  patients willhave their on-treatm ent bi opsy  on Cycle 2 Day 1 
+3days (post thi rd nivo lumab treatment) .  If a patient’s third nivo lumab dose i s delayed, 
the biopsy will st ill occur on Cy cle 2 Day  1 +3 days.
If a patient with glioblastom aundergoes a biopsy for medical reasons during the study , an 
optional biopsy  should be collected at that time.
Formalin -fixed paraffin -embedded tum our ti ssue shoul d be provi ded as a block or ( minimum 
of20) unstained slides.  Due diligence should be used t o make sure that tumo u
r specimen (not a 
norm al adjacent or a tum our m argin sam ple) is provided.  Pathology  notes accom panying 
archival t issue will also be requested .  
Archived tumo ur tissue blocks will be returned to the site.  
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 7 6
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bA n y bl oc k fr o m a n o n- st u d y bi ops y , or sli des s u b mitte d or c ut fr o m t he bl oc k at a ce ntral 
la b orat or y will not be ret ur ne d .  A n y ne w t u m o u r tiss ue ac q uire d f or a patie nt o n st u d y t h at is 
o btai ne d f or st u d y  p ur p oses is se nt t o ce ntral la b orat or y for pr ocessi n g (see la b or at or y ma n ual f or 
f urt her i nstr ucti o ns).  If t he l ocal pat h ol og y  la bor at or y pr ef ers t o pr ocess tiss ue, t he n a tiss ue 
bl oc k or mi ni m u m of [ADDRESS_1200604] u d y treat me nt.
W here l ocal re g ulat i ons a n d E R Bs all o w, t hese sa m ples will be c ollecte d f or p har mac o ge net ic 
researc h as disc usse d bel o w a n d s pecifie d i n t he sa m pli n g sc he d ule ( At tac h me nt 1).
S a m ples will  be retai ne d f or a ma xi m u m of [ADDRESS_1200605] u dies, a n d e pi [INVESTIGATOR_243983] a nal yses.  
Re gar dless of t he tec h n o l og y  us e d, ge n ot ypi n g data ge nerate d will be use d o nl y f or t he s pecific 
researc h sc o pe descri be d i n t his secti on.C CI
C CI
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 77
Galunisertib (LY2157299) /nivolumab8.2.5. Samples for Immunogenicity Research
Blood sam ples to determine the occurrence of specific antidrug ant ibodies (ADAs) to nivo lumab 
will be co llected as indicated in Attachm ent [ADDRESS_1200606] pati ent visi t for the trial at a 
facilit y selected by  [CONTACT_861330].  
The durati on allows the sponsor to respond to regulatory requests related to nivolumab.
8.3. Efficacy Evaluations
The fo llowing efficacy measures will be determined:
ORR and best overall response , time to response, durati on of  response, and PFS
— using RECIST v ersion 1.1 (Attachment 8 ) for patien ts wi th NSCLC , HCC ,and 
tumou
rs other than glioblastoma
— u
sing RANO (see Attachment 9 ) for patients with glioblastom a
survival at 6, 12, and 18 months fo llowing the start of treatment
OSdetermined fro m the date of first treatment until death due to any  cause
change in ECOG performance status
Efficacy measures will be assessed as noted in Attachment [ADDRESS_1200607] 
and/or MRI, as appropriate, will be perf ormed at baseline and every  [ADDRESS_1200608] v ersion 1.1or un til patients withdraw from the study. For patients who 
are being treated beyond init ial progressio n, thesepatientsshoul d remain on study  treatm ent until 
the next assessment period.  Patients who are treated beyo nd progression will be evaluated on an 
8 (nonglioblastoma patients)-or 12 (glioblastom apatients) -week basis to determine whether they 
shoul d cont inue on tre atment.  The use of MRI is mandatory to determine tumo u
r response when 
using RANO criteria.  Brain imaging should be performed as clinically indicated. At the 
sponsor’s discretion, scans and measurements may be collected and reviewed by [CONTACT_441904] v ersion 1.1/RANO criteria at a l ater date, or at any  time during the 
study .  
To confirm object ive responses, all lesio ns should be radio logically assessed, and the same 
radiologic m ethod used for the init ial response determinat ion should be repeated at least [ADDRESS_1200609]’s report should be entered into the eCRF 
by [CONTACT_093]’s staff.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 78
Galunisertib (LY2157299) /nivolumab8.4. Procedure/Sampling Compliance
Every  attem pt will be m ade to enrol  patients who have the abilit y to understand and co mply with 
instructi ons.  Noncom pliant pati ents m ay be discont inued fro m the study .
The collection t imes of safet y assessments, PK samples, pharm acodynamic samples, and efficacy  
measurements are given as targets, t o be achieved within reasonable limits.  The scheduled time 
points m ay be subject to minor alterations; however, the actual collect ion time must be correctly 
recorded on the e CRF.  
The scheduled co llection times may be modified by [CONTACT_861331] y 
and PK informat ion obtained during the study .  Any  major m odificat ions that might affect the 
conduct of the study , pati ent safet y, and/or data integrit y will be detailed in a protocol 
amendment.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 79
Galunisertib (LY2157299) /nivolumab9.Data Management Methods
9.1. Data Quality Assu rance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start-up training to instruct the invest igators and study  coordinators.  Th is sessio n 
will give instruction on the protocol, the completion of the CRFs, and study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_47556], 
telephone, and/or fax
review and eval uate CRF data and/or use standard computer edits to detect errors in data 
collect ion
conduct a qualit yreview of the database
In addit ion, Lilly or its representatives willperiodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_82412]/or regulatory  agencies at any  time. Invest igators will be given notice before 
an audit occu rs.
To ensure the safet y of parti cipants in the study , and to ensure accurate, complete, and reliable 
data, the invest igator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patient files as original source document s for the study .  If requested, the 
investigator will provide the sponsor, applicable regulatory  agencies, and applicable ERBs wit h 
direct access to the original source documents.
9.2. Data Capture S ystems
9.2.1. Case Report Form
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  [CONTACT_92363] -provided electronic data capture system.
CRF data collected by  [CONTACT_861332]-party organi sation (TPO) will be encoded by  [CONTACT_861333]’s database system.  Validated data will subsequent ly be transferred to 
Lilly data warehouse, using standard Lilly file transfer processes.  For any data handled by [CONTACT_861334] , it will  be managed by  [CONTACT_861335]’s 
data warehouse.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system.  Data will subsequent ly be transferred fro m the central  
vendor to the Lilly ge neric lab oratory system .
Any data for which the paper documentation provided by [CONTACT_92365] i dentified and documented by  [CONTACT_92366]’s study  file.  Paper 
docum entati on provi ded by  [CONTACT_81146] , for exam ple, a paper diary  to collect 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 80
Galunisertib (LY2157299) /nivolumabpatient-reported outcome measures (for example, a rating scale), a daily  dosing schedule, or an 
event di ary.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management sy stem .
9.2.2. Ancillary Data
Data m anaged by  a central  vendor will  be stored electronically  in the central  laboratory’s 
database system.  Data will subsequent ly be transferred from the central vendor to the Lilly 
generic labs system and TPO’s system.
Bioanaly tical data will  be stored electronically in the bioanaly tical laboratory ’s database.  Data 
will subsequently be transferred fro m the bioanaly tical laboratory  to the Lilly  generi c labs 
system  and TPO’s system.
ECG data will be stored electronically in the central database system of Lilly’s central review 
organi sation.  Data will subsequent ly be transferred fro m the central  review organi sation system 
to the Lilly generic labs system and TPO’s system.
Data from co mplaint forms submitted to Lilly will b e encoded and stored in the global product 
complaint m anagement sy stem .
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 8 1
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b1 0. D at a A n al y s e s
[ADDRESS_1200610] u d y-relate d 
materi al t o be a ut h orise d b y Lill y f or p u blicati on.
Descri pt i ve statistics (i ncl u di n g mea n, sta n dar d de viat i on, a n d ra n ge) will be deri ve d w here 
a p pr o priate.  
[ADDRESS_1200611] e Si z e
F or t he P hase 1 b C o h orts 1 a n d 2 (a n d p ossi bl y  3) d ose escalat i on, a 3 + 3 + 3 desi g n will be 
use d t o assess t he safet y of  gal u niserti b i n c om bi nati o n wit h ni v o l uma b 3 m g/ k g.  Bet wee n [ADDRESS_1200612] o p o uts or d ose i nterr u pti o ns or re d ucti o ns occ ur t hat res ult i n a pat ient  bei n g 
n o ne val ua ble f or D L Ts.
F or t he P hase 1 b C o h orts 3 a n d 4 d ose escal at i on, a 3 + 3 + 3 desi g n will be use d t o assess t he 
safety of  g alu niserti b i n c o m bi nat i on wi t h ni v ol uma b 3 m g/ k g.  Bet wee n [ADDRESS_1200613] i ve re mai ns safety of  t he c om bi nat i on f or t he P hase 2 c o h ort 
e x pa nsi o n part , t he sa m ple size a p pears t o be a de q uate t o e val uate preli mi nar y a ntitu m o u r 
acti vit y of  t he c o m bi nati on. 
  
 
 
  C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 8 2
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bW he n t he [ADDRESS_1200614] 3 c y cles, a n i nteri m a nal ysis will 
be c o n d ucte d. T w o -sta ge desi g n criteria ( Si mo n 1 9 8 9) will  be use d t o e valuate w het her
a d ditio nal  patie nts f or t h at c o h ort will be e nr o lle d.  
 
 
 
1 0. 2. P ati e nt Di s p o siti o n
All patie nt disc o nt i n uati ons will be d oc u me nte d, a n d t he e xte nt of eac h pat ient ’s partici pati on i n 
t he st u d y will be re p orte d.  If k n o w n, a reas o n f or t heir disc o nti n uati o n will be gi ve n. See 
Secti o n 6. 3 .
P ati e nt e nr ol me nt a n d dis p osit i on will be s u m mari se d a n d/ or liste d b y c o h ort i n P hase [ADDRESS_1200615] u d y c o mplet i on ( Secti o n 6. 2. 4 ).  
[ADDRESS_1200616] ics will i ncl u de a s u m mar y a n d/ or listi n g b y c o h ort i n P h ase 1 b a n d i n dicat i on 
i n P hase 2 of  t he f oll owi n g:
 P ati e nt de mo gra p hics i ncl u di n g (f or e xa m ple) a ge, se x, et h nicit y /race, w ei g ht a n d c ha n ge 
i n wei g ht fr o m baseli ne, a n d scree ni n g hei g ht will be re p orte d.
 b aseli ne disease c haracteristics a n d i n P hase [ADDRESS_1200617] ol o g y  
 p rior di sease-relate d t hera pi[INVESTIGATOR_014]
 co nc o mita nt me dicat i ons
Ot her patie nt c haracterist ics will be s u m marise d as dee me d a p pr o priate.
[ADDRESS_1200618] 1 d ose of eit her gal u nisert i b or ni v ol uma b will  be e val uat e d for 
safety a n d t o xicit y. C T C A E t er ms ( b y e nteri n g t he a p pr o priate C T C A E c o de) a n d se verit y 
gra des will be assi g ne d b y  t he i n vesti gat or usi n g C T C A E v 4. 0 3 ). Ver bati m A E t er ms will be 
ma p pe d t o c orres p o n di n g Me d D R A l ower -level ter m ( L L T) ter mi n ol og y  wi t hi n t he Me d D R A 
di ct i onar y .
B ot h t he C T C A E ter ms a n d Me d D R A L L T will be ma p pe d usi n g t he Me d D R A dict i onar y 
hierarc h y  t o pr o vide P Ts a n d b o d y s yste m or ga n class ter ms f or eac h dicti onar y .  F or C T C A E 
t er ms w here “Ot her ” is i n dicate d, t he C T C A E P T s will be t he sa me as t he P T s of t he Me d D R A 
P Ts create d fr o m ma p pi n g t hr o u g h t he ver bat i ms.  All safety s u m maries will re p ort t he P T s 
create d fr o m ma p pi n g t he i n vest i gat or assi g ne d C T C A E ter m.C CI
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 83
Galunisertib (LY2157299) /nivolumabTreatment -emergent AEs will be i dentified using the CTCAE term s by [CONTACT_861336].  Where CTCAE term is “Other, ”the matching MedDRA LLT will be used to 
determine treatment emergent.
Safety analyses mayinclude , but are not limited to, summaries of the fo llowing:
AEs, treatm ent-emergent AEs ,and SAEs , including severit y and possible rel ationship to 
study  drug
dose exposure and any adjust ments
laboratory  values
DLTs at each dose level for Phase 1b and DLT -equivalent AEs for Phase 2 for Cy cles1 
and2
vital signs to include pulse oximetry  readings and wei ght/change in weight from baseline
ECGs
ECHOreadings and cardi otoxi city serum  markers (BNP, troponin I, cy statin C)
MRI/CT scans performed for detectio n of aneurysm format ion of the ascending aorta and 
aortic arch
All recorded AEs , treatm ent-emergent AEs,and SAEs will be listed and tabulated by  [CONTACT_861337] 1b and indicat ion in Phase [ADDRESS_1200619] resul ts will  be listed and summari sed by [CONTACT_861338].  Any 
significant physical examinat ion findings and results of clinical laboratory tests will be listed .  
ECGs, collected a s indicated in Attachment 1 and Attachm ent 4 ,and baseline and 8 -week ECHO 
resul ts will be evaluated by [CONTACT_093] ; abnormalit ies, if present, will be listed. Changes 
from baseline in ECG and ECHO parameters will be calculated and summari sed at each visit.
Safety data will be co mpared over time to assess change fro m baseline, during treatment, and 
follow-up.
10.5. Pharmacokinetic Analyses
PKanalyses will be conducted on patients who have received at least [ADDRESS_1200620] had samples co llected.  
For g alunisertib, popul ationapparent cl earance, volume of distribut ion,and exposure are steady  
state for galunisert ib will be calculated .  For nivo lumab, Cminconcentrations will be reported .
Summary  statistics will be tabulated for the PKparam eters of galunisertib by  [CONTACT_861339]/week.  Dose proporti onalit y of galunisert ib when coadministered with nivo lumab during
Phase 1bwill be assessed based on a power model.  Nivo lumab Cminconcentration in Phase 1b
will be tabulated by  [CONTACT_535993].  InPhase 2, sparse PK data m ay also be pool ed wi th 
other datasets for populat ion PK analysis which will be part of a separate report. Exploratory  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 84
Galunisertib (LY2157299) /nivolumabPK/pharmacodynamic analyses may be conducted to ident ify the exposure -response 
(biomarkers) relationship in thi s study .
Addit ional exploratory  analyses will be performed if warranted by  [CONTACT_831438] (for example, NONMEM) may  be used if appropriate and approved by 
[CONTACT_764517] c management.  The versio n of any  software used f or the analysis will be 
docum ented and the program will meet the Lilly  requi rements of software validation.
Log-transform ed C maxand AUC est imates will be assessed to estimate ratios of geometric 
means and the corresponding 90% CIs.
10.6. Biomarker Anal yses
For details on bio markers, see Sect ion 8.2.[ADDRESS_1200621] igated graphically to explore patterns of change 
over time, and how the patterns differ among dose levels or exposure.  If there is a meaningful 
indicat ion in the pattern over time, further analysis (eg, b y linear mixed model) may be 
perform ed to characteri se the rel ationship.  
To identify and assess bio markers for potenti altailoring purpose, associations between baseline 
biomarker m easures and clinical outcomes will be analysed using appropri ate single-m arker or 
multi-marker analysis approaches.
10.6.1. Immunogenicity
A listing will be provided of all available immunogenicit y data.  Addit ionally, a list ing of 
immunogenicit y data f rom those pati ents wi th at least [ADDRESS_1200622] overall response outcom es 
will be tabulated by  [CONTACT_861340].  The ORR and PFS and the corresponding CIwill be 
provi ded by [CONTACT_861341], and by [CONTACT_861342].  The durati on of  response and PFS 
will be estimated by [CONTACT_5263]
-Meier m ethodol ogy by [CONTACT_861343], depending on data availabilit y.  
PFS will be similarly  estimated, based on Kaplan -Meier methodol ogy.  Presentations of efficacy 
will include patientsin cohort expansio n and patients in dose escalat ion matching those in cohort 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 85
Galunisertib (LY2157299) /nivolumabexpansio n by [CONTACT_861344].  Individual changes in the tum o ur burden over time will 
be presented graphically  within a tum our ty pe.  Landmark OSwill also be assessed as part of the 
secondary  efficacy analysis by [CONTACT_5263] -Meier pl ots and m edians for each tumo ur type.  
For the NSCLC cohort, efficacy endpo ints maybe evaluated by [CONTACT_861345]-L 1 expression
and serum TGFβ -1 levels .  
For the HCC cohort, efficacy endpo ints maybe eval uated by  [CONTACT_861346]β -1 levels andtumour PD-L1 expressio n.
10.8. Interim Analyses
Since the Phase 1 bpart i s a dose -finding study , data will be reviewed on a cohort -
by-cohort basis 
during the study , until the MTD (or PAD) is determined.  The purpose of these cohort -by-cohort 
reviews is to evaluate the safet y data at each dose level and determine whether a DLT has been 
observed that would suggest MTD has been met or exceeded.  The investigators and the Lilly 
study  team  will make the determinat ion regarding dose escalat ion based upon their review o f the 
safet y and tolerabilit y data as described in this protocol .  
After all patients who are deemed evaluable for the assessment of dose levels co mplete a DLT 
evaluat ion peri od or when MTD is determined, an interim safet y and PK analysis may be 
conducted for planning next studies.
For the Phase 2 part, if DLT -equivalent toxicit ies occur in 33% or more of pat ients within a 
tumour-specific cohort expansio n, then invest igators and the Lilly CRP will assess the nature and 
severit y of these toxi cities. No addi tional patients will be enrolled until this safety r eview is 
completed and a decisio n is made eit her to continue at the current dose or to deescalate the dose 
and define a new dose for the expansio n phase. The safet y review and decisio n will  be 
docum ented in wri ting.  T rial-level safet y reviews will be con ducted approximately  [ADDRESS_1200623];only listings and summaries will be 
carried out.  
After enro lment has completed in acohort (n= approximately 25)and the la st enrolled pat ient in 
that cohort has co mpleted or had the opportunit y to com plete 3cycle sof treatm ent, an interim 
analysis wi ll be conducted for that parti cular cohort (for a total o f 2separate interim analyses to 
be conducted when each cohort reaches [ADDRESS_1200624] 3 cycles of treatm ent).The 
intent of the interim analysis i s to evaluate preliminary antitumo ur activit yof galunisert ib in 
combinat ion of nivo lumab. These interim analyse s may be combined wit h the ongoing tri a
l-
level safet y review.  Pending review o f the interim data, approximately 16 additional patients 
may be enrolled in that particular c ohort if there are more than 4 and fewer than 9patients who 
demonstrate responses (determined by  [CONTACT_3168] f or the NSCLC cohort and by  [CONTACT_861347]) .  Enrolment of the other cohort , if not completely enrolled, will not be stopped 
during the interim analysis . No independent data mo nitoring co mmittee will be requi red for thi s 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 86
Galunisertib (LY2157299) /nivolumabstudy .  The interim  analysis will be conducted by  [CONTACT_861348] 
[ADDRESS_1200625] that increased monitoring would be appropriate; this will not require a protocol 
amendment.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 87
Galunisertib (LY2157299) /nivolumab11.Informed Consent, Ethical Review, and 
Regulatory Considerations
11.1. Informed Consent
The invest igator is responsible for ensuring that the patient understands the potential risks and 
benefits of part icipating in the study, including answering any questions the patient may have 
throughout the study  and sharing in a timely manner any  new informat ion that m ay be rel evant to 
the pati ent’s willingness to continue his or her participat ion in the study  in a timely manner.
The ICFwill be used to explain the potential risks and benefits of study  parti cipat ion to the 
patient in sim ple terms before the patient is entered into the study  and to document that the 
patient is sat isfied with his or her understanding o f the potential risks and benefits o f 
participat ing in the study and desires to participate in the study.
The invest igator i s ultimately responsible for ensuring that informed consent is given by [CONTACT_365215] l egal representati ve before the study  is started.  Thi s includes obtaining the appropriate 
signatures and dates on the ICFprior to the performance o f any protocol proc edures and prior to 
the administration o f study  drug .  
11.2. Ethical Review
Lilly or its representatives must approve all ICFs before they  are used at invest igative sites(s).  
All ICFs must be co mpliant with the International Conference onHarm onisat ionguideline on 
GCP.  
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly before the 
study  may begin at the investi gative si te(s).  The ERB(s) will review the protocol as required.
The study  site’s ERB(s) shoul d be provided wi th the following:
the current IB and Package Insert, and updates during the course of the study
ICF
relevant curri cula vi tae
11.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
1) consensus ethics principles derived fro m internati onal ethics gui delines, including the 
Declaration of Helsinki and Council forInternational Organizat ionsofMedical Sciences
International Ethical Guidelines 
2) the International Conference onHarm onisat ionGCP Gui deline [E6]
3) applicable laws and regulat ions
The investigator or designee will prompt ly submi t the protocol  to applicable ERB(s).
Some of the obligat ions of the sponsor will be assigned to a TPO.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 88
Galunisertib (LY2157299) /nivolumabAn identificat ion code assigned by [CONTACT_338296]’s name [CONTACT_65146]’s ident ity when reporting AEs and/or other study -related 
data.
11.3.1. Investigator Information
Site-specific contact [CONTACT_246689] a separate document.
11.3.2. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
11.3.3. Final Report Signature
[CONTACT_58003] , indicat ing agreement t hat, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
The invest igator with the greatest technical knowledge will serve as the final report coordinating 
investigator.  If this investigator is unable to fulfil this function, another invest igator will be 
chosen by [CONTACT_57998].
The sponsor’s responsible medical o fficer and statistician will approve the final clinical study  
report for this study , confi rming that, to the best of his or her knowledge, the report accurately  
describes the conduct and results of the study .
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 89
Galunisertib (LY2157299) /nivolumab12.References
Akhurst RJ,Derynck R. TGF -beta signaling in cancer —a doubl e-edged sword . Trends Cell Biol . 
2001;11(11):S44 -S51.
Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L . B7-H1 is a ubiqui tous anti apoptoti c 
receptor on cancer cells. Blood .2008;
111:3635-3643.
Barber DL, Wherry  EJ, Masopu st D, Zhu B, Alliso n JP, Sharpe AH, Freeman GJ, Ahmed R. 
Restori ng funct ion in exhausted CD8 T cells during chronic viral infect ion. Natur e
.
2006; 439(7077):[ADDRESS_1200626] atin and paclitaxel for patients with 
previously untreated advanced non -small -cell l ung cancer. J Clin Oncol .2008; 26:468 -473.
Bhowmick NA, Chyt il A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, 
Neilso n EG, Moses HL . TGF -beta si gnaling in fibrobl asts m odulates the oncogenic potential 
of adjacent epi [INVESTIGATOR_24603]. Science .2004;303(5659):848
-851.
Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of 
cancer. Nat Rev Cancer .2006;6(7):506 -520.
Bierie B, Moses HL.  Transforming growth factor beta (TGF -beta) and inflammat ion in cancer. 
Cytokine Growth Factor Rev . 2010 ;2
1(1):49 -59. 
[BMS] Bristol -Myers Squibb. Nivo lumab (BMS -936558) Modul e 2.7.2: Summary  of Clinical  
Pharmaco logy, 19June 2014.
[BMS] Bristol -Myers Squibb. Nonclinical Study  Report: Medarex Study  No. MDX1106 -[ADDRESS_1200627] of ant i-PD-1 monocl onal antibody  adm inistrati on on unstaged MC38 tumor growth 
rates in mice. Document Control No. 930046542. Bristol-Myers Squibb; 2006 a. 
[BMS] Bristol -Myers Squibb. Non -Clinical Study  Report: Medarex Study  No. MDX1106 -032-
R. Effects of anti -PD-1 administrati on on staged MC3 8 tum ors in mice. Document Control 
No. 930046566. Bristol -Myers Squibb; 2006 b. 
[BMS] Bristol -Myers Squibb. Nonclinical Study  Report: Medarex Study  No. MDX1106 -003
-R. 
Effects of an ant i-PD-1 monocl onal antibody  in mice challenged wit h SA1/N tumor cells. 
Docum ent Control  No. 930046552. Bristol -Myers Squibb; 2006 c.
[BMS] Bristol -Myers Squibb. Nonclinical Study  Report: Medarex Study  No. MDX1106 -006- R. 
Dose -response effects of ant i-PD-1 monocl onal antibody  on unstaged SA1/N tumor growth 
rate and immune respon se at tum or re -challenge. Document Control No. 930046559 .
Bristol-Myers Squibb; 2006 d. 
[BMS] Bristol -Myers Squibb. Nonclinical Study  Report: Medarex Study  No. MDX1106 -025
-R. 
In vitro characterizat ion of a fully  human ant i-PD-1 monocl onal antibody . Bristol-Myers 
Squibb; 2006e. Document Control No. 930046580.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 90
Galunisertib (LY2157299) /nivolumab[BMS] Bristol -Myers Squibb. Clinical Study  Report: Study  No. MDX1106- 01. A Phase 1, 
open -label, dose -escalat ion, safety  and pharmacokinet ic study  of MDX -1106 in pat ients with 
selected refractory  or rel apsed m alignancies. Bri stol-Myers Squibb Co mpany; 2011. 
Docum ent Control  No. 930044418.64.
[BMS] Bristol -Myers Squibb. Clinical Study  Report: Study  No. MDX1106- 03. A Phase 1, 
open -label, mult icenter, mult idose, dose escalat ion study  of BMS -936558 (MDX1106) in 
subjects wi th selected advanced or recurrent malignancies. Bristol -Myers Squibb Co mpany; 
2013. Document Control No. 930044417.
Bueno L, de Alwis DP, Pi[INVESTIGATOR_861285] C, Yingling J, Lahn M, Glatt S, Trocóniz IF. Semi -mechanist ic 
modelling of the tum our growth inhib itory effects of LY2157299, a new ty pe I receptor 
TGF -beta kinase antagonist, in mice. Eur J Cancer . 2008;44(1):142 -150.
Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, 
Carreno BM . PD-1:PD -L inhibitory  pathway  affect s both CD4 (+)and CD8 (+)T cells and is 
overcom e by [CONTACT_8668]-2. Eur J Immunol .2002;32(3):[ADDRESS_1200628] ivation. J Immunol .
2004; 173:945 -954.
Cockcroft DW, Gault MD. Prediction of creat inine clearance fro m serum  creat inine. Nephron . 
1976;16:[ADDRESS_1200629] .2000;92(17):[ADDRESS_1200630] RJ, Balmain A. TGF- beta signaling in tum or suppressi on and cancer 
progression. Nat Genet .2001;29(2):[ADDRESS_1200631]  and i ts rol e in the evasi on of  tumor immuni ty. J Mol Med
(Berl .).2003; 81:[ADDRESS_1200632] . Cancer immunoedit ing: from 
immunosurveillance to tumor escape. Nat Immunol .2002;3:[ADDRESS_1200633] R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumours: revised RECIST guideline (ve rsion 1.1). 
Eur J Cancer . 2009;45(2):[ADDRESS_1200634] J- Y, Waldschmidt D, Mulcahy 
MF, Costentin C, Minguez B, Papappi[INVESTIGATOR_509427] P, Gueorguieva I, Cleverly A, Desaiah D, Lahn 
MM, Ameryckx S, Benhadji KA, Raymo nd E, Gi annelli  G.  A phase 2 study  of a novel 
transforming growth factor -beta (TGF -
β1) receptor I kinase inhibitor, LY2157299 
monohydrate (LY), in pat ients with advanced hepatocellular carcino ma (HCC). J Clin Oncol . 
2014;32(3) (suppl ): abstr LBA173. 
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy  F, Kalman L, Miller V, 
LeeJS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L.
Randomized phase II trial o f docetaxel  versus vino relbine or ifso famide in subjects with 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 91
Galunisertib (LY2157299) /nivolumabadvan ced non -small -cell lung cancer previ ously  treated wi th platinum -containing 
chemotherapy. The TAX 320 Non -Small Cell Lung Cancer Study  Group. J Clin Oncol .
2000;18:2354 -2362.
Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta 
up-regulates E- cadherin and reduces migrat ion and invasio n of hepatocellular carcino ma cells. 
Hepatology .2008;47:1557 -1566.
Fransvea E, Mazzocca A, Antonaci S, Giannelli G. Targeting transforming growth factor 
(TGF) -beta RI inhibit s activat ionof beta1 integrin and blocks vascular invasio n in 
hepatocellular carcino ma. Hepatology .2009;49(3):839 -
850.
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, 
Okazaki T, By [CONTACT_175901], Horton HF, Fouser L, Carter L, Ling V , Bowm an MR, Carreno BM, 
Collins M, Wood CR, Honjo T. Engagement of the PD- 1 immuno inhibitory receptor by a 
novel B7 family member leads to negative regulat ion of lymphocyte activat ion. J Exp Med .
2000;192(7):[ADDRESS_1200635] J -Y, Waldschmidt D, 
Mulcahy  M, Costentin C, Minguez B, Papappi[INVESTIGATOR_861286], Gueorguieva I, Cleverly A, Desaiah D, 
Lahn MM, Ameryckx S, Benhadji KA, Raymo nd E. Eval uation of LY2157299 mo nohydrate
(LY) , a TGF -β receptor l kinase inhibitor, in patients with advanced hepatocellular carcino ma: 
phase 2 study  resul ts of safet y, efficacy and PK/PD. J Hepatol . 2014;60 (suppl 1):S52 -S53.  
Grady  WM, Markowi tz SD. TGF -β signaling pathway  and tum or suppressi on. In: Derynck R, 
Miyazono K, editors. The TGF- β Family. [LOCATION_001]: Cold Spring Harbor Laboratory  Press; 
2008, pp. 889 -
937.
Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family  revisi ted. Annu Rev Immunol . 
2004;23:515 -548.
Gueorgui eva I, Cl everly AL, Stauber A, Sada Pi[INVESTIGATOR_140195]  N, Rodon JA, Mi les CP, Yingling JM, 
Lahn MM. Defining a therapeutic window for the novel TGF -β inhibitor LY2157299 
monohydrate based on a pharmacokinet ic/pharmacodynamic model. Br J Clin Pharmacol . 
2014;77(5):[ADDRESS_1200636] . 2013;123(9):[ADDRESS_1200637] FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, 
Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy  K, Gervais R, Shaharyar, Manego ld 
C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial o f pemetrexed versus 
docetaxel in subjects with non -small -cell l ung cancer previ ously  treated wi th chemotherapy .
JClin Oncol . 2004;22:1589-1597.
Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y. Tumor 
cell expression o f programmed cell death -1 ligand 1 is a prognostic factor for malignant 
melano ma. Cancer . 2010;116(7):1757-1766. 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 92
Galunisertib (LY2157299) /nivolumabIgnotz RA, Massagu éJ. Cell adhesio n pro tein receptors as targets for transforming growth 
factor -beta action. Cell. 1987;51(2):[ADDRESS_1200638] E, Forman D . Global Cancer Stati stics.CA Cancer 
J Clin .2011;61:69 -90.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD -1 and i ts ligands in tol erance and immunit y. 
Annu Rev Immunol . 2008; 26:677 -704. 
Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka -Akita H, Nishimura M. B7-H1 
expressio n on non
-small  cell lung cancer cells and its relationship with tumor -infiltrat ing 
lymphocy tes and their PD -1 expressio n. Clin Cancer Res .2004; 10:5094- 5100.
Latchman Y, Wood CR, Chernova T, Chaudhary  D, Borde M, Chernova I, Iwai Y, Long AJ , 
Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, 
Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ . PD-L2 is a 
second ligand for PD -[ADDRESS_1200639] ivation. Nat Immunol .2001;2(3):261 -268.
Massagué J, Bl ain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable 
disorders. Cell.2000;103(2):295 -309.
Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Inhibit ion of transforming 
growth factor beta receptor I kinase blocks hepatocellular ca rcino ma growth through 
neo-angiogenesis regulat ion. Hepatology .2009;50(4):1140 -1151.
Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G. Down -regul ation of 
connective tissue growth factor by  [CONTACT_861349]-stroma cross -talk and tum or progressi on in hepatocellular carcino ma. Hepatology .
2010;51(2):523 -534.
Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. 
LY2109761, a novel transforming gr owth factor beta receptor ty pe I and ty pe II dual  inhibitor, 
as a therapeutic approach to suppressing pancreat ic cancer metastasis. Mol Cancer Ther .
2008;7(4):829 -840.
Murray  PT, Ratain MJ. Estimation of the glo merular filtration rate in cancer patients: a new 
formula for new drugs. J Clin Oncol . 2003;21(14):2633-2635.
Nagaraj NS, Datta PK. Targeting the transforming growth factor -beta signaling pathway in 
human cancer. Expert Opin Investig Drugs .2010;19(1):77 -91.
Nishimura H, Honj o T. PD -1: an inhibitory immunoreceptor invo lved in peripheral tolerance. 
Trends Immunol .2001; 22:265 -268.
Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuk a 
H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y. Clinical significance of 
programmed death -1 ligand -1 and programmed death -1 ligand -2 expressio n in human 
esophageal cancer. Clin Cancer Res .2005; 11:2947- 2953.
Oken MM, Creech RH , Torm ey DC, Horton J , Davis TE, McFadden ET, Carbone PP. Toxi city 
and response criteria of the eastern cooperative oncology  group .Am J Clin Oncol . 
1982;5:649 -655.
Padua D, Massagué J. Rol es of  TGFbeta in metastasis. Cell Res .2009;19(1):89 -102.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 93
Galunisertib (LY2157299) /nivolumabPardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol.
2003;21:807 -839.
Rotzer D, Roth M, Lutz M, Lindemann D, Sebald W, Knau s P. Ty pe III TGF -beta 
receptor -independent signalling o f TGF -beta2 via TbetaRII -B, an alternat ively spliced TGF -
beta ty pe II receptor. EMBO J .2001;20(3):480 -490.
Sangro B, Gom ez-Mart in C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu -Boj JI, 
Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez -Gracia JL, Melero I, Prieto J. A clinical trial o f 
CTLA-4 blockade wi th trem elimumab in patients with hepatocellular carcino ma and chronic 
hepat itis C. J Hepatol .2013;59(1):[ADDRESS_1200640] A, Park K, Patil S, Rolski J, 
Goksel  T, de Marinis F, Simms L, Sugarman KP, Gandara D . Phase III study  com paring 
cisplatin plus gemcitabine with cisplat in plus pemetrexed in chemotherapy -naive patients with 
advanced -stage non -small  cell lung cancer. J Clin Oncol .2008; 26:3543- 3551.
Serova M, Tijeras -Raballand A, Dos Santos C, Muller N, Benhadji KA, Paradis V, Faivre S, 
Raymo nd E, de Gramont A. Effects of TGF- beta signaling inhibit ion with LY2157299 in 
hepatocarcino ma models and in ex viv o whol e tumor ti ssue samples from pat ient specimen. 
Cancer Res .2013;73(s uppl 8): abstract 2094. 
Sharpe AH, Wherry  EJ, Ahmed R, Freeman GJ . The function of programmed cell death [ADDRESS_1200641] ion. Nature Immunol .2007;8:[ADDRESS_1200642] FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, 
Vincent M, Burkes R, Coughlin S, Kim Y, Berille J . Prospective rando mized trial of docetaxel 
versus best supportive care in subjects with non
-small -cell lung cancer previously treated with 
platinum -based chemotherapy . J Clin Oncol .2000;18:2095 -2103.
Siegel PM, Massagué J. Cy tostatic and apoptoti c actions of  TGF -beta in ho meostasis and cancer. 
Nat Rev Cancer .2003;3(11):807 -821.
Simon R. Optimal two -stage designs for phase II clinical trials. Control Clin Trials .
1989;10(1):1 -10.
Thom pson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Kr ejci KG, Lobo JR, 
Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED . 
Costimulatory B7 -H1 in renal cell carcino ma subjects: indicator of tumor aggressiveness and 
potenti al therapeuti c target. Proc Natl Acad Sci [LOCATION_003] .2004; 101:[ZIP_CODE]- [ZIP_CODE].
Thom pson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, 
Blute ML, Leibovich BC, Kwon ED . Costimulatory mo lecule B7 -H1 in primary  and 
metastati c clear cell  renal cell  carcinoma. Cancer .2005a; 104:2084- 2091.
Thom pson RH, Webster WS, Cheville JC, Lohse CM, Dong H, Leibovich BC, Kuntz SM, 
Sengupta S, Kwon ED, Blute ML . B7-H1 glycoprotein blo ckade: a novel strategy  to enhance 
immunotherapy  in subjects with renal cell carcino ma. Urology 2005b;66:[ADDRESS_1200643] M, Paradis V, Raymo nd E, de Gramont A, Faivre S. LY2157299 
w/wo sorafenib in hepatocarcino mas yields ant itumor effects in transgenic mice and 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 94
Galunisertib (LY2157299) /nivolumabxenografts, also inhibit ing TGF-Β signalling in freshly- grown sliced tum or specimens . In: 
International Liver Cancer Assocation 8 thannual conference meet ing program ; 5-7 Sept 2014; 
Kyoto, Japan.  p 24. P
-005.
Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K, Azuma M.Predominant 
expressio n of B7 -H1 and its immunoregulatory  roles in oral  squam ous cell carcinoma. Oral 
Oncol .2006; 42:268 -274.
Wakefield LM, Roberts AB.  TGF -beta signaling: posit ive and negat ive effects on 
tumorigenesis. Curr Opin Genet Dev .2002;12(1): 22-
29.
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, 
Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, 
Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM . Updated response 
assessme nt criteria for high-grade glio mas: response assessment in neuro -oncol ogy working 
group. J Clin Oncol .2010;28(11):1963 -19
72.
Wherry EJ. T cell exhaustion. Nat Immunol
.2011;12(6):[ADDRESS_1200644] atten M, Arpin M, Weller M. Ezrin -dependent promotion 
of glioma cell  clonogenici ty, motility, and invasi on mediated by  [CONTACT_129310] -2 and transforming 
growth factor -beta2. J Neurosci . 2001 a;21(10):[ADDRESS_1200645] atten M, Well er M. Gli oma cell invasio n: regulat ion of metalloproteinase act ivity by 
[CONTACT_4722] -beta.  J Neurooncol . 2001 b;53(2):177-
185. 
Wolchok JD, Hoos A, O’Day  S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, 
Nichol G, Hum phrey R, Hodi  FS. Gui delines for the evaluat ion of immune therapy activit y in 
solid tumors: immune -related response cri teria. Clin Cancer Res . 2009;15:7412 -7420.
Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou LF. B7-H1 is correlated with malignancy -grade 
gliomas but is not expressed exclusively on tumor stem -like cells. Neuro Oncol .
2009;11(6):[ADDRESS_1200646] KL, Sawy er JS. Development of TGF -beta signaling inhibitors for 
cancer therapy . Nat Rev Drug Discov . 2004;3(12):1011 -
1022.
Zhang YE. Non -Smad pathways in TGF -beta si gnaling. Cell Res .2009;19(1):[ADDRESS_1200647] 
primary  tumor growth and metastasis through mult ieffects on cancer, stroma, and immune 
cells. Clin Cancer Res . 2010;16(4):1191-1205.
Zitvogel L, Tesniere A, Kroem er G. Cancer despit e immunosurveillance: immunoselect ion and 
immunosubversio n. Nat Rev Immunol .2006;6:715 -727.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 95
Galunisertib (LY2157299) /nivolumabAttachment 1. Protocol JBEF Study  Schedule
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 96
Galunisertib (LY2157299) /nivolumabPhase 1 bDose Escalation —Baseline /Screening Assessments
Rela tive Day Prior to Day 1 of 
Cycle 1a28 14 7Comments
Informed consent XInformed consent f ormsigned (prior to perform ance of
any protocol -specific tests/ procedure s)
Radiological tumour assessment XThese scans can be performed locally.  See Section 8.3for 
details.  Radiologic assessment should include appropriate 
body scan for tumo ur type .  
Tumour biopsy XNew tumo ur biopsy  is required for patients with cancers 
other than glioblastoma .  Archived tissue or new tumo ur 
biopsy is required for patients with glioblastoma .  Biopsy 
should be taken only after study eligibility is confirmed.
Medical history XIncluding alcohol/tobacco use and other relevant habits
assessments
Physical examination X
Vital signs XIncluding height (baseline only), temperature, blood 
pressure, pulse rate, respi[INVESTIGATOR_39870] n rate , and pulse oximetry 
reading
Weight and change in weight for 
previous [ADDRESS_1200648] be done prior to initiation of 
therapy  on Cycle 1 Day 1.
ECHO/Doppler imaging XCan be done up to 3 days before Cycle 1 Day 1; must be 
done prio r to initiation of therapy on Day [ADDRESS_1200649] meet 
Exclusion Criterion 21 .  
MRI/CT scan (of chest) with 
contrastXFor safety :  baseline and then every 6 months .  NOTE:  at 
screening, if a MRI or CT scan with contrast has been 
done to assess the status of the primary tumo ur, this scan 
may be used for safety screening if the scan has properly 
assessed the great vessels and the heart.  Scans of other 
areas may be required for additional tumo ur assessment 
but not for safety.  
Cardiac serum markers X BNP, troponin I, cystatin C
Haematology X See Attachment 2 .
Serum chemistry  X See Attachment 2 .
HBV DNA sample X All patients : peripheral blood
HCV RNA sample X All patients:  peripheral blood
HCC antiviral activity XHCC patients only:  peripheral blood collection for 
qHBsAg 
HBsAg, HCV, HIV serology XRequired for a ll patients
PT/INR X
Tumo ur measurement ( palpable 
or visible)XIf appropriate for the tumo ur
CTCAE v 4.03 grading 
(preexisting conditions)XTo be reported only after study eligibility is confirmed.  
See Section [IP_ADDRESS] for reporting expectations
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 97
Galunisertib (LY2157299) /nivolumabPhase 1b Dose Escalation —Baseline/Screening Assessments
Relative Day Prior to Day 1 of 
Cycle 1a28 14 7Comments
Concomitant meds X
Blood biomarker samples X See Attachment [ADDRESS_1200650] X
Whole blood for 
pharmacogenetics (DNA 
collection )XMust be collected prior to dosing on Cycle 1 Day 1
Abbreviations:  BNP = brain natriuretic peptide; CT = computed tomography; CTCAE = Common Terminology 
Criteria for Adverse Events; DNA = deoxyribonucleic acid; ECG = electrocardiogram; ECHO = 
echocardiogra ph; ECOG = Eastern Cooperative Oncology Group; HBV = hepatitis B virus; HBsAg = hepatitis B 
surface antigen; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; HIV = 
human immunodeficiency virus; INR = international normali sed ratio; m eds = medications; MRI = magnetic 
resonance imaging ;PT = prothrombin time ; qHBsAg = quant itative hepatitis B surface antigen; 
RNA =ribonucleic acid; SAEs = serious adverse events ; v = version .
aWith the exception of signing of the informed consent form (may be signed up to 3 days before initial visit), visit 
windows ±3 days.  
H9H- MC-JBEF(c) Phase 1 Oncology Protocol Page 98 
Galunisertib (LY2157299)/nivolumab During and Post-Study Assessments—Phase 1b Dose Escalation 
 Cycle 1  Cycle 2  Cycle 3 -n 
Follow -Up (days)  
Comments  Relative Week 
Within a Cycle  1 2 3 4 1 2 3 4 1 2 3 4 
Relative Day 
Within a Cycle a 1 8 15 22 1 8 1
5 22 1 8 15 22 Short -term  Long -
term c 30b 100 
Galunisertib  X   X   X      14 days on/[ADDRESS_1200651] X    X    X       Predose  
Cardiotoxicity 
serum markers  X    X    X    X X X Troponin I, BNP, and cystatin C on Day 1 of every cycle  
12-lead ECG      X D 
14 
only   X*       Collect predose  (if applicable) : 
 
See Attachment 4  for timing of PK time -matched ECGs  
* Starting at Cycle 3 Day 1, ECGs will be performed at 
every odd -numbered cycle thereafter (Cycles 5, 7, 9, etc)  
ECHO         X    * X   Performed every other cycle within 5 days of when next cycle 
begins, beginning at the end of Cycle 2  (eg, Cycle 2 
Days  23-28=*).  Must be done predose .  After a normal 
baseline ECHO, if a subsequent ECHO demonstrates an 
abnormality, then a repeat ECHO should be performed after 
14 days.  If results confirm the abnormality at repeat ECHO, 
then the patient will be discontinued from study treatment.  If 
findings are normal, then the patient will continue treatment 
per stud y protocol.  
 
If patient has clinically significant cardiac findings at 30 -day 
FUP Visit, ECHO will be repeated every 2 cycles 
(approximately every 2 months) .  If no clinically significant 
cardiac findings at the last cardiac assessment conducted 
within the  last 30  days and patient has started another 
treatment, 30 -day FUP Visit will not be performed .  If no 
clinically significant cardiac findings at 30 -day FUP Visit, 
1 more ECHO will be performed after 2 months unless the 
patient is receiving another treatm ent.  If the patient is 
receiving another form of treatment, further cardiac 
assessments will not be performed.  
H9H-MC-JBEF(c) Phase 1 Oncology Protocol Page 99
Galunisertib (LY2157299) /nivolumabDuring and Post -Study Assessments —Phase 1b Dose Escalation
Cycle 1 Cycle 2 Cycle 3 -n
Follow -Up (days)
CommentsRelative Week 
Within a Cycle1 2 3 4 1 2 3 4 1 2 3 4
Relative Day 
Within a Cycle a1 8 15 22 1 81
522 1 8 15 22Short-term Long -
term c30b 100
MRI/CT scan (of 
chest) with contrast**Every 6 months during treatment (eg, just prior to beginning 
Cycle 6= **). If there were no clinically significant findings 
at the last assessment conducted within the last [ADDRESS_1200652] will not be performed.
Haematology X X X X X X X X See Attachment 2 .
Serum chemistry X X* X X* X X* X X* X X X XSee Attachment 2 .
*Only perform edif the last assessment prior to this 
assessment had an elevated value forliver function compared 
to baseline. SeeSection 8.1.4 .  
HBV DNA X X X X X All patients to be tested. Peripheral blood .  Predose .  
HCV RNA X X X X X All patients to be tested.  Peripheral blood.  Predose .
HCC antiviral 
activityXHCC patients only.  Peripheral blood collection for 
assessment of qHBsAg.  Predose Day 1 at every other cycle 
(Cycles, 3, 5, n).
CTCAE v 4.03 
GradingX X X X X X X X X Refer to Section [IP_ADDRESS] for reporting guidelines.
Concomitant meds X X X X X X X X X Throughout study as needed.
ECOG p erformance 
statusX X X X X
PK sampling XD
14X X D14 XC4 
onlySee Attachment 4 for timing.
Tumo ur 
measurement 
(palpable or visible)X X XTo occur on or between Days 22 to 28 of every other cycle. 
At long-term FUP, every 12 weeks as appropriate.
Radiological tumour 
assessmentX X XMRI/CT scan .  To occur on or between Days 22 to 28 of 
every other cycle. At short -term FUP, every 8weeks as 
appropriate.
Radiological tumour 
assessment for 
pseudoprogressionFor patients who are being treated beyond initial progression, 
these patients should remain on study treatment until the next 
assessment period.  Patients who are treated beyond 
progression will be evaluated on an 8-(non glioblastoma ) or 
12- ( glioblastoma ) week basis to determine whether they 
should continue on treatment.  
Survival X At FUP, at least every 12 weeks ±7 days until death .  
Immuno genicity XD
14X X * XWindow of ±7 days for 100-day FUP.
*Collected at Week 13 and every 16 weeks thereafter 
(ie,Week 29, 45, etc.)
H9H-MC-JBEF(c) Phase 1 Oncology Protocol Page 100
Galunisertib (LY2157299) /nivolumabDuring and Post -Study Assessments —Phase 1b Dose Escalation
Cycle 1 Cycle 2 Cycle 3 -n
Follow -Up (days)
CommentsRelative Week 
Within a Cycle1 2 3 4 1 2 3 4 1 2 3 4
Relative Day 
Within a Cycle a1 8 15 22 1 81
522 1 8 15 22Short-term Long -
term c30b 100
Bio-
marker 
samplesTumo ur 
biopsy1/2 1/2Required for patients with cancers other than glioblastoma , 
with half of patients randomly assign to biopsies on either 
Cycle [ADDRESS_1200653] nivolumab dosing.  If a 
patient with glioblastoma undergoes a biopsy during the study 
for other medical reasons, tissue should be collected at that 
time.  Note glioblastoma patients are in Phase 1b only.
For glioblastoma patients only (Phase 1b) , if tumo ur biopsy is 
performed to distin guish b etween radiologic progression and 
pseudoprogression (not required), see Section 7.2.5 for 
instructions for proper handling of specimen .
Blood 
bio-
marker 
samplesD1 
and
D2X X X XC4 
onlyX See Attachment 4 for sampling times .  
Abbreviations:  BNP = brain natriuretic peptide; BP = blood pressure; BSA = body surf ace area; C = cycle; CT = computed tomography; CTCAE = Common 
Terminology Criteria for Adverse Events; D = day; DNA = deoxyribonucleic acid ;ECG = electrocardiogram; ECHO = echocardiogra phy; ECOG = Eastern 
Cooperative Oncology Group; FUP = Follow -Up Period ; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; HR = heart 
rate; hrs = hours; IV=intravenous; MRI = magnetic resonance imaging; n = cycle number ; PK=pharmacokinetic; qHBsAg = quantitative hepatitis B surface 
antigen; RNA =ribonucleic acid; RR= respi[INVESTIGATOR_1487] ; SAEs = serious adverse events ; v = version .
aVisit windows ±3 days.
bSometimes referred to as the end of treatment visit .  
cLong -Term Follow -Up begins the day after 100 -day follow -up is completed and continues until the patient’s death or end o f trial (approximately every 
12weeks ± 7 days the patient will be contact[INVESTIGATOR_530]).
H9H-MC-JBEF(c) Phase 1 Oncology Protocol Page 101
Galunisertib (LY2157299) /nivolumabPhase 2Dose Expansion —Baseline /Screening Assessments
Relative Day Prior to Day 1 
of Cycle 1a28 14 7 Comments
Informed consent XInformed consent form signed (prior to performance of 
any protocol -specific tests/procedures)
Radiological tumour 
assessmentXThese scans can be performed locally and transmitted to a 
central imaging vendor .  See Section 8.3for details.  
Radiologic assessment should include appropriate body 
scan for tumo ur type.
Tumour biopsy XNew tumo ur biopsy  is required.  Biopsy should be taken 
only after study  eligibility  is confirmed.
Medical history XIncluding alcohol/tobacco use and other relevant habits 
assessments
Physical exam X
Vital signs XIncluding height (baseline only), temperature, blood 
pressure, pulse rate, respi[INVESTIGATOR_1487] , and pulse oximetry 
reading
Weight and change in weight 
for previous [ADDRESS_1200654] be done prior to initiation of 
therapy  on Cycle 1 Day 1.
ECHO/Doppler imaging XCan be done up to 3 days before Cycle 1 Day 1; must be 
done prio r to initiation of therapy on Day [ADDRESS_1200655] meet 
Exclusion Criterion 21.
MRI/CT scan (of chest) with 
contrastXFor safety :  baseline and then ever y 6 months.  NOTE:  At 
screening, if a MRI or CT scan with contrast has been 
done to assess the status of the primary tumo ur;this scan 
may be used for safety screening if the scan has properly 
assessed the great vessels and the heart.  Scans of other 
areas may be required for additional tumo ur assessment 
but not for safety.  
Cardiac serum markers X BNP, troponin I, cystatin c
Haematology X See Attachment 2 .
Serum chemistry X See Attachment 2 .
HBV DNA sample X All patients :  peripheral blood
HCV RNA sample X All patients :  peripheral blood
HCC antiviral activity XHCC patients only:  peripheral blood collection for 
qHBsAg 
HBsAg, HCV, HIV serology X Required for all patients
PT/INR X
Tumour measurement 
(palpable or visible)X
CTCAE v 4.03 grading 
(preexisting conditions)XTo be reported only after study eligibility is confirmed.  
See Section [IP_ADDRESS] for reporting expectations.
Concomitant meds X
H9H-MC-JBEF(c) Phase 1 Oncology Protocol Page 102
Galunisertib (LY2157299) /nivolumabRelative Day Prior to Day 1 
of Cycle 1a28 14 [ADDRESS_1200656] X
Whole blood for 
pharmacogenetics (DNA 
collection )X Must be collected prior to dosing on Cycle 1 Day 1
Abbreviations:  BNP = brain natriuretic peptide; CT = computed tomography; CTCAE = Common Terminology 
Criteria for Adverse Events; DNA = deoxyribonucleic acid; ECG = electrocardiogram; 
ECHO =echocardiograph; ECOG = Eastern Cooperative Oncology Group; HBsA g = hepatitis B surface antigen; 
HBV =hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; HIV = human 
immunodeficiency virus ; INR = international normali sed ratio; m eds = medicatio ns; MRI = magnetic resonance 
imaging ; qHBsAg = quan titative hepatitis B surface antigen; PT=prothrombin time ; RNA = ribonucleic acid; 
SAEs = serious adverse events ; v = version .
aWith the exception of signing of the informed consent form (may be signed up to 3 days before initial visit), visit 
windows ± 3days.  
H9H-MC-JBEF(c) Phase 1 Onc ology Protocol Page 103
Galunisertib (LY2157299) /nivolumabDuring and Post -Study Assessments —Phase 2Dose Expansion
Cycle 1 Cycle 2 Cycle 3 -n
Follow -Up (days)
CommentsRelative Week Within 
a Cycle1 2 3 4 1 2 3 4 1 2 3 4
Relative Day Within a 
Cycle a1 8 15 22 1 81
522 1 8 15 22Short-term Long -
term c30b 100
Galunisertib X X X14 days on/[ADDRESS_1200657] X X X Predose
Cardiotoxicity serum 
markersX X X X X XTroponin I, BNP, and cystatin C on Day 1 of every cycle
12-lead ECG XD 
14
onlyX*Collect predose ( if applicable ):
See Attachment 4 for timing of PK time -matched ECGs .
* Starting at Cycle 3Day 1, ECGs will be performed at every 
odd-numbered cycle thereafter (Cycles 5, 7, 9, etc)
ECHO X * XPerformed every other cycle within 5 days of when next cycle 
begins, beginning at the end of Cycle 2 (eg, Cycle 2 
Days 23-28=* ).  Must be done predose.  After a normal 
baseline ECHO, if a subsequent ECHO demonstrates an 
abnormality, then a repeat EC HO should be performed after 
14days.  If results confirm the abnormality at repeat ECHO, 
then the patient will be discontinued from study treatment.  If 
findings are normal, then the patient will continue treatment 
per stud y protocol.
If patient has clinically significant cardiac findings at 30 -day 
FUP Visit, ECHO will be repeated every 2 cycles 
(approximately every 2 months).  If no clinically significant 
cardiac findings at the last cardiac assessment conducted 
within the last 30 days and patient has started another 
treatment, 30 -day FUP Visit will not be performed.  If no 
clinically significant cardiac findings at 30 -day FUP Visit, 
1more ECHO will be performed after 2 months unless the 
patient is receiving another treatm ent.  If the patient is 
receiving another form of treatment, further cardiac 
assessments will not be performed.
H9H-MC-JBEF(c) Phase 1 Onc ology Protocol Page 104
Galunisertib (LY2157299) /nivolumabDuring and Post -Study Assessments —Phase 2 Dose Expansion
Cycle 1 Cycle 2 Cycle 3 -n
Follow -Up (days)
CommentsRelative Week Within 
a Cycle1 2 3 4 1 2 3 4 1 2 3 4
Relative Day Within a 
Cycle a1 8 15 22 1 81
522 1 8 15 22Short-term Long -
term c30b 100
MRI/CT scan with 
contrast**Every 6 months during treatment (eg, just prior to beginning 
Cycle 6= **).  If there were no clinically significant findings 
at the last assessment conducted within the last [ADDRESS_1200658] will not be performed.   
Haematology X X X X X X X X See Attachment 2 .
Serum c hemistry X X X X X X X X See Attachment 2 .
HBV DNA X X X X X All patients to be tested. Peripheral blood.  Predose 
HCV RNA X X X X X All patients to be tested .  Peripheral blood.  Predose
HCC antiviral activity XHCC patients only :  peripheral blood collection for 
assessment of qHBsAg.  Predose Day 1 at every other cycle 
(Cycles, 3, 5, n)
CTCAE v 4.03 g rading X X X X X X X X X Refer to Section [IP_ADDRESS] for reporting guidelines.
Concomitant m eds X X X X X X X X X Throughout study as needed
ECOG performance 
StatusX X X X X
PK s ampling XD 
14X XD 
14XC4 
onlySee Attachment 4 for timing .  
Tumour measurement 
(palpable or v isible)X X XTo occur on or between Days 22 to 28 of every other cycle.  
At long-term FUP, every 12 weeks as appropriate.
Radiological tumour 
assessmentX X XMRI/CT scan.  These scans can be performed locally and 
transmitted to a central imaging vendor.   To occur on or 
between Days [ADDRESS_1200659] initial 
progressionMRI/CT scan.  These scans can be performed locally and 
transmitted to a central imaging vendor.  For patients who are 
being treated beyond initial progression, these patients should 
remain on study treatment until the next assessment period.  
Patients who are treated beyond progression will be evaluated 
on an [ADDRESS_1200660] every 12 weeks until death .  
Immunogenicity XD 
14X X * XWindow of ±7 days for 100 -day FUP.
* Collected at Week 13 and every 16 weeks thereafter (ie, 
Week 29, 45, etc.)
H9H-MC-JBEF(c) Phase 1 Onc ology Protocol Page 105
Galunisertib (LY2157299) /nivolumabDuring and Post -Study Assessments —Phase 2 Dose Expansion
Cycle 1 Cycle 2 Cycle 3 -n
Follow -Up (days)
CommentsRelative Week Within 
a Cycle1 2 3 4 1 2 3 4 1 2 3 4
Relative Day Within a 
Cycle a1 8 15 22 1 81
522 1 8 15 22Short-term Long -
term c30b 100
Bio-
marker 
samplesTumo ur 
biopsy1/2 1/2Required, with half of patients randomly assign to biopsies on 
either Cycle [ADDRESS_1200661] nivolumab dosing .  
Blood 
Bio-
marker 
sampleD1 
& 
D2X X X XC4 
onlyX See Attachment 4 for sampling times .
Abbreviations:  BNP = brain natriuretic peptide; BP = blood pressure; C = cycle; CT = computed tomography; CTCAE = Common Terminology Criteria for 
Adverse Events; D = day; ECG = electrocardiogram; ECHO = echocardiography; ECOG = Eastern Cooperative Oncology Group; FUP = Follow -Up Period; 
HBV = hepatitis B virus ; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; HR = he art rate; hrs = hours; n = cycle number; PK =pharmacokinetic; 
qHBsAg = quantitative hepatitis B surface antigen; RNA = ribonucleic acid; RR= respi[INVESTIGATOR_39870] n rate; SAEs = serious adverse events; v = version.
aVisit windows ±3 days.
bSometimes referred to as the end of treatment visit.
cLong -Term Follow -Up begins the day after 100 -day follow -up is completed and continues until the patient’s death or end o f trial (approximately every 
12weeks ± 7 days the patient will be contact[INVESTIGATOR_530]).
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 106
Galunisertib (LY2157299) /nivolumabAttachment 2. Protocol JBEF Clinical Laboratory  Tests
Clinical Laboratory Tests
Haematology a Clinical Chemistry a,b
Haemoglobin Serum Concentrations of:
Haematocrit Sodium
Magnesium
Erythrocy te count (RBC) Potassium
Leukocytes (WBC) Total bilirubin
Neutrophils Alkaline phosphatase
Lymphocy tes Alanine aminotrans ferase
Monocytes Aspartate aminotransferase
Gamma -glutamyl transpeptidase
Eosinophils Blood urea nitrogen 
Basophils Creatinine
Platelets Uric acid
Calcium
Glucose, random
PT/INR a Albumin
Total protein
Chloride
Bicarbonate
Amylase
Lipase
Thyroid-stimulating hormone a,b,c
Reflex to fT3/ fT4a,b,c
Troponin I b
BNP b
Cystatin C b
HBsAg a,b
qHBsAg d
HBV DNA d
Hep C Ab a,b
HCV RNA d
HIV b
Serum Pregnancy Test (females only) a
Abbreviations:  aPTT = activated partial thromboplastin time, BNP = brain natriuretic peptide; DNA = 
deoxyribonucleic acid; fT3 = free triiodothyronine; fT4 = free thyroxine; HBsAg = hepatitis B surface antigen; 
HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus ;Hep C Ab = hepatitis C 
antibody ; HIV = human immunodeficiency virus ;PT/INR =internatio nal no rmali sed ratio of prothrombin time; 
qHBsAg = quantitative hepatitis B s urface antigen ; RBC = red blood c ells; RNA = ribonucleic acid; WBC = 
white blood cells .
aAssay ed by [CONTACT_12117] .  
bAssay ed by [CONTACT_11007] -designated laboratory .  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 107
Galunisertib (LY2157299) /nivolumabClinical Laboratory Tests
cIf thyroid-stimulating hormone test is abnormal, reflex to fT3/fT4 test must be performed .  
dBaseline t ests(screening) will be assayed by a local and a Lilly-designated laborato ry.  Testing during the trial 
will be performed by a Lilly -designated laboratory.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 108
Galunisertib (LY2157299) /nivolumabAttachment 3. Protocol JBEF Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly  CRP .
Hepatic Monitoring Tests
Hepatic h aematology a Haptoglobin a
Haemoglobin
Haematocrit Hepatic coagulation a
RBC Prothrombin time
WBC Prothrombin time, INR
Neutrophils, segmented
Lymphocy tes Hepatic s erologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic c hemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Antinuclear antibody a
AST
GGT Anti –smooth muscle antibody a
CPK 
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotran sferase; CPK = creatine phosphokinase; 
GGT = gamma glutamyl transferase; Ig = immunoglobulin; INR = international normalised ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated andlocal laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 0 9
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bAt t a c h m e nt 4. Pr ot o c ol J B E F P h ar m a c o ki n eti c , Bi o m ar k er ,
P K Ti m e -M at c h e d E C G, a n d I m m u n o g e ni cit y S a m pli n g 
S c h e d ul e
   
 
 
 
 
  
 
  C CI
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 1 10
Galunisertib (LY2157299) /nivolumabBlood Biomarker Sampling Schedule
Pharmacodynamic
Sample # Cycle DaySampling Windows for 
Blood Collection
1 1 1 Predose
2 1 1 2 hourspostdose ± 10 
minutes
3 1 2 Predose
4 1 8 Predose
5 1 15 Predose
6 2 1 Predose
7 2 15 Predose
8 4 1 Predose
9 Follow -Up
Abbreviation: V =visit.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 111
Galunisertib (LY2157299) /nivolumabAttachment 5. Protocol JBEF Recommendations for 
Reporting Serious Adverse Events
Recommendations for Reporting Serious Adverse Events
When contact[CONTACT_338297] a n SAE , please have the fo llowing inform ation available:
Patient Demographics
patient identificat ion (number), sex, date of birth, origin, height, and weight
Study Identification
full trial protocol number, invest igator's name, investigator’s number
Study Drug
drug code or drug name, unit dose, total daily dose, frequency, route, start dose, 
cycle details, start date and last dose date (if applicable)
Adverse Event
descript ion, date of onset, severit y, treatm ent (including hospi[INVESTIGATOR_73256]), acti on 
taken wi th respect to study  drug, clinical significance, test and procedure results 
(if applicable)
Relationship to Study Drug & Protocol Procedures
Concomitant Drug Therapy
indicat ion, total  daily dose, duration of treatment, start date, action taken
In Case of Death
cause, autopsy  finding (if available), date, relat ionship to study  drug and protocol 
procedures
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 112
Galunisertib (LY2157299) /nivolumabAttachment 6. Protocol JBEF ECOG Performance Status
ECOG Performance Status
Activity Status Description
0 Fully active, able to carry on all predisease performance without restriction
1 Restricted in phy sically  strenuous activity butambulatory and able to carry out 
performance of a light or sedentary nature , for example, light housework, office work
2 Ambulato ry and capable of all self -care but unable to carry out any work activities.  
Up and about more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking 
hours
4 Completely disabled.  Cannot carry on any self -care.  Totally confined to bed or chair
5 Dead
Abbreviation :  ECOG = Eastern Cooperative Oncology Group .
Source:  Oken et al. 1982.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 113
Galunisertib (LY2157299) /nivolumabAttachment 7. Protocol JBEF Creatinine Clearance Formula
Note:   This formula is to be used for calculat ing CrCl fro m local laboratory results only.  
For serum creatinine 
concentration in mg/dL:
CrCl = (140 – agea) (wt) 0.85 (if female) , or1.0 (if male)
(mL/min) 72serum creatinine (mg/dL )
For serum creatinine concentration in mol/L:
CrCl = (140 – age a) (wt) 0.85 (if female) , or1.0 (if male)
(mL/min) 0.81serum creatinine 
(mol/L )
Abbreviation:  CrCl = creatinine clearance.
aAge in y ears, weight (wt) in kilograms.
Reference:  Cockcroft and Gault 1976.
-OR-
GFR(mL/min/1.73m 2) = 170 x [PCr] -0.999 x [age] -0.176
x [0.762 if pat ient is female] x [1.18 if pat ient is black]
x [SUN] -0.17 x [Alb] [PHONE_17832]
PCr= plasma creatin ine, m g/dL; SUN = serum  urea nitrogen, m g/dL; Alb = serum  albumin, 
g/dL .
Source:  Murray and Ratain 2003 .
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 1 4
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bAt t a c h m e nt 8. Pr ot o c ol J B E F
 
 
  
  
 
 
  
 
  
 
  
 
 
 
  
 
 
 
  
 
 
 
 C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 1 5
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b  
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
   
 
 
 
 C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 1 6
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b 
  
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 C CI
C CI
C CI
C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 1 7
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b 
 
 
 
  
 
 
 
  
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 1 8
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b 
 
 
 
 
 
 
  
 
 
 
 
  
.
  C CI
C CI
C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 1 9
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 2 0
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b 
 
  C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 2 1
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bAt t a c h m e nt 9. Pr ot o c ol J B E F  C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 2 2
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 2 3
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C CI
C CI
C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 2 4
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b  
 
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 C CI
C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 2 5
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 2 6
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bT a ble 1 :   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 2 7
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bT a ble 2 :  
 
  
 
  
 
  
  
 
 
 
  
  
  
 
 
  
  
 
  
 
 
 
  C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 2 8
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a b  
 
 
 
 
 
 
 
 
T a ble 3:  
  
  
   
  
   
 
  
 
  C CI
C CI
H 9 H -M C -J B E F ( c) P h a s e 1 O n c ol o g y Pr ot o c ol P a g e 1 2 9
G al u ni s erti b ( L Y 2 1 5 7 2 9 9)/ ni v ol u m a bR ef er e n c e
 
 C CI
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 130
Galunisertib (LY2157299) /nivolumabAttachment 10. Protocol JBEF Echocardiographic 
Guidelines
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 131
Galunisertib (LY2157299) /nivolumabEchocardiography
In thi s study , ECHO images will be acquired with the purpose of ascertaining that patients 
enrolled in the study  have (and m aintain during the study ) baseline norm al cardi ac structure and 
funct ion, normal pulmo nary artery  pressure, and absence of significant valvular disease (defined 
herein as no valvular regurgitation except for mild tricuspid, mild mitral, or mild aortic 
regurgitation, and no more than mild mitral or aortic valvular stenosis).  Repeated ECHOs in 
each patient will be performed to establish the cardiac safet y of galunisert ib by [CONTACT_861350].  Dete rminat ion of normalcy status requires objective evaluation o f cardi ac 
chamber size and funct ion and attention to the use of appropriate techniques in the performance 
of the ECHO examinat ions, in parti cular the use of standardised settings during the acquis itions 
of colour fl ow Doppler imaging.  Therefore, because quant itative ECHO is the goal, stringent 
criteria for image qualit y and reproducibilit y are essential.
In addit ion to qualitat ive assessment of valvular regurgitation when or if detected (trace, mi ld, 
moderate, or severe according to Singh et al. [1999] and Zoghbi et al. [2003] [see below]) and 
qualitat ive/quant itative assessment of valvular stenosis when or if detected (mild, moderate, or 
severe, using mean and peak pressure gradient in mm Hg and o rifice area in cm 2as applicable), 
other ECHO parameters to be serially quant ified are:  LV cavit y size (di ameters, vol umes), LV 
ejection fraction, LV m ass and mass index, diastolic function based on mitral flow velocit y, 
mitral decelerat ion time, pulmo nary venous flow pattern, tissue Doppler, extrapolat ion of LV 
end-diastolic pressure by  E/Em , left atri al volume index, and extrapol ation of pulmo nary artery  
systolic pressure when obtainable .  
An ECHO with no clinically significant abnormalities is one defi ned specifically as:  the LV 
(Schiller et al. 1999) internal dimensio n in diastole should be 2.8 cm /m2, the l eft atri al (Tsang 
et al. 2002) end -systolic vo lume shoul d be 36 mL/M 2, the LVejection fraction (Oh et al. 2006) 
shoul d be 50% wi thout regi onal wall motion abnorm alities, 2 -dimensio nal ECHO -derived LV 
mass index 1shoul d be 115 g/M 2for males and 99 g/M 2for females, the pulmo nary artery  
pressure should be normal (tricuspid regurgitation jet velocit y 2.5 m /s and/or pulmo nary valve 
flow accelerat ion time 120ms), the LV diastolic funct ion (Khouri et al. 2004) should be normal 
(screening:  mitral deceleration time 150ms and 250 m s, mi tral E/A rati o 0.75 and 1.5, 
mitral E velocit y divided by  [CONTACT_861351] [E/Em ] <15), and the re shoul d be no 
evidence for pericardial or congenital or heart disease.  In addition, there should be no evidence 
for more than mild mitral or aortic stenosis (mitral valve area should be >2.0 cm 2and aorti c 
valve area should be >1.5 cm 2) and no evi dence of more than mild mitral or aortic regurgitation 
(Singh et al. 1999; Zoghbi et al. 2003).  Patients enrolled in the study  may have evi dence for 
tricuspid (trace or mild), pulmo nary, mitral (trace or mild), or aortic (trace or mild) regurgitation 
by [CONTACT_861352] (Singh et al. 1999; Zoghbi et al. 2003).
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 132
Galunisertib (LY2157299) /nivolumabReferences
Khouri  SJ, Maly  GT, Suh DD, Wal sh TE. A practical approach to the echocardiographic 
evaluat ion of diastolic function. J Am Soc Echocardiogr. 2004;17(3):[ADDRESS_1200662] ed. Philadelphia: Lippi[INVESTIGATOR_10354], Williams 
Wilkins; 2006.
Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, 
Reicheck N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendat ions for quantitation 
of the left ventricle by [CONTACT_1192] -dimensio nal echocardiography : American Soci ety of 
Echocardi ography  Commi ttee on Standards, Subcommittee on Quant itation of  
Two-Dimensio nal Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358 -367.
Singh JP, Evans JC, Levy D, Larson M G, Freed LA, Fuller DL, Lehman B, Benjamin EJ. 
Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the 
Framingham Heart Study ). Am J Cardiol. 1999;83(6):[ADDRESS_1200663] ion and rel ation to 
cardi ovascular risk burden. Am J Cardiol. 2002;90(12):1284 -1289.
Zoghbi WA, Enriquez -Sarano M, Foster E, Grayburn PA, Craft CD, Levine RA, 
Niho yannopoul os P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, 
Weissman NJ; American Societ y of Echocardiography . Recommendat ions for evaluat ion of 
the severit y of native valvular regurgitation with two -dimensio nal and Doppler 
echocardiography. J Am Soc Echo cardiogr. 2003;16(7):777 -802.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 133
Galunisertib (LY2157299) /nivolumabAppendix:  Qualitative and Quantitative Parameters for Grading Valvular 
(Mitral and Aortic) Regurgitation Severity
Please refer to references below for informat ion on qualitative and quant itative param eters f or 
grading valvu lar (mitral and aortic) regurgitation severit y.
Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ. 
Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the 
Framingham Heart Study ). Am J Cardiol. 1999;83(6):897 -902.
Zoghbi WA, Enriquez -Sarano M, Foster E, Grayburn PA, Craft CD, Levine RA, 
Niho yannopoul os P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, 
Weissman NJ; American Societ y of Echocardiography . Recommendat ions for evaluat ion of 
the severit y of native valvular regurgitation with two -dimensio nal and Doppler 
echocardiography. J Am Soc Echocardiogr. 2003;16(7):777 -802.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 134
Galunisertib (LY2157299) /nivolumabReferences
Henson J W, Ulmer S, et al. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol.
2008:29(3 ):419 -424.
Kreisl TN, Kim L, et al. Phase II trial of single -agent bevacizumab fo llowed by  [CONTACT_861353]. J Clin Oncol.
2009;27(5):740 -745.
Shi Y, Massagué J. Mechanisms o f TGF -beta si gnaling fro m cell membrane to the nucleus. Cell.
2003;113(6):685 -700.
Sorensen A, Patel S, et al. Comparison of diameter and perimeter methods for tumor volume 
calculat ion. J Clin Oncol. 2001;19(2):[ADDRESS_1200664] Oncol. 2008.
Verhaak RG, Hoadley  KA, et al . Integrated genomic analysis ident ifies clinically relevant 
subtypes of glio blastom a characterised by  [CONTACT_861354], IDH1, EGFR, and NF1. 
Cancer Cell. 2010;17(1):98 -110.
Wick W, Puduva lli VK, et al. Phase III study  of enzastaurin com pared wi th lomustine in the 
treatm ent of recurrent intracranial glio blastom a. J Clin Oncol. 2010;28(7):1168 -1174.
Wong ET, Gautam S, et al. Bevacizumab for recurrent glio blastoma mult iforme:  a 
meta -analysis. J Natl Compr Canc Netw. 2011;9(4):403 -407.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 135
Galunisertib (LY2157299) /nivolumabAttachment 11. Protocol JBEF Management A lgorithms 
for Immuno -Oncology  Agents
These general guidelines const itute guidance to the i nvest igator and may be supplemented by 
[CONTACT_861355] .  The gui dance applies to all immuno -oncol ogy agents and 
regimens.  
A general principle is that different ial diagnoses shoul d be diligent ly evaluated according to 
standard m edical practice.  Noninflammatory  aetiologies shoul d be considered and appropriat ely 
treated.  
Corti costeroi ds are a primary  therapy  for immuno -oncol ogy drug -related AEs.  The oral 
equivalent of the recommended IV doses may be considered f or ambulatory  patients with 
low-grade toxi city.  The l ower bi oavailabili ty of oral corti costeroi ds shoul d be taken into account 
when switching to the equivalent dose of oral corticosteroids.  
Consultat ion with a medical or surgi cal specialist, especially  prior to an invasive di agnost ic or 
therapeuti c procedure, is recommended.  
The frequency and sev erity of the related AEs covered by  [CONTACT_861356] -oncol ogy agent or regimen being used.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 136
Galunisertib (LY2157299) /nivolumab

H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 137
Galunisertib (LY2157299) /nivolumab

H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 138
Galunisertib (LY2157299) /nivolumab

H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 139
Galunisertib (LY2157299) /nivolumab

H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 140
Galunisertib (LY2157299) /nivolumab

H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 141
Galunisertib (LY2157299) /nivolumab

H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 142
Galunisertib (LY2157299) /nivolumab

H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 143
Galunisertib (LY2157299) /nivolumabAttachment 12. Protocol JBEF CYP3A 4 Modulators
CYP3A4 InducersStrong
CYP3A4 InhibitorsModerate
CYP3A4 Inhibitors
aminoglutethimide clarithromycin amiodarone
bosentan chloramphenicol amprenavir
carbamazepi[INVESTIGATOR_861287] (in liver only) conivaptan atazanavir
fosphenytoin Cremophor EL cimetidine
nafcillin cyclosporine ciprofloxacin
nevirapi[INVESTIGATOR_861288]1706
St. John's wort indinavir and ritonavir fluconazole 
itraconazole fluvoxamine
ketoconazole haloperidol
lopi[INVESTIGATOR_861289] 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 144
Galunisertib (LY2157299) /nivolumabAttachment 13. Protocol JBEF Protocol A mendment 
H9H-MC-JBEF( c) Summary  
A Phase 1b/2 Dose Escalation and Cohort Expansion 
Study  of the Safety , Tolerability  and Efficacy  of a Novel 
Transforming Growth Factor –βReceptor I Kinase Inhibitor 
(Galunisertib) A dministered in Combination with A nti–PD-1 
(Nivolumab) in A dvanced Refractory  Solid Tumours 
(Phase 1b) and in Recurrent or Refractory  Non –Small Cell 
Lung Cancer orHepatocellular Carcinoma (Phase 2)
Overview
Protocol  H9H -MC-JBEF (b)has been amended.  The new protocol is indicated by  
[CONTACT_11827] (c) and will be used to conduct the study in place of any preceding version o f the 
protocol .
H9H -MC-JBEF protocol  (b) was am ended f or the fo llowing reasons:
Phase 2 portion of study : to remove the glio blastoma cohort and update the protocol  text 
to reflect this change .  Resul ts from [ADDRESS_1200665] indicated a lack of sufficient efficacy 
with galunisertib in glio blastoma.  
To cl arify the rati onale for the changes to the ECHOs in Attachment 1 made in protocol 
amendment (b) (see Section 5.5bullet 6) :  the requirement for ECHO (echocardiography) 
at the 30 -day follow-up visit was restored into the protocol as this requirement had be en 
inadvertent ly remo ved during Amendment A; for the Phase 2 portion, clarificat ion was 
provi ded that imaging is to be collected centrally .  
Attachm ent 2 :  to add hepati tis B surface ant igen testing, which was inadvertently 
excluded previously ; to cl arify that all hepat itis testing at baseline will be assayed by a 
local and a Lilly -designated l aboratory andduring the tri al will be perform ed by a Lilly -
designated laboratory ; and to clarify footnotes.  
Attachm ent 4 :  to add a ±[ADDRESS_1200666] of text changes is below.
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 145
Galunisertib (LY2157299) /nivolumabRevised Protocol Sections
Note: All deletions have been ident ified by [CONTACT_58001] .
All additions have been ident ified by [CONTACT_58002] .
Title page
A Phase 1b/2 Dose Escalat ion and Cohort Expansion Study  of the Safet y, Tolerabilit y and 
Efficacy of a Novel Transforming Growth Factor –β Receptor I Kinase Inhibitor (Galunisert ib) 
Administered in Combinat ion with Anti –PD-1 (Nivo lumab) in Advance d Refractory  Solid 
Tumours (Phase 1b) and in Recurrent orRefractory Non –Small Cell Lung Cancer or 
Hepatocellular Carcino ma, or Gli oblastom a (Phase 2)
…
This is a multicentre, nonrandomi sed, open -label, dose -escalation Phase 1b study of 
galunisertib combi ned with nivolumab in patients with advanced refractory solid tumours 
followed by a 3 -cohort expansion Phase 2 study in patients with refractory or recurrent 
non–small cell lung cancer orhepatocellular carcinoma , or glioblastoma .  
…
Protocol Electronically Signed and Approved by [CONTACT_11007]:  17 April 2015
Amendm ent (a) Electronically Signed and Approved by [CONTACT_11007]:  24 July2015 
Amendm ent (b) Electronically Signed and Approved by [CONTACT_11007]:  [ADDRESS_1200667] 2016
Amendm ent (c) Electronically Signed and Approve d by [CONTACT_443190] :  30-Aug-2016 GMT
Synopsis
…
This study  is a Phase 1b/[ADDRESS_1200668] of an open -label, dose -escalat ion assessment of the safet y and 
tolerabilit y of galunisertib administered at 50 mg daily  (QD), 50 m g twi ce daily  (BID), 80 m g 
BID, or 150 mg BID in combinat ion with nivo lumab 3 m g/kg in pat ients with advanced 
refractory  solid tum ours.  The Phase 2 part of thi s study  will be disease restricted and include 
23expansio n cohorts of patients in tumours with documented monotherapy  activit y with 
nivolumab (non –small cell lung cancer; n =approximately  25 pati ents) or gal unisert ib 
(hepatocellular carcino ma [n = approximately 25patients] and glio blastom a [n = approximately  
25 pati ents] ).  Pati ents in the 23cohorts will be enrolled independent ly and will be assigned to 
treatm ent concurrent ly;, and enrolment for each cohort will be co mplete when thatallcohort
hasvereached the prespecified enrolment target.  Galunisertib will be used to attempt to augment 
nivolumab activit y via suppression o f the immune suppressive function o f TGF -β at the 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 146
Galunisertib (LY2157299) /nivolumabmaximum tolerated dose or pharmaco logically  active dose.  Addi tional cohorts of pati ents with 
specific alternat ive tumour histologies may be added and will require an amendment.
3. Table of Contents
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the 
Safety, Tolerability, and Efficacy of a Novel Transforming Growth 
Factor –Recepto r I Kinase Inhibitor (Galunisertib) Administered in 
Combination with Anti –PD-1 (Nivolumab) in Advanced Refractory 
Solid Tumours (Phase 1b) and in Recurrent or Refractory Non –Small 
Cell Lung Cancer or,Hepatocellular Carcinoma , or Glioblastoma
(Phase 2)
…
5. Introduction
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the 
Safety, Tolerability, and Efficacy of a Novel Transforming Growth 
Factor –Receptor I Kinase Inhibitor (Galunisertib) Administered in 
Combination with Anti –PD-1 (Nivolumab) in A dvanced Refractory 
Solid Tumours (Phase 1b) and in Recurrent or Refractory Non –Small 
Cell Lung Cancer or,Hepatocellular Carcinoma , or Glioblastoma
(Phase 2)
5.5. Rationale for H9H -MC-JBEF Protocol Amendment (b)
…
InAttachm ent 1 , Study  Schedules, a requirement was added for echocardiography
(ECHO) at the 30 -day follow-up visit, and, for the Phase 2 portion, clarificat ion was 
provi ded that imaging is to be collected centrally [see clarificat ion in Sect ion5.5].  
…
A detailed list of changes may  be found in Attachment 13 .
5.6. Rationale for H9H -MC-JBEF Protocol Amendment (c)
H9H -MC-JBEF protocol  (b) was am ended f or the fo llowing reasons:
Phase 2 portion of study : to remove the glio blastoma cohort and update the protocol  text 
to reflect this change.  Results from [ADDRESS_1200669] indicated a lack of sufficient efficacy 
galunisertib in glio blastoma.  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 147
Galunisertib (LY2157299) /nivolumabTo cl arify the rati onale for the changes to the E CHOs in Attachment 1 made in 
protocol  amendment (b) (see Section 5.5bullet 6) :  the requi rement for ECHO 
(echocardiography ) at the 30 -day follow-up visit was restored into the protocol as 
this requi rement had been inadvertently removed during Amendment A; for the 
Phase 2 portion, clarificat ion was provided that imaging is to be collected 
centrally .  
Attachm ent 2:  to add hepati tis B surface ant igen testing, which was inadvertently 
excluded previously ; to cl arify that all hepat itis testing at baseline will be assayed by a 
local and a Lilly -designated l aboratory andduring the tri al will be perform ed by a Lilly -
designated laboratory ; and to clarify footnotes.  
Attachm ent 4:  to add a ±[ADDRESS_1200670] of changes may be found in Attachm ent 13 .
[IP_ADDRESS]. Galunisertib
…
Glioblastoma
In glio blastoma (GB), anaplastic astrocy tomas, anapl astic oligoastrocy toma, or anaplast ic 
oligodendroglio ma, galunisertib is expected to reduce neoangiogenesis; enhance ant itumour 
cytotoxi c T cells; and reduce fibrogenic remodelling associated with tumour necrosis, radiat ion, 
and surgery .  Of [ADDRESS_1200671] -in-human dose study  (Study  H9H -MC-JBAH [JBAH]), partial tumour responses 
were reported in [ADDRESS_1200672] progression.  In thi s study , 
158 pati ents were randomly  assigned to 3 treatm ent arms:  gal unisertib + lo mustine(n=79), 
galunisertib al one (n=39), and placebo + lo must ine (n=40) (Brandes et al. 2015).  
The m edian OS (95% CI) was 6.7 months (5.3, 8.5) for the galunisert ib + lomust ine arm, 
8.0 m onths (5.7, 11.7) for the galunisert ib arm, and 7.5 months (5.6, 10.3) for the placebo 
+ lomustine arm .  Success cri teria for superi ority of the galunisert ib + lo must ine arm over 
the placebo + lo must ine arm was not met (p [hazard ratio<1]<85%).
The median progression -free survival (PFS) (95% CI) was 1.8 months (1.7, 1.8) for the 
galunisertib + l omustine arm, 1.8 months (1.6, 3.0) for the galunisert ib arm, and 
1.9months (1.7, 1.9) for the placebo + lo mustine arm .  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 148
Galunisertib (LY2157299) /nivolumabBest overall response as determi ned using Response Assessment in Neuro -Oncology 
(RANO) criteria included 1 CR in the galunisert ib + lomust ine arm and 2 PRs in the 
galunisertib arm .  
Thirty-four patients (24% patients in the galunisertib + lo must ine arm; 13% in the 
galunisertib arm; 26% in the placebo + lo mustine arm ) had Grade 3/[ADDRESS_1200673] comm on drug -related Grade 3/4 AEs (galunisertib + lo mustine, 
galunisertib, pl acebo + l omustine, respectively) were thrombocy topeni a (8%, 0%, 13%), 
lymphopenia (9%, 3%, 0%), and neutropenia (8%, 0%, 5%).  
Study  JBAL efficacy outcomes including OS and PFS were similar in all 3 treatment arms.  The 
treatm ent was safe and well tolerated.  Outcomes of an IDH -1–mutated subgroup is being 
analysed for clinical outcome to determine w hether i t is different from the general glio blastom a 
popul ation.  In addi tion, in Study  JBAL, higher baseline expressio n of MDC/CCL22 was a 
prognosti cator of improved outcome, and patients whose CCL22 remained higher over the 
course of treatment had better outcom es (Hanks et al . 2013).  In addit ion, higher baseline levels 
of CD3, CD4, CD4CD25, CD8, and FoxP3 correlated with improved outcome, suggest ing that a 
more intact immune funct ion improves outcome.
Study  H9H -MC-JBAI is an ongoing Phase 1b study evalua ting galunisertib in the first -line 
setting in co mbinat ion with temozolomide and radiation .  
…
[IP_ADDRESS]. Nivolumab
…
Glioblastoma 
Recent improvements in OS achieved wit h immunotherapeutics in melano ma and prostate cancer 
suggest that immunotherapy  approac hes m ay offer promise in other difficult to treat cancers such 
as GB (Heimberger and Sampson 2011).  More specific immuno logic data in support of this 
hypothesis include the longer survival observed in patients with elevated IgE levels co mpared to 
those wi th norm al levels (Lin et al. 2011; Schleho fer et al. 2011; Schwartzbaum et al. 2012; 
Turner 2012) and upregulat ion of immune checkpoint receptors such as PD -L1 in glio blastomas 
(Parsa et al. 2007; Jacobs et al. 2009).  Studies have also suggested an associ ation between 
malignancy grade of astrocy tic tum ours and tum our cell PD -L1 expressio n (Wilmotte et al. 2005; 
Yao et al.2009).  Addi tionally, use of an inhibitor of PD -L1 in mouse glio blastoma models 
suggests benefit in co mbinat ion with radiation therapy  (Zeng et al. 2013).  
Although the efficacy o f check point inhibitors such as nivo lumab and ipi[INVESTIGATOR_861290], a mult icentre, Phase 2 study  to evaluate the response of brain 
tumour m etastases to i pi[INVESTIGATOR_861291] (CA184042).  Pati ents (n=71) wi th 
advanced Stage IV melano ma and measurable act ive brain metastases were rando mly assigned to 
ipi[INVESTIGATOR_861292] .  The study  dem onstrated that i pi[INVESTIGATOR_861293] y in 
patients wi th melano ma brain metast ases with so me patients showing prolonged clinical 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 149
Galunisertib (LY2157299) /nivolumabresponses, disease control, and prolonged survival.  Ipi[INVESTIGATOR_861294].
Nivo lumab monotherapy  is being evaluated in Study  CA209143.   
…
5.9.1. Primary Objective
…
Phase [ADDRESS_1200674] ive of the Phase 2 part (expansion cohorts) of this study  is to assess the safet y 
of the combinat ion of galunisertib and nivo lumab in patients with refractory  or recurrent NSCLC
or,HCC , or glioblastoma who have failed 1 prior line of therapy .  
5.9.2. Secondary Objectives
The secondary  objectives of this study  are:
…
Phase 2 only :  To assess the preliminary  antitumour activit y including PFS, ORR, 
durati on of  response, and t ime to response of the combinat ion of galunisertib and 
nivolumab in pat ients with NSCLC or,HCC , or glioblastoma   
6.1.1. Inclusion Criteria
Patients m ay be included in the study  if they  meet all  of the f ollowing cri teria during screening 
prior to fi rst dose of study  drug.
…
[2] For Phase 2, must have 1 of the following tumour types:  recurrent or 
refractory  NSCLC (any  histol ogy) or, HCC wi th AFP ≥200 ng/mL , or 
glioblastoma (primary) .  
[3] For Phase 2, Mmust have histol ogical or cy tological confirmat ion of recurrent 
disease based upon standard diagnostic criteria for the tumour ty pe.  
For glio blastom a, pati ents m ust have:
1)  previous or current histol ogically  confirmed di agnosis of WHO glioblastom a 
(ICD -O 9440/3, WHO grade IV) ; and  
2)  first recurrence of glio blastoma as determined by  [CONTACT_861357] (see
Attachm ent 9 ) following standard chemoradiat ion (Stupp protocol [Stupp et al. 
2009]).  If first recurrence of glio blastoma is documented by  [CONTACT_9268], an int erval o f 
at least 12 weeks after the end of prior radiation therapy  is requi red unless there 
is eit her:  i) histopathologic confirmat ion of recurrent tumour, or ii) new 
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 150
Galunisertib (LY2157299) /nivolumabenhancement on MRI outside of the radiotherapy  treatm ent field (beyond the 
high-dose re gion or 80% isodose line) (Wen et al. 2010) .  For glio blastoma 
patients, bi opsy  confirmati on of  recurrent di sease is not requi red as l ong as new 
enhancement on MRI outside of the radiotherapy  treatm ent field is documented.
[4] For pati ents other than glioblastom a patients, n New (nonarchived) baseline 
tumour bi opsies (defined as a biopsy specimen taken since co mpletion of the 
first-line treatment regimen) are required for all cohorts (see Section 8.2.1).  
In addit ion, in the Phase [ADDRESS_1200675] agree to undergo an 
on-study  biopsy; pati ents in the Phase 1b part of this study  are strongly 
encouraged to agree to undergo an on -study  biopsy.  See Secti on [IP_ADDRESS].  
For Phase [ADDRESS_1200676] either anew 
biopsy or archived tumour tissue available.  
Fine- needle aspi[INVESTIGATOR_499754].
[5] For NSCLC, HCC or other nonneuro -oncol ogy tumours:  have measurable 
disease as defined by [CONTACT_861358] n 1.1 (Eisenhauer et al. 2009; 
Attachm ent 8).  
For any For glioblastom a patient in Phase 1 of the study :  have m easurable 
disease as defined by [CONTACT_95733] (Wen et al. 2010; Attachment 9) .  for the first [ADDRESS_1200677] ion and postresection radiat ion. …
[6] For Phase [ADDRESS_1200678] had disease progression or be refractory  or intol erant 
to 1 prior line of therapy (first -line therapy) for recurrent or refractory for
NSCLC or,HCC , or glioblastoma and have refused currently  approved 
second -line o f therapy . …
For glio blastom a:
previous first -line of therapy wit h at l east radi otherapy and temozolo mide except 
for pati ents wi th MGMT unmethylated newly  diagnosed GB (Stupp et al . 2009).  
Patients wi th MGMT unmethylated newly  diagnosed GB m ay have received 
radiation therapy  only (Hegi et al. 2005).
…
[9] Have adequate organ funct ion, including:
…
For Phase 2 only :
…
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 151
Galunisertib (LY2157299) /nivolumabFor glio blastoma cohort only:
Haematologic:  platelets 100x10 9/L, and haemoglobin 9g/dL or 5.6 mmo l/L, 
ANC 1.5x10 9/L.  Patients may  receive ery throcyte transfusio ns to achieve this 
haemoglo bin level at the discretion o f the invest igator (at least 3 days before 
starting study  drug).  Initial treatm ent m ust not begin unt il 2 days after the 
erythrocyte transfusio n and after t he confirmat ion of haem oglobin level  ≥9 g/dL.
Hepati c:  total  bilirubin ≤1.5xULN (except pati ents wi th Gilbert Syndro me who 
must have a total bilirubin level o f <3.0xULN) ; alkaline phosphatase, AST, and 
ALT ≥3.0xULN .  
6.1.2. Exclusion Criteria
Potenti al study  patients m ay not be included in the study  if any of the fo llowing apply during 
screening.
…
[24] Are receiving immunosuppressive agents (eg, cy closporine ) for any  reason 
except for corticosteroids for transfusions.  In the Phase 1 bporti on of  the 
study, lL ow-dose corticosteroids for glio blastoma are permitted (eg, 
prednisone 10 mg [ approximately equivalent to 2 mg of dexamethasone ] or 
less daily or equivalent dose of other corticosteroid).
…
[29] Receiving any concurrent antineoplast ic therapy (ie, chemotherapy, hormonal 
therapy , immunotherapy , extensive, nonpalliat ive radiat ion therapy , or 
standard or investigat ional agents for treatm ent of NSCLC, HCC, or 
glioblastoma ).  
[30] Have had prior radio therapy  within [ADDRESS_1200679] 
recovered fro m all radiation -related toxi cities, not requi re more than l ow-dose 
corticosteroi ds (except for low -dose corti costeroi ds for gli oblastom ain the 
Phase 1b porti on of  the study , eg, prednison e 10 mg or less daily or equivalent 
dose of other corticosteroid), and not have had radiation pneumo nitis.  A 
1-week washout is permitted for palliat ive radiat ion to non -CNS disease with 
Lilly physician approval.
[31] For glio blastoma patients in the Phase 1bporti on of the study only, have 
diffuse leptomeningeal disease.
[32] For nonglio blastoma pat ients, pPatients with known act ive central nervous 
system (CNS) m etastases and/or carcinomatous meningit is.  Pati ents wi th 
stable, previously  treated brain meta stases m ay parti cipate if neurologic 
symptoms have reso lved, they have been off steroids for at least [ADDRESS_1200680] dose of study  treatm ent.
…
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 152
Galunisertib (LY2157299) /nivolumab[36] For glio blastoma pat ients in the Phase [ADDRESS_1200681] 6 m onths pri or to randomi sation.  
6.2. Summary of Study Design
. …The second part (Phase 2) of the study  will be di sease restri cted to include 23expansio n 
cohorts in patients wi threcurrent or refractory  NSCLC (n = approximately 25 patients) orHCC 
(n=approximately  25patients) or glio blastom a (n=approximately 25 pa tients )allreceiving 
nivolumab 3 mg/kg Q2W plus galunisert ib at the dose determined fro m the Phase 1b part .  
Addit ional expansio n of individual cohorts may  occur depending upon activit y based upon a 
2-stage design after 3 cy cles.  Details are found in Sec tion10.1.1 .  NSCLC has a historically 
good activit y under nivo lumab monotherapy; HCC and glio blastoma have hasdocum ented 
activit y with galunisert ib therapy.
…
[[Updated design figure ]]
Figure JBEF. 6.1. Study H9H -MC-JBEF design.
6.2.2. Phase 2 Cohort Expansion
… .  Three Two expansio n cohorts will be tested in order to demonstrate efficacy o f the 
combinat ion in NSCLC and,HCC , and glio blastoma .  IfDLT -equivalent toxicit ies occur in 33% 
or more of patients within a tumour -specific cohort expansio n in the first 2 cycles, then 
investigators and the Lilly CRP will assess the nature and severit y of these toxi cities.  No 
additional patients will be accrued un til this safet y review is completed and a decisio n is made 
either to continue at the current dose or to deescalate the dose and define a new dose for the 
expansio n phase.  The NSCLC cohort ( NSCLC has demonstrated activit y with nivo lumab 
monotherapy ),and t he glioblastoma and HCC cohort s (HCC has docum ented m onotherapy  
activit y with galunisert ib),will be used to assess activit y of the combinat ion. …
7.2.3. Phase 2 Cohort Expansion
…
The Phase 2 part of the study  will ini tially include 23expansio n cohorts ( NSCLC and , HCC ,
and glio blastom a[n = approximately 25 patients per cohort]). …
7.5. Concomitant Therapy
…
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 153
Galunisertib (LY2157299) /nivolumabAny concurrent ant ineoplastic therapy (ie, chemotherapy, hormonal therapy, immunotherapy, 
extensive, nonpalliat ive radiat ion therapy , or standard or invest igational agents for treatment of 
NSCLC , HCC, or glioblastoma any other tum ourtype) will not be allowed.
…
8.1.4. Safety Monitoring
…
The Lilly CRP/CRS will, as is appropriate, consult with the funct ionally independent Global 
Patient Safet y therapeutic area physician or CRS, and periodically review:
…
Except for patients with liver metastases or HCC, for any pat ient who If a study  patient 
with NSCLC or glio blastoma experiences elevated ALT > 3xULN and elevated total 
bilirubin > 2xULN, clinical and laboratory  monitoring shoul d be ini tiated by  [CONTACT_1275].  
…
10.1.1. Sample Size
…
For HCC and glio blastoma , the response is defined based on ORR or survival at 10 months. …
10.7. Efficacy
…
For the glio blastom a cohort, efficacy  endpoints m ay be eval uated by  [CONTACT_861359] 1/2 
expressio n, serum TGFβ -1 levels, and tumour PD -L1 expressio n.
10.8. Interim Analyses
…
After enro lment has completed in acohort (n = approximately 25) and the last enrolled pat ient in 
that cohort has completed or had the opportunit y to com plete 3 cy cles of treatm ent, an interim 
analysis will be conducted for that particular cohort (for a total o f [ADDRESS_1200682] 3 cy cles of treatm ent).  The 
intent of the interim analysis is to evaluate preliminary  antitumour activit y of galunisert ib in 
combinat ion of nivo lumab.  These interim analyse s may be combined wit h the ongoing trial -
level safet yreview.  Pending review o f the interim data, approximately  16 addi tional patients 
may be enro lled in that particular cohort if there are more than 4 and fewer than 9 patients who 
demonstrate responses (determined by  [CONTACT_3168] f or the NSCLC cohort ,and by [CONTACT_861360] s).  Enrolment of the other cohort(s) , if not com pletely  enrolled, 
will not be stopped during the interim analysis. ...  
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 154
Galunisertib (LY2157299) /nivolumab12. References
…
Brandes AA, Carpent ier A, Kesari, Sepulveda J, Wheeler H, Chinot O, Cher L, Steinbach J, 
Specenier P, Cleverly  A, Smi th C, Gueorguieva I, Guba SC, Desaiah D, Lahn MM, Wick W. 
A phase [ADDRESS_1200683] 144596 
to be presented at: Annual Meet ing of the American Society for Clinical Onco logy; 
29May-2June 2015; Chicago, Illino is, [LOCATION_003].  
…
Hegi  ME, Di serens AC, Gorlia T, Hamou MF, de Tribo let N, Weller M, Kros JM, Hainfellner 
JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimano ff RO, Cai rncross JG, Janzer RC, 
Stupp R. MGMT gene silencing and benefit fro m temozolomide in glio blastoma. N Engl J 
Med. 2005;352(10):997-1003.
Heimberger AB, Sampson JH. Immunotherapy  coming of age: what will i t take to m ake i t 
standard of care for glio blastom a? Neuro Oncol. 2011;13(1):3 -13.
…
Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, Grotenhuis JA, 
Hoogerbrugge PM, de Vries IJ, Adema GJ. Regulatory  T cells and the PD -L1/PD -[ADDRESS_1200684]  
mediate immune suppressio n in malignant human brain tumors. Neuro Oncol . 
2009;11(4):394 -402.
…
Lin Y, Jin Q, Zhang GZ, Wang YJ, Jiang T, Wu AH, Wang JF, Qiu XG. Increase o f plasma IgE 
during treatment correlates with better outcome of patients with glio blastom a. Chin Med J
(Engl ). 2011;124(19):3042-3048.
…
Parsa AT, Waldron JS, Panner A, Crane CA, P arney IF, Barry  JJ, Cacho la KE, Murray  JC, Tihan 
T, Jensen MC, Mischel PS, Stokoe D, Pi[INVESTIGATOR_51706]. Loss of tumor suppressor PTEN function 
increases B7 -H1 expressio n and immunoresistance in glio ma. Nat Med. 2007;13(1):84 -88.
…
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 155
Galunisertib (LY2157299) /nivolumabSchleho fer B, Siegmund B, Linseis en J, Schüz J, Rohrmann S, Becker S, Michaud D, Melin B, 
Bas Bueno -de-Mesquita H, Peeters PH, Vineis P, Tjonneland A, Olsen A, Overvad K, Romieu 
I, Boeing H, Aleksandrova K, Trichopoulou A, Bamia C, Lagiou P, Sacerdote C, Palli D, 
Panico S, Sieri S, Tumino R, Sanchez MJ, Rodriguez L, Dorronsoro M, Duell EJ, Chirlaque 
MD, Barricarte A, Borgquist S, Manjer J, Gallo V, Allen NE, Key TJ, Ribo li E, Kaaks R, 
Wahrendorf J. Primary  brain tum ours and specific serum immunoglobulin E: a case -control  
study  nested in th e European Prospectiv2e Invest igation into Cancer and Nutrit ion cohort. 
Allergy . 2011;66(11):1434- 1441.
Schwartzbaum J, Ding B, Johannesen TB, Osnes LT, Karavodin L, Ahlbo m A, Feycht ing M, 
Grimsrud TK. Associat ion between prediagnostic IgE levels and risk of glioma. J Natl Cancer 
Inst. 2012;104(16):1251 -1259.
…
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, 
Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, 
Mokhtari  K, Wesseling P, Villa S , Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross 
JG, Mi rimano ff RO; European Organisation for Research and Treatment of Cancer Brain 
Tumour and Radiat ion Onco logy Groups; Nati onal Cancer Institute of Canada Clinical Trials 
Group. Effects of radiot herapy with conco mitant and adjuvant temozolo mide versus 
radiotherapy  alone on survival in glio blastoma in a randomised phase III study : 5-year analysis 
of the EORTC -NCIC trial. Lancet Oncol. 2009;10(5):459 -466.
…
Turner MC. Epi[INVESTIGATOR_145975]: allergy  history , IgE, and cancer. Cancer Immunol Immunother
2012;61(9):1493 -1510.
…
Wilmotte R, Burkhardt K, Kindler V, Belkouch MC, Dussex G, Tribo let Nd, Walker PR, 
Dietrich PY. B7 -homo log 1 expressio n by [CONTACT_861361]: a new mechanism o f immune 
evasio n. Neuroreport. 2005 ;16(10):1081 -1085.
…
Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Mey er C, Harris TJ, 
Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran 
PT, Pardoll D, Drake CG, Lim M. Ant i-PD-[ADDRESS_1200685] ereotactic radiation produce 
long-term survival  in mice wi th intracranial glio mas. Int J Radiat Oncol Biol Phys.
2013;86(2):343 -349.
Attachment 1. Protocol JBEF Study Schedule
…
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 156
Galunisertib (LY2157299) /nivolumabDuring and Post -Study Assessments —Phase 1b Dose Escalation
Cycle 1 Cycle 2 Cycle 3 -n
Follow -Up (days)
CommentsRelative Week 
Within a Cycle1 2 3 4 1 2 3 4 1 2 3 4
Relative Day 
Within a Cycle a1 8 15 22 1 81
522 1 8 15 22Short-termLong -
term c30b 100
…
12-lead ECG XD 
14 
onlyX*Collect predose (if applicable):
SeeAttachment 4 for timing of PK time -matched ECGs
* Starting at Cycle 53Day 1, ECGs will be performed at 
every odd -numbered cycle thereafter (Cycles 5,7, 9, etc) 
…
Bio-
marker 
samplesTumour 
biopsy1/2 1/2Required for patients with cancers other than glioblastoma, 
with half of patients randomly assign to biopsies on either 
Cycle [ADDRESS_1200686] nivolumab dosing.  If a 
patient with glioblastoma undergoes a biopsy during the study 
for other medical r easons, tissue should be collected at that 
time.  
For glioblastoma patients only (Phase 1b) , if tumour biopsy is 
performed to distinguish between radiologic progression and 
pseudoprogression (not required), see Section 7.2.5 for 
instructions for proper ha ndling of specimen.
…
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 157
Galunisertib (LY2157299) /nivolumabPhase 2 Dose Expansion —Baseline/Screening Assessments
Relative Day Prior to Day 1 
of Cycle 1a28 14 7 Comments
…
Tumour biopsy XNew tumour biopsy is required for patients with NSCLC 
and HCC.  Archived tumour tissue or new tumour biopsy 
is required for patients with glioblastoma .  Biopsy should 
be taken only after study eligibility is confirmed.
…
Tumour measurement 
(palpable or visible)X If appropriate for the tumour
…
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 158
Galunisertib (LY2157299) /nivolumabDuring and Post -Study Assessments —Phase 2 Dose Expansion
Cycle 1 Cycle 2 Cycle 3 -n
Follow -Up (days)
CommentsRelative Week Within 
a Cycle1 2 3 4 1 2 3 4 1 2 3 4
Relative Day Within a 
Cycle a1 8 15 22 1 81
522 1 8 15 22 Short-termLong -
term c
…
12-lead ECG XD 
14 
onlyX*Collect predose ( if applicable):
See Attachment 4 for timing of PK time -matched ECGs .
* Starting at Cycle 35Day 1, ECGs will be performed at 
every odd -numbered cycle thereafter (Cycles 5,7, 9, etc )
…
Radiological tumour 
assessment for 
pseudoprogression treat
ment past initial 
progressionMRI/CT scan.  These scans can be performed locally and 
transmitted to a central imaging vendor.  For patients who are 
being treated beyond initial progression, these patients should 
remain on study treatment until the next assessment period.  
Patients who are treated beyond progression will be evaluated 
on an 8 (nonglioblastoma) or 12 -(glioblastoma) -week basis 
to determine if they should continue o n treatment.  
…
Bio-
marker 
samplesTumour 
biopsy1/2 1/2Required for patients with cancers other than glioblastoma , 
with half of patients randomly assign to biopsies on either 
Cycle [ADDRESS_1200687] nivolumab dosing.  If a 
patient with glioblastoma undergoes a biopsy during the study 
for other medical reasons, tissue should be  collected at that 
time.  
For glioblastoma patients only, if tumour biopsy is performed 
to distinguish between radiologic progression and 
pseudo progression (not required), see Section 7.2.5 for 
instructions for proper handling of specimen.
…
H9H-MC-JBEF (c)Phase 1 Oncology Protocol Page 159
Galunisertib (LY2157299) /nivolumabAttachment 2. Protocol JBEF Clinical Laboratory Tests
Clinical Laboratory Tests
Haematology a Clinical Chemistry a,b,c
Haemoglobin Serum Concentrations of:
…
Thyroid-stimulating hormone a,b,c
Reflex to fT3/fT4 a,b,cd
…
cAssay ed by [CONTACT_861362] -designated laboratory.
dIf thyroid-stimulating hormone test is abnormal, reflex to fT3/fT4 test must be performed.  
dBaseline tests (screening) will be assayed by a local and a Lilly-designated laborato ry.  Testing during the trial 
will be performed by a Lilly -designated laboratory.
Attachment 4. Protocol JBEF Phar macokinetic, Biomarker, PK Time -Matched 
ECG, and Immunogenicity Sampling Schedule
…
Blood Biomarker Sampling Schedule
Pharmacodynamic 
Sample # Cycle DaySampling Windows for 
Blood Collection
1 1 1 Predose
2 1 1 2 hours postdose ± 10 
minutes
...
L e o  D o c u m e n t  I D  =  1 7 3 a 3 2 d f - 7 7 9 3 - 4 4 7 b - a 1 2 d - 6 8 5 2 0 0 4 e 2 6 5 3
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  3 1 - J a n - 2 0 1 7  1 3 : 4 0 : 4 7  G M T
S i g n a t u r e  m e a n i n g :  A p p r o v e d
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  3 1 - J a n - 2 0 1 7  1 5 : 4 0 : 1 8  G M T
S i g n a t u r e  m e a n i n g :  A p p r o v e dP P D
P P D